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Abstract
Chemoselective ligation between two peptides can be used to produce synthetic 
peptides and proteins that cannot easily be synthesised as single peptides by solid 
phase peptide synthesis. Chemoselective reaction between an aldehyde and hydrazine 
or hydroxylamine, masking the aldehyde as a 1, 2-amino alcohol, has been 
investigated as a method of sequential ligation that will allow synthesis of individual 
peptides in high yield and purity, enabling more than two peptides to be ligated.
Protected amino acids were used as precursors for the synthesis of 1, 2-amino alcohol 
derivatives that could be used in solid phase peptide synthesis for the production of 
peptides bearing a C-terminal 1, 2-amino alcohol, as a masked aldehyde for use in 
ligation reactions. Limitations of this method led to alternative investigations, using 
peptides bearing an N-terminal serine as a masked aldehyde, and a C-terminal 
hydrazide. Bovine pancreatic ribonuclease A was chosen as an example protein for 
sequential ligation and using this method, peptides were synthesised in high yield and 
purity for use in ligation reactions. Trial ligation reactions with short test peptides 
were performed successfully, however problems were experienced during ligations 
using peptide fragments of ribunuclease due to involvement of the cysteine side 
chains. Methods to overcome these unwanted reactions resulted in insoluble peptide 
fragments.
Computer modelling using molecular dynamics simulations has been used to 
investigate the effect of replacing native peptide bonds in ribonuclease on the structure 
of the protein. The method of molecular dynamics simulation was validated through 
comparison of the structure of a mutant of ribonuclease from experimental NMR data 
to the structure produced after a molecular dynamics simulation. Results of the 
modelling simulations suggest that replacement of native peptide bonds with the 
chemoselective bond formed through reaction of an aldehyde and hydrazine will have 
only minor implications for the structure of ribonuclease, and therefore should only 
have a small impact on enzyme activity.
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Chapter 1: Introduction
1.0 introduction
Deoxyribonucleic acid (DNA) is often called the molecule of life, but it is the 
proteins encoded by DNA that are responsible for the cellular structure and 
biological processes that we call life. Proteins provide structural support in cells, they 
are catalysts for most cellular chemical reactions, and they are antibodies, transport 
molecules and cell receptors. Proteins are polymers of amino acids, the sequence 
being determined by the order of nucleotide bases in DNA, and it is this sequence of 
amino acids and the three-dimensional structure it adopts that determines the 
protein’s biological function. The study of protein sequence, structure, function and 
interaction is essential for the more detailed understanding of the biological 
processes of life.
The study of a protein’s structure and function requires a source of that protein. 
Some proteins, particularly the earliest examples studied, can be extracted from cells 
and purified. Early protein purification was achieved using crystallisation techniques 
such as precipitation from ammonium sulphate, used by Kunitz (1940) for isolation 
of crystalline Bovine Ribonuclease A. This technique works if the protein is present 
in the cell in large quantities, for example digestive enzymes, but very few proteins 
are that abundant. Ion exchange chromatography, which can separate proteins with 
different net charge, was first used in 1950 by Paléus et al to purify cytochrome C. 
This technique allowed proteins to be purified to a much higher purity than simple 
precipitation, for example Hirs et al (1953) separated ribonuclease A from 
ribonuclease B (which differs from the A form only by a single carbohydrate 
molecule) by ion exchange chromatography. However the problem still remained 
that only those proteins abundant in cells could be extracted and purified.
Recombinant technology, developed by Cohen et al (1973) can be used to insert the 
gene for a protein of interest into a prokaryotic organism like E. Coli, which can then 
be induced to express that protein in large quantities. Recombinant proteins however
1
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are costly and time consuming, particularly if many mutant versions are required. 
The process of producing recombinant protein first requires the synthesis of 
recombinant DNA. Recombinant DNA means DNA that has been created through 
molecular cloning techniques, usually combining DNA from the protein of interest 
with other DNA sequences that are required for the host cell to replicate the DNA 
and express it to produce protein. Using enzymes that break and join DNA, the 
recombinant DNA is inserted into a cyclic DNA ring called a plasmid, and this 
plasmid is transplanted into the host bacterial cell in a process called transfection. 
The transfected bacteria are fermented and the plasmid DNA is replicated along with 
the host cell DNA, and the protein of interest is expressed.
Recombinant proteins are limited to the twenty natural amino acids. There are a large 
number of proteins that undergo enzymatic post-translational modification of the 
natural amino acids, for example glycosylation, and these modifications cannot be 
copied in recombinant cells, as the host cells do not have the enzymes required. 
There are also a number of proteins that cannot be produced by prokaryotic 
expression, either because the proteins are toxic to the host cell, or because they are 
folded incorrectly in prokaryotic cells. This insoluble protein precipitates in the cell 
to form an inclusion body that cannot be easily purified. Eukaryotic expression 
systems such as yeast cells can be used (Botstein et al. (1979)), but are significantly 
more expensive and lower yielding than prokaryotic expression.
Total chemical synthesis can provide an alternative source of protein, with the 
advantage that amino acid substitutions can easily be made with either natural or 
unnatural amino acids. Total synthesis of proteins is in its infancy compared to 
recombinant protein production, but a number of small proteins have been 
synthesised, for example the chemical synthesis of a HIV-1 protease analogue by 
thioether ligation (Englebretsen et al (1995)) and the review by Kent and Dawson 
(2000) gives the details of several proteins synthesised by chemical ligation. A 
number of other synthetic proteins are discussed in more detail in Section 1.3.
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1.1 Peptides and Proteins
Amino acids when joined together by an amide bond are called peptides; from two 
amino acids, which form a dipeptide, up to many amino acids, known as 
polypeptides or proteins. There are twenty natural amino acids, which have a general 
structure consisting of an amino and a carboxylic acid group, with each amino acid 
bearing a different chemical group on the side chain. The characteristics of the side 
chain groups can be split into either hydrophobic or polar residues, with some of the 
polar side chains also having acidic or basic properties. An amino acid chain folds to 
form a three-dimensional structure due to interactions between these amino acid side 
chains. It is this structure together with specific side chain functionalities that give a 
protein its biological activity.
It has become common practice to define any chain of less than 100 amino acids as a 
peptide, and longer chains as either polypeptides or proteins. A more accurate 
definition for a protein is an amino acid sequence determined by the order of 
nucleotide base pairs in the DNA that encodes that protein \  In practice there are 
very few proteins that contain fewer than 100 amino acids, because short peptides do 
not have enough side chain groups to interact and form a specific three-dimensional 
structure. Chemical synthesis has a size limit on the number of amino acids that can 
easily be joined together of about 100, which is why this figure is often incorrectly 
used to define the difference between peptides and proteins.
Peptide and protein sequences are, by convention, written from the N to C direction 
(Section 1.2.1). This is called the primary sequence and it gives just the order of 
amino acids within the peptide or protein, with no structural information. The folding 
of a peptide or protein sequence is called secondary structure. Secondary structure 
includes covalently bonded disulfide bridges between cysteine residues and regions 
of the protein that form loops or structural motifs called alpha helixes and beta 
sheets, which are held by non-covalent hydrogen bonds. Figure 1.1 shows the 
relationship between an individual amino acid, a peptide primary sequence and a full 
protein sequence (bovine ribonuclease A) showing simple secondary structure loops 
and disulfides, but not areas of alpha helix or beta sheet. The full three dimensional
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Structure of all the amino acids within a protein is called tertiary structure, and the 
tertiary structure of ribonuclease A, represented in a ribbon structure is shown in 
Figure 1.9
Figure 1.1: Amino Acid, Peptide and Protein (Bovine Ribonuclease A used as the 
example protein, adapted from
Peptide
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1.2 Peptide Synthesis
The synthesis of even a small peptide requires many individual chemical steps. 
Traditional solution peptide synthesis is an extremely time consuming process which 
often produces low yields of peptides. The invention of Solid Phase Peptide 
Synthesis (SPPS) by Merrifield (1963) revolutionised the synthesis of peptides, and 
now allows the routine synthesis of high yielding peptides in up to kilogram 
quantities. Solution phase synthesis is often still the technique of choice for multi­
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gram scale peptide synthesis, mainly due to the much higher cost of the reagents for 
solid phase synthesis; however, a huge amount of process development is required to 
determine a solution phase strategy for each individual peptide. Recently solid phase 
synthesis has started to be used for large scale manufacture of peptide drugs. The 
HIV fusion inhibitor T20 (Fuzeon® enfuvirtide) manufactured by Hoffmann-La 
Roche, Inc was the first peptide drug synthesised by solid phase peptide synthesis in 
multi-ton quantities. In collaboration between Trimeris and Roche, a synthesis 
strategy was developed to synthesise the peptide in three fragments by solid phase 
synthesis and then use solution phase synthesis to join the fragments together, 
producing the peptide in higher yield and purity than synthesis by solid phase 
synthesis alone (review by Bruckdorfer et al. (1994)). The increase in demand for 
Fmoc protected amino acids and the polymeric solid support required for this 
synthesis is reputed to be responsible for the dramatic worldwide drop in price for 
these reagents in the early 2000s
1.2.1 Solid Phase Peptide Synthesis
In solid phase peptide chemistry an amino acid is attached to a solid polymeric 
support through the carboxylic acid, and amino acids are sequentially added by 
forming a peptide bond between the two amino acids. The amino acid to be added is 
activated with a coupling agent, which forms an active ester of the carboxylic acid. 
This reacts with the amino acid attached to the solid support to form the amide bond. 
The technique is outlined in the diagram in Figure 1.2 and described below, but 
more information can be found in the book Solid Phase Synthesis: A Practical 
Approach, by Atherton et al. (1989). Synthesis proceeds from the C to the N 
direction while peptide sequences are written from N to C, which can be confusing to 
those outside the field. The convention of N to C which is the same direction as the 
term “amino acid” was defined before the invention of solid phase synthesis, which 
was synthetically less challenging in the C to N direction.
The peptide synthesis and cleavage from the resin occurs in a reaction vessel 
containing a frit which retains the resin, as the peptide is bound to the solid support
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Figure 1.2: Scheme for Solid Phase Peptide Synthesis
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during synthesis. Large excesses of the amino acids with respect to the growing 
peptide chain are used to force the reactions to completion, and the excess is simply 
washed away from the resin after the reaction. The amino group has a temporary 
protection, to prevent more than one amino acid reacting per peptide chain, which is 
removed after addition of that amino acid to the growing peptide chain, ready for 
addition of the next amino acid. The two most common amine protecting groups 
used are tertiary-butoxycarbonyl (t-Boc or Boc) and 9 fluorenyl methoxycarbonyl 
(Fmoc). The amino acid side chain reactive groups are protected with chemical 
groups to prevent them participating in the coupling reaction, that are stable to the 
conditions used for removing the amine protecting group, but can be removed at the 
end of the synthesis. The side chain protecting groups are usually removed using the 
same chemical conditions as cleavage of the peptide from the solid support. The use 
of a set of protecting groups on the amino group and the side chain of an amino acid, 
which have different conditions of removal, is known as orthogonal protection 
(Merrifield et al (1977)). Orthogonal protection means that under the deprotection 
conditions of one protecting group the other is stable and vice versa. An example of 
this is the Fmoc and Boc amine protecting groups which can be used for example on 
the alpha and epsilon amines of lysine during peptide synthesis. The Fmoc group is 
removed under basic conditions during chain extension, and the Boc group is 
removed under acidic conditions to deprotect the side chain. At the end of synthesis 
the peptide is cleaved from the resin which releases the peptide from the solid 
support, allowing the peptide to be filtered and collected while the resin is retained 
on the frit in the reaction vessel. The side chain protecting groups are usually 
removed using the same chemical conditions as cleavage of the peptide from the 
solid support, but if protected peptides are required then a solid support can be used 
that allows cleavage without deprotection of the side chains.
Synthesis by Fmoc chemistry has become the most common strategy used, due to the 
requirements in Boc chemistry for hydrogen fluoride (HF) to cleave the peptide from 
the solid support. Synthesis by Boc chemistry often produces higher quality crude 
peptides, attributed to use of trifluoroacetic acid for deprotection of the Boc group 
breaking up chain aggregation, but the safety considerations with using HF have 
meant that most solid phase synthesis is now performed using Fmoc chemistry.
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There is a limit to the size of peptides that can be synthesised on the solid support, 
due to formation of secondary structure, and aggregation of the peptide, making it 
difficult for the incoming amino acid to access the end of the growing peptide chain. 
The number of amino acids that can be joined is dependent on the peptide sequence, 
but it is difficult to synthesise any peptide sequence longer than approximately 100 
amino acids. Even if each individual reaction is very high yielding, after 100 reaction 
cycles the cumulative effect of small impurities makes the final protein difficult to 
purify.
1.3 Synthesis of Proteins
Although solid phase peptide synthesis has physical limits on the size of peptides that 
can be made, this has not prevented the total chemical synthesis of much larger 
peptides and proteins. The solution has been to join together peptide fragments 
synthesised on the solid phase, a process that is called peptide ligation. Many 
different ligation techniques have been successfully employed in the production of 
peptides that cannot be synthesised as a single peptide chain by SPPS. The ligation 
methods can be split into two broad classes, fragment condensation and 
chemoselective ligation.
1.3.1 Fragment Condensation
Fragment condensation is used to join a side chain protected peptide fragment to 
another side chain protected fragment, either with both fragments in solution or with 
one fragment still attached to the solid phase. Peptide fragments are usually 
synthesised on an acid labile solid support, such as 2-chlorotriryl chloride resin, 
allowing cleavage of the peptide from the solid support, but leaving the side chain 
protections in place. A normal coupling reaction can be employed for the 
condensation of the two fragments as the side chain functionalities are protected 
from participation. Typically the reaction requires long coupling times, in part due to 
the low solubility of protected peptide fragments, which means large excesses of the
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carboxyl-containing peptide are required. This often leads to racémisation at the 
coupling site. Racémisation can be avoided by ensuring that the site for fragment 
condensation contains a glycine, proline, or a pseudoproline (a protected dimer 
containing serine or threonine with a structure similar to proline developed by Mutter 
et al (1995)) as the carboxyl-containing residue. Glycine is an achiral residue, and 
proline or pseudoproline does not undergo épimérisation during the coupling 
reaction, allowing racemisation-free fragment condensation.
Protected peptide fragments cannot easily be purified due to difficulty in solubilising 
the peptides, so impurities in both fragments will be present in the final product, 
which is therefore often difficult to purify to high purity. For this reason fragment 
condensation is most useful for the synthesis of short peptides of 20-40 amino acids 
that have proven difficult to synthesise as a single peptide, using fragments of about 
10-20 amino acids. Short peptides can be made more easily to high purity so it is not 
so important that the fragments are not easily purifiable. A thorough review of 
peptide synthesis via fragment condensation can be found in Methods in Molecular 
Biology, Vol 35 Peptide Synthesis Protocols (Nyfeler, R. (1994)).
1.3.2 Chemoselective Ligation
The solubility and purification problems associated with protected fragments as seen 
with fragment condensation have been avoided by using unprotected peptides, which 
are more readily soluble in aqueous solution. Unprotected peptide fragments can be 
purified by high performance liquid chromatography (HPLC) and analysed by mass 
spectrometry in the same way as any other synthetic peptide, so purification of the 
final protein simply requires separation of the product from any unreacted peptide 
fragments, to yield a high purity protein. The use of unprotected fragments requires a 
specific reaction between the N-terminus of one fragment and the C-terminus of the 
other, without unwanted side reactions from the participation of the unprotected side 
chain functional groups. This reaction that produces the ligation of the peptides is 
called chemoselective ligation and it can be any chemical reaction that achieves the 
specific ligation of the two peptides. Chemoselective ligation reactions can be split
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into two types, non-amide ligation and native chemical ligation. Non-amide ligation 
uses mutually reactive groups on the peptide fragments, which once ligated form an 
unnatural or non-amide linkage (Section 1.3.2.1). Native chemical ligation forms a 
natural peptide bond at the ligation site, and is a two-stage reaction where first a non­
amide ligation occurs, followed by an intramolecular transfer reaction to form the 
natural peptide bond (Section 1.3.2.2).
An important feature of any ligation technique is the ease in which the groups 
required for ligation can be incorporated into the synthesis of the peptide fragments. 
Ideally the C-terminal group is added by reacting a linker or small molecule to a 
commercially available resin at the start of synthesis, and then normal SPPS can be 
used to construct the peptide fragment. For the fragment containing the N-terminal 
functionality, the specific functional group is coupled to the peptide on the solid 
phase at the end of synthesis, before cleavage from the resin.
1.3.2.1 Non-Amide Ligation
There have been many different chemical reactions used for non-amide ligation, and 
they have been used for a number of different applications. These applications 
include the joining of two peptide segments (Liu et al (1994)), the formation of 
peptide dendrimers, where a peptide is ligated multiple times onto a template 
molecule as demonstrated by Tuchscherer (1993) and Rose (1994), and as a disulfide 
bridge replacement (Wahl et al (1996)). One common approach uses an aldehyde, 
which at acidic pH is unreactive towards any natural amino acid side chain, reacting 
with a nucleophile. Nucleophiles of choice have been either an N-terminal cysteine 
residue, which forms a thiazolidine ring on reaction with an aldehyde, or a hydrazine 
or amino-oxy group, which produces hydrazone or oxime bonds (Figure 1.3). The 
aldehyde can be generated from periodate oxidation of a 2 amino alcohol or 1, 2-diol. 
The ligation reaction is carried out in acidic aqueous buffer (usually about pH 5.5) at 
room temperature (Rose (1994)).
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Figure 1.3: Non-native chemoselective ligation of a C-terminal aldehyde to an N- 
terminal hydrazine, amino-oxy or cysteine functionality (adapted from Tam et al 
(1995))
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c) Cysteine ligation
An example of thiazolidine ligation was used by Zhang et al (1998) to ligate an 
active peptide fragment to a membrane permeable sequence (MPS) so that the 
functional peptide could be imported into cells (Figure 1.4). A C-terminal aldehyde 
was created in one of two ways. Either a serine was added to the side chain of a C- 
terminal lysine residue, or 3-amino 1-2-propanediol was attached to chlorotrityl 
resin, and then the MPS was synthesised on this functionalised resin. Periodate 
oxidation of the cleaved peptide generated an aldehyde at the C-terminus. Ligation in 
aqueous buffer to the functional peptide fragment which contained an N-terminal 
cysteine produced a cell-permeable bioactive peptide, which could be used in 
biological assays immediately after ligation, without product isolation or purification.
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The presence of a non-amide bond did not affect the peptide’s cell uptake or function 
when compared to peptide synthesised as a single chain.
Figure 1.4: Thiazolidine ligation of a membrane permeable sequence to a functional 
domain (Zhang et al (1998))
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MPS: Membrane permeable sequence 
FD: Functional domain
Oxime ligation has been a popular choice in the assembly of peptide dendrimers. 
Tuchscherer (1993) used a template with four aldehyde groups to ligate four identical 
peptide fragments each containing an N-terminal hydroxylamine functionality to 
form an oxime bond. Similarly Rose (1994) used the oxime bond to synthesise a 
20kD peptide dendrimer, by ligating six identical peptides with aminooxyacetic acid 
at the C-terminus to a template molecule containing six aldehyde groups. An oxime 
bond has also been used to replace the disulfide in Oxytocin, a pituitary hormone, by 
Wahl et al (1996) by replacing the two cysteine residues with a serine, as an 
aldehyde precursor, and a side chain hydroxylamine group.
Most of the reagents for these non-native ligation techniques are now commercially 
available with the appropriate protecting groups for use in solid phase peptide 
synthesis. The hydrazine group can be introduced as tri-Boc-hydrazinoacetic acid, 
and the hydroxylamine group as bis-Boc-amino-oxyacetic acid, and both groups can 
be coupled onto the N-terminus of a peptide at the end of synthesis. Fmoc-3-
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amino, 1 -2-propanediol functionalised chlorotrityl resin is also available, enabling the 
facile incorporation of the groups required for ligation into solid phase synthesis. 
Other reagents are available which contain the groups for non-native ligation on the 
side chains of modified amino acids, allowing the formation of branched or cyclic 
ligated products (several commercially available reagents are detailed in Chapter 3).
The inclusion of a non-natural bond in a protein would be expected to have some 
effect on the structure of that protein. The three-dimensional structure adopted by a 
protein is formed through interactions between amino acid side chain groups and also 
through interactions with the backbone amide groups. When a non-amide linkage is 
inserted, this not only replaces the amide bond with an alternative structure, but often 
one or both of the amino acid side chains at the ligation site are either structurally 
altered or absent (Chapter 3, Figure 3.1). In order to minimise the effect that this 
non-amide bond may have, the ligation site must be chosen carefully. An obvious 
site for non-native ligation is at a glycine-glycine bond, due to the absence of side 
chain groups. A thioether bond was used by Englebretsen et al (1995) as a glycine- 
glycine bond replacement to synthesise enzymatically active HIV-1 protease. The 
bond was formed between an N-terminal bromoacetylated fragment and a C-terminal 
thiol. The protein had very similar activity and substrate specificity to the native 
protein, which suggests that a non-native bond has a minimal effect on protein 
structure, if the ligation sites are carefully chosen. However, there have been no 
investigations into the precise conformations of these non-amide linkages or the 
structures of the ligated proteins, which is one of the objectives of this study.
1.3.2.2 Native Chemical Ligation
The one major disadvantage to non-native ligation is the presence of a non-amide 
bond within the protein product. These non-amide bonds not only have different 
structures to the natural amide bond but they are also less stable at high or low pH. A 
more desirable chemoselective ligation is one that forms an amide bond at the site of 
ligation.
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In an extension to thiazolidine ligation, Liu and Tam (1994) demonstrated that if a 
glyoxylaldehyde is used instead of a simple aldehyde, then ligation to form a 
thiazolidine ring is followed by an acyl transfer reaction to give a thiaproline bond 
(Figure 1.5). This thiaproline linkage is an amide bond so has similar properties to a 
proline peptide bond, unlike the thiazolidine ring formed in non-amide ligation, 
which is unstable at high and low pH. Replacement of Pro39 in HIV-1 protease with 
a thiaproline bond did not affect the folding, conformation or activity of the protein 
Liu and Tam (1996).
Figure 1.5: Scheme showing thiaproline ligation via a thiazolidine intermediate 
(adapted from Liu and Tam (1994))
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O
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Although the thiaproline bond is an amide bond it does not have the same structure 
as the natural peptide bond. A chemoselective ligation methodology has been 
developed that does create a native peptide bond at the ligation site, given the term 
native chemical ligation (NCL).
NCL, like the thiaproline ligation, is a two-stage reaction, first forming a 
chemoselective linkage, which then undergoes a rearrangement reaction to form the 
native peptide bond. It is based on the reaction and acyl rearrangement of a thioester 
with an amino thiol, first reported by Wieland (1953). The use of this reaction in the 
ligation of peptides was developed by the group directed by Kent (Dawson et al. 
(1994)) and it was Kent who gave the reaction the name native chemical ligation. A 
peptide containing a C-terminal thioester and another peptide containing an N- 
terminal cysteine are reacted in aqueous buffer at pH7. Firstly a thio- 
transesterification reaction occurs by nucleophilic substitution of the thiol in the N- 
terminal cysteine for the thiol in the thioester. This forms an intermediate that 
spontaneously rearranges by S to N acyl shift to form a natural peptide bond at the 
site of ligation (Figure 1.6).
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Figure 1.6: Native chemical ligation (adapted from Kent and Dawson ((2000))
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If the peptides for ligation contain other cysteines in addition to the N-terminal 
cysteine, the thio-transesterification reaction can occur with any of the cysteine thiols 
as a reversible reaction, but it is only when this occurs with the N-terminal cysteine 
that the amine is positioned for the spontaneous S to N acyl shift to form the amide 
bond. The stability of the amide bond is such that the acyl shift reaction can be 
considered irreversible.
Peptides containing a C-terminal thioester can be synthesised directly using Boc 
chemistry, as the thioester is stable to the reaction conditionsused in Boc chemistry. 
Initial synthesis of C-terminal thioester peptides by Boc chemistry (Hacking et al. 
(1999)) utilised a mercapto-carboxylic acid at the C-terminus, attached to the solid 
support through the carboxyl. Cleavage of the peptide from the solid support would 
yield the crude thioester peptide which after purification can be used in the NCL 
reaction. However, the use of Boc chemistry has become disfavoured due to the 
requirement for HF cleavage. The synthesis of C-terminal thioesters by Fmoc
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chemistry is more challenging. This is mainly because the thioester bond is not stable 
to the conditions of amino acid deprotection used in each cycle of Fmoc peptide 
synthesis. Therefore, in Fmoc chemistry, the thioester must be formed after synthesis 
of the peptide sequence. One method is to react the C-terminus of a fully side chain 
and N-terminal protected peptide with a thiol compound, followed by removal of 
protecting groups. This causes racémisation with any amino acid other than glycine 
so is not an ideal method. Alternatively the Kenner safety catch linker (Kenner et al. 
(1971)) has been used by Ingenito et al. (1999) to release the C-terminal thioester 
using a thiol as the nucleophile for peptide cleavage. None of the current methods of 
synthesis of thioesters by Fmoc chemistry are high yielding and so synthesis of the 
thioester containing fragment continues to be a challenge, and a serious limitation of 
the technique.
Another major limitation of NCL is the requirement for a cysteine residue at the site 
of ligation. More recent research has focused on adaptations of the NCL reaction to 
remove this requirement. A simple modification has been the use of homocysteine in 
place of cysteine (Tam (1998)), which can be methylated after ligation to form 
methionine. In a similar way cysteine has been de-sulfurised to alanine by Yan and 
Dawson (2001). The most promising development was the use of a removable 
auxiliary l-phenyl-2-mercaptoethyl by Low et al. (2001) which is removed from the 
peptide bond after ligation. These adaptations have allowed synthesis of ligated 
peptides and proteins without a cysteine at the ligation site. However, the yields of 
these reactions are considerably lower than for standard NCL, and so these methods 
have not been adopted as routine methods of synthesis.
An alternative native chemical ligation technique that does not require a cysteine 
residue at the ligation site is known as Staudinger ligation, developed by Nilsson et 
al. (2000). It utilises a reaction by Staudinger (1919) where an azide and a trialkyl 
phosphine react to form an iminophosphorane intermediate, which then rearranges to 
form an amidophosphonium salt. Hydrolysis yields an amine and a phosphine oxide 
(Figure 1.7).
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Figure 1.7: Putative scheme for Staudinger ligation (adapted from Nilsson et al 
(2000))
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Staudinger ligation has been used for ligation of a number of dipeptides with C- 
terminal glycine phosphinethioester to longer peptide fragments without 
racémisation (Nilsson et al (2000), Soellner et al (2002)), but the Staudinger 
reaction has not yet been successfully extended to the ligation of longer peptide 
fragments. In the recent review by Schilling et al (2011), there are numerous 
examples where Staudinger ligation has been adopted as a successful method of 
bioconjugation, used for labelling of biomolecules with biotin and fluorescent dyes 
as an alternative to other bioconjugation methods such as Michael addition of a
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maleimide to a thiol. Research regarding Staudinger ligation for peptide to peptide 
ligation has focused on extending the method to other amino acids than glycine as 
the C-terminal phosphinethioester, and Lue et al (2004) concluded that although 
ligation using glycine and alanine C-terminal phosphinethioesters is possible, that 
valine C-terminal phosphinethioester is not possible. This limitation of the technique 
together with presumed problems in extending the ligation to longer peptides mean 
that this method of ligation has not been a successful replacement for NCL.
The limitations of NCL requiring a cysteine at the ligation site and difficulties in 
synthesising thioester peptides in high yields by Fmoc chemistry have meant that 
although NCL is a more desirable ligation, from the perspective that the ligated 
product has a fully stable natural peptide bond, non-amide ligation is a serious 
alternative, with the major advantage that there are no restrictions on the positions of 
ligation sites. Of course consideration needs to be made of the effect of a non amide 
bond, which is one of the aims of this investigation.
1.3.3 Orthogonal and Sequential Ligation for Joining More Than
Two Peptide Fragments
Chemoselective ligation can be used to join two peptide segments together, enabling 
the synthesis of longer peptides and proteins than can be synthesised by stepwise 
SPPS in a single chain. If the chemical synthesis of much larger proteins is to be 
realised, then several fragments must be joined together, as the size of individual 
fragments is limited to the length of a peptide that can be synthesised by SPPS.
Orthogonal ligation describes where two mutually exclusive ligation techniques are 
used, allowing three peptide fragments to be joined together, for example a non­
native ligation followed by native chemical ligation. An advantage of orthogonal 
ligation is that because the two ligation techniques use different chemistries, one 
ligation technique can be used followed by the other with no alterations to the 
chemistries of the reactive groups. In a proof of principle experiment Nilsson et al 
(2003) ligated the dipeptide ribonuclease A 110-111 to RNase A 112-124 via
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Staudinger ligation. This was then ligated to ribonuclease A 1-109 by native 
chemical ligation, to produce enzymatically active ribonuclease, with natural amide 
bonds at the sites of ligation, as both methods of ligation generate natural peptide 
bonds.
An alternative to orthogonal ligation techniques is sequential ligation, where the 
same ligation method is used to join several peptide fragments. This is more 
complicated than orthogonal ligation as a temporary protection is required to mask 
one of the chemoselective groups during the first ligation, which is then removed to 
allow ligation of a third peptide fragment. Depending on the ligation strategy used, 
different temporary protecting groups have been developed.
Sequential NCL was used by Hackeng et ah (1999) to join four peptide fragments 
together to create the 124 amino acid human secretory phospholipase A2 (hsPLAi). 
The N-terminal cysteines of peptide fragments 2 and 3 were temporarily protected 
with 2-(methylsulfonyl) ethyl carbonate (Msc) (Balvert-Geers, et al. (1975)). After 
ligation of peptide fragments 4 and 3, the Msc group was removed by a five-minute 
treatment at pH 13, unmasking the cysteine residue ready for ligation to peptide 2. 
The cycle of deprotection and ligation was repeated to ligate peptide fragment 1, 
yielding synthetic hsPLAi that was indistinguishable from recombinant protein.
A combination of both non-amide ligation, and native chemical ligation was used by 
Muir et al. (1997) to assemble four peptide fragments. Two peptides, one bearing a 
C-terminal aldehyde and the other a C-terminal hydroxylamine group, were ligated 
to form an oxime bond. Each peptide contained an N-terminal cysteine, which were 
orthogonally protected with either Msc or S-5-thio-2-nitrobenzoic acid (SNB). After 
oxime ligation the SNB group was removed with tris(2-carboxyethyl) phosphine 
(TCEP), and a peptide thioester was ligated to this by native chemical ligation. The 
Msc group was then removed in high pH from the other N-terminal cysteine, which 
was then ligated to a second thioester-bearing peptide, to yield the final ligated 
product.
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Sequential non-amide ligation has been used to ligate three peptide fragments, to 
create a peptide based on the C-terminus of a cytokine that had proven problematic 
to synthesise as a single chain or by fragment condensation (Broadbridge et al 
(2001)). The Fmoc-3-amino-l-2-propanediol (glycine diol) method of creating C- 
terminal aldehydes was adapted by synthesising diols of other amino acids. This 
allows a chemoselective ligated peptide to more closely mimic the structure of a 
native peptide, by including the side chain of the amino acid close to the ligation site. 
The diol, which is a masked aldehyde, was used as the temporary protection during 
the ligation reactions. This work is reviewed in more detail in Chapter 2 Section 
2.2. A significant limitation of the diol is, with the exception of Fmoc glycine diol, 
the low level of substitution achieved with chlorotrityl resin. A 1, 2-amino alcohol is 
an alternative masked aldehyde to the 1, 2-diol, and the amino functionality is 
significantly more reactive towards chlorotrityl resin than the alcohol. An objective 
of this study was the development of a synthetic route for the preparation of 1, 2- 
amino alcohol derivatives of Fmoc protected amino acids, and the use of these 
derivatives in the preparation of peptides containing C-terminal aldehydes for use in 
non-amide chemoselective ligation.
1.4 Bovine Pancreatic Ribonuciease A
Bovine pancreatic ribonuclease A (RNase A) was chosen as an example for the total 
synthesis of a protein using sequential chemoselective (non-amide) ligation. It is a 
pancreatic enzyme that catalyses the hydrolysis of ribonucleic acid (RNA), and 
consists of a single peptide chain of 124 amino acids with four disulfide bridges 
(Figure 1.8). RNase A is the unmodified form of ribonuclease produced in the 
pancreas, where the “A” is used to distinguish the protein from RNase B, C and D, 
which are different glycosylated forms of ribonuclease, also produced by the 
pancreas. Ribonuclease A, mainly due to its small size and ease of availability, is 
probably the most studied and the best characterised protein. Between 1960 and 1963 
the work of Hirs, Spackman and Smyth (Hirs (1960) Hirs et al (1960) Spackman et 
al (1960) Smyth et al (1962) and Smyth et al (1963)) lead to the determination of 
the primary sequence of ribonuclease, the first protein to have been sequenced. It was
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also the first whole protein to be synthesised by stepwise solid phase peptide 
synthesis by Gutte and Merrifield (1971) using Boc chemistry.
Figure 1.8: Structure of Bovine Pancreatic Ribonuclease A ^
[65-72]
[40-95]
[26-84]
1.4.1 Catalytic Mechanism of Ribonuclease
RNase A catalyses the hydrolysis of RNA by cleaving the phosphodiester backbone 
on the 3’ side of uracil and cytosine. The catalysis involves two histidine residues, 
His 12 and His 119, as proton donors and acceptors (Findlay et al. (1961).
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Figure 1.19: Mechanism of Ribunuclease A Catalysis adapted from Schultz et al 
(1998)
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The catalysis is a two step reaction, firstly a fast transphosphorylation reaction 
forming a pentavalent phorphorus intermediate, then a separate slower hydrolysis 
reaction (Figure 1.19). The use of various single site mutants have been used to 
elucidate the mechanism and active site residues involved in the catalytic 
mechanism. For example, replacement of either Hisl2 or H isll9  with Ala by 
Thompson et al (1994) produced little change in the structure of ribonuclease, but 
had a dramatic decrease in the catalytic activity of the enzyme.
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1.4.2 Other Important Active Site Residues
Aspl21 lies in close proximity to H isll9  and was shown by Sehultz et al (1998) to 
form a catalytic dyad with Hisl 19 in a similar manner to the catalytic triad of serine 
proteases, aligning Hisl 19 with the protonated nitrogen in the correct position for 
catalysis. Replacement of Aspl21 with Asn or Ala by site directed mutagenesis did 
not affeet the crystal structure of ribonuclease but did have a 10-100 fold decrease in 
the catalysis of cleavage of poly-(cytidylic acid), a synthetic ribonuclease substrate.
Phel20 has an interesting role in catalysis. Mutagenesis of this residue to a number 
of other amino acids such as Gly, Ala and Trp had very little effect on rates of 
catalysis, despite its close proximity to the active site (Tanimizu et al fl998) and 
Chatani et al (2001)). However, a mutant containing an ester bond as a non-amide 
bond replacement was reported by Raines (2004) to cause a 1 x 10"^  deerease in 
catalytic activity suggesting that the backbone amide from Phel20 has an important 
role in ribonuclease catalysis.
Lys41 is another residue known to be important at the active site of ribunuclease. 
Work by Murdock et al (1966) using chemical modification of lysine had suggested 
that this residue was important, and mutagenesis experiments performed by 
Trautwein et al 1991, replacing Lys with Arg confirmed this, showing with 
hydrolysis of eytidine 2 ',3 '-cyclic phosphate that the mutant had only 2% of the 
native ribonuclease activity.
A number of other residues, although not at the active site of the enzyme, have been 
found through a series of mutagenesis experiments to be essential for catalytic 
activity. Tarragona-Fiol et al (1993) confirmed the importance of residues Asn71 
and G lulll, through site-directed mutagenesis experiments replacing with Ala 
resulting in a 40-fold reduction in the catalytic activity for the hydrolysis of 
dinucleotides. The review by Nogues et al (1995) details these and other important 
non-active site residues.
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1.4.3 Anfinsen’s Folding Experiments
Ribonuclease A was the enzyme used in Anfinsen’s famous protein refolding 
experiments (Anfinsen et al (1960) and Anfinsen et al (1961)). He showed that after 
protein denaturing and reduction of the disulfides with urea and (3-mercaptoethanol, 
the denatured protein, which lacked any enzymatic activity, would slowly gain full 
catalytic activity after dialysis to remove the urea and p-mercaptoethanol. Denatured 
protein, reoxidized in the presence of urea, would only gain 1% of its full eatalytic 
activity once the urea was removed. This showed that under denaturing conditions 
the four disulfides form randomly, with only one combination having enzymatic 
activity. Addition of a small quantity of P-mercaptoethanol catalysed the 
rearrangement of the disulfides, with full catalytic activity restored after about 10 
hours.
One reason RNase A was chosen for this study is its spontaneous oxidation to form 
the active conformation. If the unnatural bonds incorporated into ribonuclease do not 
significantly affect its ability to fold, then the correct disulfides should form under 
oxidizing conditions to produce active protein.
1.5 Molecular Modelling of Proteins
Molecular dynamics (MD) is the term used to describe the modelling of molecules 
by computer simulation over time. These simulations complement the structural 
experimental data obtained from NMR and X-ray crystal structures, and have aided 
the development of a greater understanding of molecular structure, particularly of 
large biomolecules.
The first molecular dynamics simulation of a protein was performed by MeCammon 
et al (1977) on the bovine pancreatic trypsin inhibitor (BPTI), which is a small 
globular protein whose crystal structure was first solved by Deisenhofer (1975). The 
results of this simulation and other similar studies revealed that proteins do not have
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a rigid structure, but instead are a dynamic system of interconnected atoms that can 
exhibit complex movement.
MD simulations of proteins have been used in a number of different applications. 
Simulations can mimic laboratory experimental conditions, generating data for the 
movement of a protein in solution over a period of time. This can be used to study a 
protein’s structure, or used to predict experimental properties, for example 
thermodynamic properties of a system. The study of processes such as ligand 
docking and binding to a protein have been studied using a proeess called simulated 
annealing, which simulates a decrease in temperature from a high temperature to a 
low temperature, reducing the kinetic energy of the system and resulting in a static 
structure. This can be used to compare to known crystal structures of bound ligands 
and to allow predictions to be made for other ligand binding. MD can be used for the 
limited study of dynamic processes such as protein folding, however with current 
algorithms and computing capabilities it is only just possible to simulate compete 
folding of some simple proteins. Recently, increases in the length of simulation time 
due to increased processing speeds have allowed dynamic studies towards ms 
timescales. Piana et al (2011) designed a variant of a fast-folding p-sheet containing 
protein and have modelled reversible folding and unfolding of the protein over a 
600ps simulation, starting from an extended confirmation. Their results closely 
matched experimental folding times, and allowed them to make accurate predictions 
about the folding times of a triple amino acid mutant of their protein.
1.5.1 Molecular Dynamics Simulations of RNase A
MD simulations of RNase A have been performed by a number of different 
investigators, in studies of RNase structure, disulfide formation, protein folding and 
enzyme catalysis. Santoro et al, (1993) used MD simulations to generate eight 
different structures of RNase A. They compared the root mean square deviation 
(RMSD) of these eight structures to an X-ray crystal structure of the protein and 
found close structural similarity.
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A dynamics study by Merkley et al (2008) looked at the change in conformation of 
RNase A at different temperatures by performing six simulations of RNase A over a 
range of temperatures from 278 K up to 340 K. They used RMSD of the Ca atoms to 
allow comparison of the structures as a function of temperature. There is thermal 
transition known to occur in RNase A at approximately 320 K, and the results of 
their dynamics simulations showed the presence of a conformational transition 
between 310 and 320 K.
An investigation by Formoso et al (2010) used molecular dynamics simulations to 
study the dynamics, relaxation and solvation of RNase A at different stages of the 
transestérification and cleavage reaction that occurs during enzyme catalysis. The 
MD simulations were run on nanosecond timescales, and their results have provided 
interesting insight into the catalysis mechanism. Their results suggest that Lys41 
rather than His 12 could be the acid/base catalyst of the transphosphorylation and 
hydrolysis reactions, which presents further scope for research into the mechanism of 
RNase A catalysis. This recent research demonstrates a role that computer 
simulations are taking in developing our understanding of protein structure, and 
enzyme mechanisms.
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1.6 Aim and Objectives
The aim of this study was to identify and develop a methodology for synthesis and 
sequential chemoselective ligation of peptide fragments, facilitating the total 
chemical synthesis of peptides and proteins that cannot easily be synthesised as 
single peptides by solid phase peptide chemistry.
Ribonuclease A was chosen as the example protein for the following reasons.
1. It is a small protein which formed the focus of early research into the 
structure/function relationship of proteins, and therefore has been well 
characterised.
2. The native protein has full catalytic activity after denaturing and refolding.
3. At 124 amino acids, it is beyond the length that a peptide can reliably be 
synthesised by solid phase peptide synthesis in a single chain.
Specific objectives were to:
1. Identify and develop a ligation strategy that enables the synthesis of peptide 
fragments by solid phase peptide synthesis, in high yield for ligation
2. optimise the conditions for resin loading, fragment synthesis and ligation 
reactions,
3. synthesise biologically active Ribonuclease A by sequential chemoselective 
ligation, and
4. use molecular modelling to model the chemoselective bonds and predict the 
implications of these non-amide bonds to protein structure and function.
If sequential non-amide ligation is going to become a viable technique for the 
assembly of large synthetic proteins, development of a methodology for sequential 
ligation and detailed investigations into the conformation of these ligation bonds and 
their effect on protein structure and activity are necessary.
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2.0 Introduction
Chemoselective ligation by an oxime or hydrazide bond has a requirement for an 
aldehyde at the N or C terminus of one of the peptides for ligation, and initial studies 
for this thesis were directed towards reactions between peptides containing a C- 
terminal aldehyde and an N-terminal amino-oxy or hydrazide. This work was an 
extension of the studies initiated by Sharma et al. (1979) and improved by 
Broadbridge (1998) which used C-terminal 1, 2-diols as precursors for the synthesis 
of C-terminal peptide aldehydes. These C-terminal diols were used as masked 
aldehydes in sequential chemoselective ligation (Broadbridge et al. (2001)), but 
limitations with the method lead to the proposal for this thesis of using a 1, 2-amino 
alcohol in place of a 1, 2-diol.
An amino acid derivative bearing either a 1,2-diol or 1, 2-amino aleohol functionality 
in place of the carboxylic acid is a desirable building block for the synthesis of C- 
terminal peptide aldehydes, as oxidation with sodium metaperiodate produces the 
aldehyde in high yield (Clamp et al. (1965)). However the only commercially 
available amino acid derivatives bearing either the 1, 2-diol or 1, 2-amino alcohol 
functionality are derivatives of the simple amino acid glycine. Therefore derivatives 
of any other amino acid requires a method of synthesis.
This chapter summarises the historical synthesis of 1, 2-diol derivatives of amino 
acids other than glycine by Sharma et al. (1979) and improvements to the synthesis 
of these diols that were made by Broadbridge (1998) and Broadbridge et al. (2001). 
The chapter then focuses on studies into the suitability of 1, 2-amino alcohols as 
replacement for 1, 2-diols, and development of a synthetic route to 1, 2-amino 
alcohol derivatives of amino acids. Finally this chapter details the use of these 
derivatives in the synthesis of peptides containing C-terminal 1, 2-amino alcohols.
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and oxidation of the amino alcohol to produce C-terminal peptide aldehydes, with the 
aim of preparing several peptide fragments each containing a C-terminal 1, 2-amino 
alcohol as a masked aldehyde for use in sequential chemoselective ligation.
2.1 Synthesis of C-terminai Peptide Aldehydes
The generation of long peptide fragments bearing a C-terminal aldehyde can be 
problematic. Methods currently used include the reduction of a peptide-Weinreb 
amide (Fehrentz et al. (1995), Figure 2.1), (the Weinreb amide was first described 
by Nahm and Weinreb (1981)) or the attachment of an Fmoc amino aldehyde to a 
threonine resin via an oxazolidine ring (Ede et al (2000)), followed by standard 
Fmoc peptide synthesis, and a two stage deprotection of amino acid side chains and 
cleavage from the solid support. Both of these methods have only been applicable to 
the formation of short peptide aldehydes.
Figure 2.1 Reduction of Weinreb Amide
R  HN
N
Hz+ Cl
R  HN
LiAlH,
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With the Weinreb amide resin the number of equivalents of reductant required to 
cleave the peptide aldehyde from the solid support increases with every amide bond, 
which makes this method unsuitable for the synthesis of long peptide aldehydes due 
to increasing amounts of side reactions when large excesses of reductant are used
Using the threonine oxazolidine linker, acylation of the oxazolidine ring resin during 
peptide synthesis often resulted in very low yields for this method, even for short 
peptide sequences, leading to protection of the oxazolidine nitrogen with Boc to 
prevent acylation (Al-Gharabli et ah (2006)). Resins preloaded with Fmoc amino 
aldehydes and Boc protected on the oxazolidine ring are now available for some 
amino acids (amino aldehydes attached to H-Thr-Gly-NovaSyn® TG resin, 
Novabiochem) but significant side reactions during the two stage deprotection and 
cleavage is reportedly responsible for low yields of peptides (Tanaka et al (2007)).
Recent improvements to the oxazolidine linker by Tanaka et al (2007) are reported 
to have improved yields of a model lOmer peptide from 17% to 45% and to allow 
synthesis of a 33mer with a C-terminal leucine aldehyde at a yield of 19% which 
could not be synthesised on other oxazolidine linkers. This is the first example of 
solid phase synthesis of a long C-terminal peptide aldehyde with a residue other than 
glycine at the C-terminus. However this method produces aldehyde peptides directly 
by cleavage from the resin making it inappropriate for sequential chemoselective 
ligation, which requires masked aldehydes on all but one of the peptide fragments.
2.1.1 The 1,2-diol as a Masked Aldehyde
A 1, 2-diol or 1, 2-amino alcohol is a convenient aldehyde precursor (Figure 2.2) , as 
oxidation with sodium periodate proceeds cleanly to the aldehyde under mild 
conditions (Clamp et al (1965)). Historically this reaction has been used for the 
generation of either N or C-terminal peptide aldehydes by the periodate oxidation of 
an N-terminal serine (Geoghegan et al. (1992)) or C-terminal 1-amino-2, 3-
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propanediol (Zhang et al. (1998)). 1-amino-2, 3-propanediol as an aldehyde 
precursor can conveniently be incorporated into the peptide sequence at the start of 
solid phase peptide synthesis, but inserts a spacer between the peptide and the 
aldehyde. The synthesis of diol derivatives of other amino acids allows the synthesis 
of C-terminal peptide aldehydes bearing the amino acid side chain at the C-terminus.
Figure 2.2 Oxidation of a diol or amino alcohol to aldehyde
Amino alcohol
2.2 History of Diols and Improvements
The original synthesis of amino acid diols from protected amino acids was published 
by Sharma et al (1979). This method converted a Boc protected amino acid to the 
diol via acid decomposition of a diazomethyl ketone to a trifluoroacetoxy ketone and 
reduction with borohydride to the diol. The main limitation with this synthesis was 
production of a cyclic impurity on treatment with trifluoroacetic acid, which 
accounted for a loss of over half the yield of product. It was suggested that this may
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have been due to involvement of the Boc protected amine, and so this method was 
improved upon by Broadbridge (1998), by changing the amino protection to phthalyl 
which fully protected the amine, and using aqueous perchloric acid rather than 
trifluoroacetic acid for the acid decomposition to form an a-hydroxyketone which on 
reduction with borohydride resulted in a much improved yield of the amino 1, 2-diol 
((Broadbridge (1998) (Figure 2.3)).
Figure 2.3 Synthesis of amino acid diols from phthalyl protected amino acids 
(adapted from Broadbridge (1998))
Ethyl chioroformate 
Triethylamine
Sodium Borohydride 
HO
Perchloric acid
Diazomethane
Acetic acld/Water
Further improvements were made by Broadbridge and Winsor et al. (2001) to the 
diol synthesis. Instead of phthalyl protection and acid decomposition of the 
diazoketone with perchloric acid, the Fmoc protected amino acid was converted to 
the bromomethyl ketone via HBr treatment of the diazoketone. This was reacted with
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sodium acetate, and then sodium borohydride to produce the Fmoc protected diol 
(Figure 2.4). This route allowed synthesis of diols directly from Fmoc protected 
amino acids, with their corresponding side chain protections for Fmoc chemistry 
(Broadbridge et al (2001).
Figure 2.4: Synthesis of diols directly from Fmoc protected amino acids, 
Broadbridge et al. (2001)
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2 .2.1 Use of C-terminal Diols as Masked Aldehydes in Sequential 
Chemoselective Ligation
This improved method of synthesis for diols was used for the synthesis of a peptide 
based on the C-terminus of a cytokine, that had proven difficult to synthesise as a 
single peptide (Broadbridge et al. 2001). The peptide sequence was split into four 
peptide fragments, which were sequentially ligated using chemoselective ligation by 
oxime bonds.
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In sequential ligation a temporary protection is used to mask one of the 
chemoselective groups during the first ligation, which is then removed to allow 
ligation of a third peptide fragment. The diol was used as a masked aldehyde for this 
purpose. Two of the four peptide fragments required just a single reactive group at 
either their N or C-terminus, a C-terminal aldehyde on one and an N-terminal 
hydroxylamine on the other. The two central fragments required both an N-terminal 
hydroxy lamine and a C-terminal masked aldehyde.
Leucine diol and Valine diol were synthesised via the method outlined in Figure 2.4 
and attached to chlorotrityl resin, then each of the three peptides requiring C-terminal 
aldehydes were synthesised on the chlorotrityl resin and purified. The fourth peptide 
required an amide at the C-terminus and so was synthesised on Rink amide resin. 
The hydroxylamine was incorporated onto the N-terminus of the three appropriate 
peptides using bis-Boc protected amino-oxy acetic acid. Bis-Boc protection prevents 
double acylation of the hydroxylamine that can occur when using the mono-Boc 
protected reagent. The scheme detailing the sequential ligation of the peptide 
fragments is shown in Figure 2.5 and MS data for the ligated peptide is shown in 
Figure 2.6.
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Figure 2.5: Sequential chemoselective ligation of four peptides by oxime bond 
(Broadbridge et al. 2001)
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Figure 2.6: ESMS of Peptide formed by oxime sequential chemoselective ligation
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2.3 Amino Alcohols -  New Synthetic Route and Method 
Development
A major restraint with the diol system was the low level of substitution achieved with 
chlorotrityl resin with any derivative other than glycine-diol (Broadbridge et al. 
2001). This contributed to very low yields of product. An amine is significantly more 
reactive to trityl chloride than an alcohol, and the 1, 2-amino alcohol functionality 
has often been used at the N-terminus of a peptide as an aldehyde precursor 
(incorporated as an N-terminal serine) leading to this investigation of the 1, 2-amino 
alcohol as a replacement for the diol at the C-terminus of the peptide.
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2.3.1 1, 3-amino-2-hydroxypropane (Glycine Amino Alcohol)
The potential of amino alcohols as replacements for diols for the synthesis of C- 
terminal peptide aldehydes, and their application in sequential chemoselective 
ligation was investigated using the commercially available 1, 2- amino alcohol 
derivative of glycine, 1, 3-amino-2-hydroxypropane. 1, 3 -amino-2-hydroxypropane 
was attached to 2 chlorotrityl chloride resin. The amino functionality is significantly 
more reactive than the hydroxyl, so it was assumed that attachment to the resin 
would be via either of the amino groups. The optimum conditions found were 2 
equivalents of 1, 3-amino-2-hydroxypropane, using DMF/DCM 1:1 and one 
equivalent of DIPEA, for 2 hours (Chapter 7, Section 7.2.7.1).
The 1, 3-amino-2-hydroxypropane substituted resin was then used in the synthesis of 
peptides containing a C-terminal glycine-amino alcohol. After HPLC purification, 
peptides were oxidised using NaI0 4  (Chapter 7, Section 7.2.10) to produce C- 
terminal peptide aldehydes. Following the successful development of this method it 
was adopted as a standard procedure for the custom synthesis of peptides containing 
C-terminal glycine aldehydes at Peptide Protein Research Ltd. Although detailed 
studies comparing yields of peptides synthesised using 1, 3 -amino-2-hydroxypropane 
(glycine amino alcohol) and 1-amino-2, 3-propanediol (glycine diol) were not 
performed, yields of long peptide glycine aldehydes were improved with use of the 
amino alcohol, attributed to the increased stability of the amine attached to trityl 
linker compared to the alcohol, during peptide synthesis.
2.3.2 A New Synthetic Route to 1-amino, 2-alcohol Derivatives of
Amino Acids
Once it had been demonstrated that the amino alcohol was a suitable replacement for 
the diol, a synthetic route for the synthesis of amino alcohol derivatives of amino 
acids had to be devised, as the glycine derivative was the only amino acid
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commercially available. A route was prefered that would convert an Fmoc protected 
amino acid with appropriate side chain protection directly to the amino alcohol, 
without the need to change the amine protecting group. It was important that any 
method developed for use in peptide fragment preparation for chemoselective 
ligation was cost effective, which would allow them to be used in commercial 
applications at Peptide Protein Research Ltd. Fmoc protected amino acids (Chapter 
7, Table 7.2) are inexpensive due to their use in standard Fmoc peptide synthesis, 
whereas amino acids with Fmoc compatible side chain protecting groups but 
alternative amine protection are vastly more expensive.
2.3.2.1 Epoxide Derivatives of Fmoc Amino Acids
It was known that an epoxide derivative of an N-a-Boc protected amino acid could 
be reacted with an amine to give the amino alcohol functionality. Opening of the 
epoxide with either ammonia, or a primary amine is not compatible with an N- 
a-Fm oc protected epoxide, as the amine is sufficiently basic to remove the Fmoc 
protecting group under the refluxing conditions of the reaction. However, several 
papers reported the opening of epoxides with amines under mild conditions (room 
temperature reactions in solvents such as DCM), using a metal salt as catalyst. 
Originally lithium perchlorate was used (Chili et al (1990)), but this was required in 
stoichiometric (100% mol) quantities, and perchlorates can undergo dangerous 
dcomposition reactions in the presence of organic molecules, so safer alternatives 
were investigated. Lithium or lanthanide III trifluoromethanesulfbnates (triflates), 
which were safer, more efficient catalysts, were shown to be required in 10-50% mol 
quantities, and required only short reaction times at room temperature (Chini et al 
(1994)). Therefore for this study it was attempted to react Fmoc protected epoxides 
with amines using the catalyst lithium triflate, which was the cheapest of these 
catalysts. Particularly of interest was the reaction of the epoxide with an amine 
functionalised solid support, for example Rink amide resin, which is employed as a 
standard linker in SPPS for the synthesis of C-terminal amides, and therefore could
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be used to yield the amino alcohol directly upon cleavage of the peptide from the 
resin (Figure 2.7).
Figure 2.7: Putative synthetic strategy for attachment of epoxide to Rink amide 
resin
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The epoxide of Fmoc-phenylalanine was synthesised as described in Chapter 7, 
Section 7.2.4. Fmoc-phenylalanine was activated using ethyl chioroformate and 
reacted with diazomethane to generate the diazomethylketone (Chapter 7, Section 
7.2.4.1). This was purified by column chromatography and analysed by IR, NMR 
(Figure 2.8) and NMR and CHN analysis.
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Figure 2.8: NMR of Fmoc-phenylalanine diazomethylketone
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The NMR spectrum was assigned with the aid of the COSY spectrum. The peaks 
at 7.1-7.8 were assigned as 13 aromatic protons. The peak at 5.4 was identified as the 
NH proton, and showed correlation with the peak at approximately 4.5, part of a 
multiplet signal. This was therefore assigned as the CH proton at position 3. This 
peak in turn correlated to the peak at 3.0, assigned as the two CH2 protons at position
4. The singlet peak at 5.1 showed no correlation to other peaks and was assigned as 
the CH proton in position 5. The peak at 4.2 showed correlation to the double 
integral peak at 4.4, and so were assigned as the CH in position 1 and the CH2 in 
position 2 respectively. The 'H NMR spectrum was therefore considered to be 
consistent with the diazomethylketone.
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Figure 2.9: 'H NMR of Fmoc-phenylalanine bromomethylketone
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The 'H NMR spectrum was assigned with the aid of the COSY spectrum. The peaks 
at 7.1-7.8 were assigned as 13 aromatic protons. The peak at 5.3 was identified as the 
NH proton, and showed correlation with the peak at 4.8, which was therefore 
assigned as the CH proton at position 3. This peak in turn eorrelated to the double 
integral peak at 3.1, assigned as the two CH2 protons at position 4. The CH2 peak at 
3.9 showed no correlation to other peaks and gave a eoupling constant of J ~12Hz 
consistent with only geminal coupling, and so was assigned to the two CH2 protons 
at position 5. The peak at 4.2 showed correlation to the double integral peak at 4.4, 
and so were assigned as the CH in position 1 and the CH2 in position 2 respectively. 
The ’H NMR spectrum was therefore considered to be consistent with the 
bromomethylketone.
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Fmoc-phenylalanine diazomethylketone was reacted with hydrogen bromide to form 
the bromomethylketone (Chapter 7, Section 7.2.4.2). The bromomethylketone was 
not further purified, and was analysed by IR, NMR (Figure 2.9) and NMR 
and CHN analysis.
Fmoc-phenylalanine epoxide was reacted with a number of different primary amines, 
and Rink amide resin, using lithium triflate as a catalyst, however even the mild 
reaction conditions of room temperature reactions in DCM resulted in the removal of 
the Fmoc protecting group by the primary amine, making this an unsuitable route of 
synthesis for the amino alcohol directly from Fmoc protected amino acids. It was 
decided that rather than using Boc chemistry and the epoxide, that an alternative 
route to the 1-amino, 2-alcohol derivative directly from the Fmoc protected amino 
acid would be attempted.
2.S.2.2 Amino Alcohol Derivatives Directly from Fmoc-protected 
Amino Acids
Returning to the synthetic route for the synthesis of diols directly from Fmoc 
protected amino acids, a strategy was developed that converted the bromomethyl 
ketone to an azido methyl ketone, which on reduction of the ketone and 
hydrogenation of the azide would yield an amino alcohol (Figure 2.10). Fmoc 
phenylalanine was the first amino acid chosen to test the synthetie strategy (Chapter 
7 Section 7.2.5).
The bromomethylketone derivative of phenylalanine (Figure 2.10, [2]) was 
synthesised as before, and this was converted to a azidomethylketone (Figure 2.10, 
[4]) by reaction with sodium azide (Chapter 7, Section 7.2.5.1). The bromomethyl 
ketone was very hydrophobic so would not dissolve in polar solvents, and sodium 
azide was only soluble in aqueous or aqueous miscible solvents, therefore a number
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of different solvent systems were tried. The most successful solvent system found 
was a biphasic system, having the bromomethyl ketone dissolved in ethyl acetate and 
vigorously stirring with sodium azide dissolved in water, which gave a yield of the 
azidomethylketone of greater than 90% for all amino acids investigated (Chapter 7, 
Section 7.2.5.1 [4], 7.2.S.4.3 [9], 7.2.5.4.S [14] and 7.2.5.4.13 [19]). Fmoc- 
phenylalanine azidomethylketone was analysed by IR, NMR (Figure 2.11) and 
NMR and CHN analysis.
Figure 2.10: Synthesis of 1,2 amino alcohol derivative of Fmoc phenylalanine
(a, b, 0 ) Fmoc.
Fmoc. OH
H OH O
Fmoc (e) N
I
H
[4]
Fmoc. NHz
OH
[6]
Reagents and conditions: (a) EtOCOCl, TEA (2:2 equiv.), THF, 4h; (b) CH2N2 Et20 3 h; (c) 
HBr (48% aq, 1 equiv.) acetone 5 min; (d) NaNs (10 equiv), Et0Ac/H20 24h; (e) NaBH4 
(1.4 equiv.) MeOH 10 min; (f) Ammonium formate (4 equiv.) Pd-C 10%, MeOH, 60°C, 30 
min.
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Figure 2.11: NMR of Fmoc-phenylalanine azidomethylketone
LH Fmoc-Phenylalanine azidomethyl ketone in CDC13 300KHz proton spectrum
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The H NMR spectrum was assigned with the aid of the COSY spectrum. The peaks 
at 7.1-7.8 were assigned as 13 aromatic protons. The peak at 5.4 was identified as the 
NH proton, and showed correlation with the peak at 4.5, which was therefore 
assigned as the CH proton at position 3. This peak in turn correlated to the double 
integral peak at 3.0, assigned as the two CH2 protons at position 4. The CH2 peak at 
3.75 showed no correlation to other peaks and gave a coupling constant of J ~12Hz 
consistent with geminal coupling, and so was assigned to the two CH2 protons at 
position 5. The peak at 4.2 showed correlation to the double integral peak at 4.4, and 
so were assigned as the CH in position 1 and the CH2 in position 2 respectively. The 
'H NMR spectrum was therefore considered to be consistent with the 
azidomethylketone.
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Reduction of the ketone to the alcohol (Figure 2.10, [5]) was perfomed using sodium 
borohydride and the same conditions that were used by Broadbridge (1998) in the 
final step of production of Fmoc protected diols (Figure 2.4) (Chapter 7, Section 
7.2.S.2). Fmoc-phenylalanine azidomethyl alcohol was analysed by LCMS, IR, 
(Figure 2.12) and NMR and CHN analysis. Reduction of the ketone produced 
mixed isomers at the hydroxyl. The presence of the chiral centre of the L amino acid 
means that two diastereomers were formed which are separable by HPLC, estimated 
to be approximately 60:40 (Figure 2.13 [5]). The stereochemistry of the hydroxyl 
was not important as oxidation of the amino alcohol to produce the aldehyde 
removes this chiral centre.
Figure 2.12: ^H NMR of Fmoc-phenylalanine azidomethylalcohol
IH Fmoc-Phenylalanine azidomethyl alcohol in CDC13 3G0MHz proton spectrum
: L:
3
.1 ,1 .1 L
The 'H NMR spectrum was assigned with the aid of the COSY spectrum. The 
spectra were not as clear as for the previous samples, attributed to the fact that the 
amino alcohol was a pair of diastereomers. The peaks at 7.1 -7.8 were assigned as 13
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aromatic protons. The peak at 5.1 was identified as the NH proton, and showed 
correlation with the peak at 3.7, which was therefore assigned as the CH proton at 
position 3. This in turn correlated to the peak at 3.3, which was assigned as the two 
CH2 protons in position 4. The peak at 4.2 showed correlation to the double integral 
peak at 4.4, and so were assigned as the CH in position 1 and the CH2 in position 2 
respectively. The peak at 4.8 was assigned as the OH proton. This showed 
correlation to the peak at 3.9, which was assigned as the CH proton in position 5. 
This showed correlation to the double integral peak at 2.9, which was assigned as the 
CH2 peak in position 6. The ^H NMR spectrum was therefore considered to be 
consistent with the azidomethylalcohol.
The final step of the synthesis required hydrogenation of an azide to a primary 
amine. Hydrogenation using hydrogen gas requires special equipment, and there is a 
safety consideration associated with the use of hydrogen gas. For this reason, the use 
of catalytic hydrogen transfer was investgated. This methodology has been 
thoroughly reviewed by Ram and Ehrenkaufer (1988 and references within). Of 
particular interest to this study was the findings of Gatriser et al (1983) who 
employed ammonium formate as a source of hydrogen for hydrogenation of azides to 
amines. This method of catalytic hydrogen transfer has been used in a number of 
publications at room temperature. In this study, no reaction was observed for 
hydrogenation of the azidomethylalcohol (Figure 2.10, [5]) using ammonium 
formate and 10% Pd-C at room temperature (approx 20 °C). Hydrogenation of a 
diazide using ammonium formate was reported at 60 °C by Glaçon et al (1996) and 
heating the reaction to 60 °C resulted in rapid conversion to the amine with no 
observable side reactions (Chapter 7, Section 7.2.S.3). Analysis by HPLC of the 1,2 
amino alcohol (Figure 2.13, [6]) gave the expected shift in retention time due to the 
increased hydrophilicity from the amine. There was no visible separation of the two 
diastereomers, but the peak width was broadened consistent with coelution of the 
diastereomers.
47
Chapter 2: Synthesis of Amino Acid Derivatives for use in the
Preparation of C-terminai Peptide Aldehydes
Figure 2.13: HPLC and MS data for intermediates and products in the synthesis of 
the 1, 2 amino alcohol derivative of Fmoc phenylalanine
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2.Z.2.Z Stability of Amino Alcohol Derivatives of Fmoc Amino 
Acids
It was noticed that upon storage of the 1, 2-amino alcohol derivatives of Fmoc amino 
acids it became more difficult to solubilise the compound in organic solvent. 
Analysis by mass spectrometry revealed that the Fmoc group was not stable and was 
slowly being removed from the alpha amine. Mass spectrometry is a very sensitive 
method of detecting small quantities of Fmoc removal. The diamine dégradant gives 
a stronger MS signal than the Fmoc protected compound as it more easily ionised, so 
even a very small amount of Fmoc removal can be detected. For this reason MS 
cannot be used to quantify the level of degradation as the peak size is not 
proportional to the quantity, but as the compound is a diamine with one amine 
protected, any significant level of Fmoc deprotection would render the derivative 
unsuitable for subsequent reactions, as resin loading could be to either amine.
The likely explanation is that the amine of the 1-amino 2-alcohol was sufficiently 
basic to remove the N-a-Fmoc group. A stability study was performed on both the 
amino alcohol and the azido alcohol, stored at 4° C, and analysed after 24 h, 1 week 
and 1 month (Chapter 7, Section 7.2.6). The azido alcohol showed good stability 
after 1 month, and had no sign of Fmoc removal by MS. The amino alcohol had 
detectable quantities of Fmoc removal after 24 hours, and after 1 week the quantity 
of Fmoc removal was considered significant (Figure 2.14). After 1 month there was 
a further increase in the proportion missing the Fmoc group.
Amino acid derivatives were therefore stored as the azido alcohol until required, then 
hydrogenated to the amino alcohol and immediately attached to chlorotrityl resin to 
avoid the problems of Fmoc removal.
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Figure 2.14: ESMS of Fmoc-Phe amino alcohol immediately after synthesis (a) and 
after storage for 1 week at 4°C (b)
.1 u  1-
ISO 175 200 » S  250 Z7i XA Z n  400 425 450 *76 SOO 525 SSCI 575 500 625 m / z JOO 300 .........400 500 600 fO) »0C m / z
Fmoc-Phe-amino alcohol [M + H] 403 Phe amino alcohol [M + H] 181
2.4 Protection of the Alcohol during Peptide Synthesis
Following attachment of the N-a-Fmoc protected 1, 2-amino alcohol to chlorotrityl 
resin, protection of the alcohol as a tertiary butyl ether is required to prevent 
acylation during peptide synthesis. The method of protection used with glycine diol 
by Zhang et al. (1998) and in this study was ^-butyl protection using ^-butyl-2,2,2- 
trichloroacetamidate in DCM. If the hydroxyl is not protected then the steric bulk of 
the chlorotrityl linker prevents reaction of the hydroxyl with most reagents. However 
acetic anhydride, which is used to cap any unreacted amino groups in difficult 
coupling reactions and therefore prevents production of deletion peptides, (Chapter 
7, Section 7.2.1.4) is a small molecule which is able to acetylate the hydroxyl. If this 
occurs then cleavage of the peptide does not yield a C-terminal amino alcohol, but 
instead the acetylated derivative, which cannot be oxidised to an aldehyde through 
treatment with sodium metaperiodate.
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Protection of the hydroxyl of 1, 3-amino-2-hydroxypropane (glycine amino alcohol) 
was considered to have proceeded to completion, as use of capping steps with acetic 
anhydride during peptide synthesis did not produce any acétylation of the hydroxyl. 
However synthesis of the test peptide Ac-AAA-amino alcohol, where the N-terminus 
was acetylated with acetic anhydride, showed by ESMS in addition to the expected 
product peak, an additional peak +42 mass units which would correspond to the 
acetylated hydroxyl (Figure 2.15). Peptides were therefore synthesised without use 
of acetic acid capping to prevent undesirable acétylation.
Figure 2.15: HPLC of Ac-AAA-amino alcohol
+t (+42) 
331 25
160 180 200....  220 240 260 280 300 320 340 360 380 400 420 440 460 480 IT l/z
Ac-AAA-amino alcohol [M+H] 289, acetylated hydroxyl [M+H] 331
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2.5 Synthesis of a Small C-termlnal Peptide Aldehyde
The peptide Z-RLF-aldehyde, which is an analogue of the proteinase inhibitor 
chymostatin, was synthesized to demonstrate the use of the amino alcohol derivative 
in the synthesis of a C-terminal peptide aldehyde (Figure 2.16). This small peptide 
allowed characterisation of the aldehyde by HPLC (Figure 2.17), ESMS (Figure 
2.18) and NMR (Figure 2.19).
Figure 2.16: Synthesis of the peptide aldehyde Z-RLF-H
(a) (b)
(c)
Z-Arg-Leu
(e )
Z -A rg-L eu \
(d)
Reagents and conditions: (a) /-butyl-2,2,2-trichloro acetamidate, DCM, Ih; (b) 20% 
piperidine/DMF, 20min; (c) Fmoc-Leu-OH, HBTU, HOBt (3 equiv.), DIPEA (9 equiv.) Ih; 
20% piperidine/DMF, 20min; Fmoc-Arg(Pbf)-OH, HBTU, HOBt (3 equiv.), DIPEA (9 
equiv.) Ih; 20% piperidine/DMF, 20min; Z- chioroformate (3 equiv.), DIPEA (9 equiv.), 
DMF; (d) TFA/TIS/H2O 95:2.5:2.5 2h; (e) NaI04, O.lM NaOAc buffer pH5.5, 30min.
Fmoc-Phe amino alcohol was synthesized (Chapter 7 Section 7.2.5) and attached to
2-chlorotrityl chloride resin using similar conditions to that used for attachment of I ,
3-amino-2-hydroxypropane. The resin substitution was calculated by measuring the 
absorbance at 304 nm for the deprotection of the Fmoc group (Chapter 7, Section 
7.2.1.8). Resin loading for Fmoc-Phe amino alcohol was very low compared to 1,3-
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amino-2-hydroxypropane, and after 1-2 hours no detectable loading had occurred. 
Reaction times of up to 24 hours were required to achieve a resin substitution of 0.1 
mmol/g, which was sufficient resin substitution to allow for subsequent peptide 
synthesis. Extending reaction times further was not performed due to the risk of 
Fmoc removal from the alpha amine, which could lead to attachment of the 
derivative through this amine, which would insert the derivative in the wrong 
direction.
The peptide Z-RLF-amino alcohol was then synthesised by manual solid phase 
peptide chemistry (Chapter 7, Section 7.2.7.3.1), cleaved from the resin and purified 
by RP-HPLC (Figure 2.13). After purification, the peptide Z-RLF-amino alcohol 
was oxidised with sodium metaperiodate (Chapter 7, Section 7.2.9.2) to yield the 
final peptide Z-RLF-H (Chapter 7, Section 7.2.7.3.2, Figure 2.16).
Figure 2.17; HPLC of Z-RLF-amino alcohol
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53
Chapter 2: Synthesis of Amino Acid Derivatives for use in the
Preparation of C-terminal Peptide Aldehydes
Figure 2:18 HPLC of Z-RFL-aldehyde
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A broad HPLC peak was seen for the aldehyde (F ig u re  2.18), which is normal for C- 
terminal peptide aldehydes as in aqueous solution they predominantly exist in the 
hydrated form, as seen by ESMS (F ig u re  2.19). The broad peak can be explained by 
the aldehyde and its hydrated form coeluting by HPLC. The low yield of peptide Z- 
RLF aldehyde meant that only a low resolution 'H NMR spectrum was obtained 
(F ig u re  2.20). The NMR spectrum was not fully assigned, but showed a weak 
aldehyde signal at 5 9.5 ppm due to exchange of the aldehyde proton with water.
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Figure 2.19: ESMS of Z-RLF-aldehyde
650 700 7S0 800 850 m / z
Z-RLF-aldehyde [M + H] 553, hydrated form [M + H] 571
F igu re  2 .20: NMR spectrum of Z-RLF-aldehyde
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2.6 Synthesis of Longer C-terminal Peptide Aldehydes
After synthesis of the small C-terminal aldehyde peptide Z-RLF-H, longer peptides 
were synthesised as a step towards the process of making long peptide fragments for 
use in chemoselective ligation. Bovine ribonuclease A had been chosen as the 
example protein for use in the ligation studies (Chapter 1, Section, 1.4), and so the 
two peptides sequences shown below corresponding to short regions of bovine 
ribonuclease A were synthesised.
KPVNTFVHESL-aldehyde l lm e r  
YQSYSTMSI-aldehyde 9mer
Amino alcohol derivatives of leucine (Chapter 7, Section 7.2.5.4.4, [11]) and 
isoleucine (Chapter 7, Section 7.2.S.4.9, [16]) were synthesised following the same 
method as for synthesis of Fmoc-Phe amino alcohol (Chapter 7 Section 7.2.S.4). 
and attached to 2-chlorotrityl resin (Chapter 7, Section 7.2.6.3). The peptide amino 
alcohols KPVNTFVHESL-amino alcohol and YQSYSTMSI-amino alcohol were 
synthesised by standard Fmoc chemistry as detailed in Chapter 7, Section 7.2.1.
The peptide amino alcohols were cleaved from the solid support and purified by RP- 
HPLC, and the purified peptides oxidised to their corresponding C-terminal 
aldehydes (Figure 2.21) using a polymer supported periodate, synthesised from 
amberlyst ion exchange resin (Chapter 7, Section 7.2.10.1, Figure 2.22).
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Figure 2.21: ESMS data for C-terminal aldehyde peptides
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Figure 2.22: Amberlyst ion exchange resin treated with sodium periodate
NalO,
CH2 NM6 3  Cl "CH2NMe3 IO4
The advantage of using a polymer supported periodate is that the pure peptide 
aldehyde peptide can be filtered away from the resin, which after solvent removal 
requires no further purification. Reactions of polymer supported reagents such as 
periodate have been reported to be solvent specific (Chesney, (1999)), with several 
reactions only possible in methanol. For the oxidation of the peptide amino alcohols 
detailed above, methanol was found to be the only solvent suitable for the reaction to 
proceed. This limits use of this method to peptides that are readily soluble in 
methanol, which was the case for these two test peptides, but was predicted to be 
problematic for longer peptides.
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Yields for the two test peptides were very low. After HPLC purification, 
KPVNTFVHESL-amino alcohol yielded 3.1 mg and YQSYSTMSI-amino alcohol 
yielded 2.4 mg, which corresponded to lower than 5% yield based on the starting 
resin substitution. Synthesis of peptides of this length would be expected to give a 
yield of approximately 50 mg (50% yield based on starting resin substitution. After 
oxidation to the aldehydes no further purification was performed and recovery from 
the polymer supported periodate was approximately 80%. A discussion of the low 
yields of the peptides with C-terminal amino alcohols follows in Section 2.7.
2.7 Synthesis of Ribonuclease Fragments Bearing a C-terminal
Amino Alcohol
Synthesis of ribonuclease by sequential chemoselective ligation would require the 
synthesis of several long peptides with C-terminal amino alcohols as masked 
aldehydes. Chapter 4, Section 4.1.1 describes how ligation sites were chosen using 
the available published data and crystal structures. Ligation sites in the positions 
planned required the synthesis of amino alcohol derivatives of alanine, leucine and 
isoleucine, and the replacement of two alanine residues and one threonine residue 
with either amino oxy acetic acid or hydrazino acetic acid (Figure 2.23).
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Figure 2.23: Primary sequence of bovine pancreatic ribonuclease A, split into four 
peptide fragments
KETAAAKFERQHMDSSTSAASSSNYCNQMMKSRNLTKDRCKPVNTFVHESLADVQAVCSQK
NVACKNGQTNCYQSYSTMSITDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
Peptide 1) KETAAAKFERQHMDSSTSA-al
Peptide 2) X-SSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-al
Peptide 3) X-DVQAVCSQKNVACKNGQTNCYQSYSTMSI-al
Peptide 4) X-DCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
X = N-terminal hydroxylamine or hydrazide
In addition to amino alcohol derivatives of leucine and isoleucine synthesised for use 
in the preparation of the peptides detailed in Section 2.6, Fmoc-Ala amino alcohol 
(Chapter 7, Section 7.2.5.4.15, [21]) was synthesised following the same method as 
for synthesis of Fmoc-Phe amino alcohol (Chapter 7 Section 7.2.5.4). The amino 
acid derivatives were attached to 2-chlorotrityl resin as described previously for 
phenylalanine derivatives (Chapter 7 Section 1.2.63). Peptides 2 and 3 (Figure 
2.23) were longer versions of the short peptides detailed in Section 2.6 above, and 
peptide 1 was a new peptide sequence. Peptide 4 had a C-terminal acid and so was 
synthesised on resin pre-loaded with Fmoc valine on the Wang linker. Peptide 4 was 
synthesised and purified and yielded 76 mg of purified peptide (49% yield from 
initial resin substitution). This peptide required a number of attempted syntheses to 
optimise the route and maximise the yield, and this is discussed in further detail in 
Chapter 4, Section 4.1.2. Several attempts at synthesis of the peptides with C- 
terminal amino alcohol were made, but none yielded full length peptide fragments in 
sufficient yield to use in further reactions. Extension of the peptide sequences beyond 
the 9mer and 1 Imer peptides detailed in Section 2.6 resulted in such low yields, even 
for the shortest 19mer peptide fragment (Figure 2.23, peptide 1) of ribonuclease.
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that although peptide of the correct mass could be detected by ESMS in the crude 
product (data was so poor that it is not presented here), no peptide was isolated after 
cleavage and HPLC purification. The lowering of final peptide yield during peptide 
elongation is likely to be due to cleavage of the peptide from the solid support during 
synthesis.
Previous ligation studies performed using C-terminal diols (Broadbridge et al 
(2001), Section 2.2.1) had been performed using low milligram quantities of 
peptides, which could be monitored by LCMS and HPLC, but resulted in only just 
detectable quantities of peptides after a series of sequential ligations. The resin 
substitution for these amino acid diols was known to be low compared to glycine diol 
and although the yields of these peptides relative to starting resin substitution levels 
were not calculated, yields appear to be consistent with those seen for the 
ribonuclease peptides synthesised in this study (approx 5% yield. Section 2.7), 
suggesting that initial substitution levels are not solely responsible for low yields of 
peptides. Yields of peptides synthesised on commercially available glycine diol and 
glycine amino alcohol attached to chlorotrityl resin can be achieved at similar levels 
to those achieved with a carboxylic acid attached to chlorotrityl resin, ie with yields 
of approximately 50% based on the starting resin substitution level. Therefore it 
appears that for both diol and amino alcohol derivatives of other amino acids than 
glycine, not only are starting resin substitution levels lower, but also cleavage of the 
peptide from the resin occurs during synthesis leading to very low yields of peptides.
The following explanation for peptide cleavage during synthesis is proposed. One 
difference between glycine and the other amino acids was the ability to fully protect 
the hydroxyl of the amino alcohol or diol after attachment to the solid support with 
both glycine diol and glycine amino alcohol, but not with the other amino acids 
synthesised for this investigation (Section 2.4). Chlorotrityl resin is succeptible to 
cleavage by alcohols (for example trifluoroethanol (TFE) or hydroxybenotriazole 
(HOBt) can be used to cleave protected peptides from chlorotrityl resin), and an
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unprotected hydroxyl could be sufficiently acidic to slowly cause cleavage of the 
peptide during peptide synthesis. More research would be required to confirm this 
hypothesis and to quantify the loss of peptide at each reaction cycle, however at this 
stage of the investigation it was decided that no further research would be continued 
into C-terminal masked aldehydes, and alternative strategies would be considered. 
Each peptide fragment would be required in at least 100 mg quantities, to allow for 
loss of product at each stage of ligation and oxidation, for any method of sequential 
ligation to become a viable method for peptide and protein synthesis.
2.8 Conclusion
A novel route for the synthesis of 1, 2 amino alcohol derivatives of Fmoc protected 
amino acids has been developed. The amino alcohol derivative of Fmoc amino acids 
can be used as a replacement for Fmoc-amino acid diols in the production of C- 
terminal peptide aldehydes. The route of synthesis of the Fmoc amino alcohol is high 
yielding and uses standard Fmoc protected amino acids as the building block. The 
route for synthesis was only tested using amino acids that did not require side chain 
protection, so further work would be required to determine the suitability of this 
method of synthesis for other amino acids.
Investigation showed the Fmoc amino alcohol to be unstable when stored at 4°C , as 
the free amine is sufficiently basic to remove the Fmoc group from the alpha amine 
during storage. However, if the derivative is stored as the azide precursor at 4°C, and 
the amine generated just prior to attachment to the polystyrene resin, this issue is 
resolved.
The aim of the amino alcohol was to achieve higher levels of substitution o f the 
residue on chlorotrityl resin compared to diols, which would enable higher yields of 
peptides for use in chemoselective ligation reactions. Unfortunately, although an
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amine is more reactive towards chlorotrityl resin than an alcohol, it appears that the 
amine in a 1, 2 amino alcohol is not significantly more reactive than the alcohol in a 
1, 2 diol. However it was also discovered that it was not only the low level of 
substitution that was responsible for low yields of peptide. Spontaneous cleavage of 
peptide from the linker during peptide synthesis may have resulted in low yields of 
peptides. Therefore although development of a route of synthesis of C-terminal 
aldehydes via the synthesis of peptides containing C-terminal amino-alcohol has 
been achieved, it has not proven to be useful in the production of high yielding 
peptide fragments for use in sequential chemoselective ligation.
Returning to the literature for chemoselective ligation, and with the knowledge that 
an N-terminal serine is a convenient 1, 2 amino alcohol for use as an aldehyde 
precursor in peptides, the decision was made to investigate swapping of the groups 
for ligation so that the aldehyde was at the N-terminus with the hydrazide or amino- 
oxy group at the C-terminus. Chapter 3 expands on this idea and details the 
synthesis of peptides for use in chemoselective ligation, and optimisation of the 
oxidation and ligation reactions. Chapter 4 describes the synthesis of peptide 
fragments using these functional groups for synthesis of RNase A by chemoselective 
ligation.
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3.0 Introduction
Chemoselective ligation describes any chemical reaction used to join two
unprotected peptides in solution, usually joining the the N-terminus of one peptide to 
the C-terminus of another peptide, replacing a natural peptide bond. The main aim of 
this work was to optimise a method of synthesis of peptide fragments for 
chemoselective ligation and to look at the effects of these unnatural linkages on the 
structure and function of a protein.
This chapter examines the structure of the linkages formed by a number of different 
chemoselective ligation reactions. The chapter then details the synthesis of peptides 
containing N-terminal serine as a precursor to an N-terminal glyoxal, and peptides 
containing a C-terminal hydrazide, for use in chemoselective ligation, and
optimisation of the oxidation and ligation reactions. The aim of this section of study 
was to verify that ligation of an N-terminal glyoxal to a C-terminal hydazide is a
viable method of ligation, allowing peptides to be synthesised and ligated in high
yield.
3.1 Comparison of Structure of Non-amide Chemoselective
Bonds
Non-amide chemoselective ligation has several aspects that must be considered when 
it is chosen as a method for peptide or protein synthesis. One is the ease of synthesis 
of the individual peptide fragments with their modified termini for the ligation, 
which is an important aspect of this thesis. Another is the rate and yield of reaction of 
the ligation reaction. However a third important feature is the structure of the bond 
formed at the ligation site, and how this differs from the natural peptide bond. 
Chapter 5 details the molecular dymanics study that was performed to look at the 
effect of chemoselective bonds used in this thesis on the structure of an example
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protein, bovine pancreatic ribonuclease A. In this chapter a more simple structural 
comparison of the bonds is made.
For the purpose of this thesis, only the structures of chemoselective bonds formed 
through reaction between an aldehyde and a hydrazine or hydroxylamine are 
compared. There are a number of commercial reagents available for use in peptide 
synthesis which can be used to generate peptides with terminal aldehydes, hydrazine 
and hydroxylamine functionalities. Hoewever, use of these reagents results in loss of 
one or more amino acids from the ligation site and generate a bond that does not 
closely resemble the natural peptide bond. These reagents are useful when using 
chemoselective ligation to join two molecules, such as linking a dye to a protein, or 
for template assembly of a number of peptides onto a scaffold. However for protein 
synthesis it is desirable that the ligated bond most closely mimics the natural peptides 
bond and that it includes as many amino acid side chains as possible close to the 
ligation site.
Figure 3.1 shows several different structures formed through chemoselective ligation 
of an aldehyde to a hydrazine or hydroxylamine, either using commercial reagents of 
peptide synthesis, or the methods used in this thesis.
Structure 1 shows the structure of a natural tripeptide, with the amino acids 
represented in three letter code with Xaa representing any of the 19 natural amino 
acids. Structures 2 and 3 show the ligated bonds formed using commercially 
available reagents for chemoselective ligation. Structure 2 is formed through the 
reaction of a peptide bearing a C-terminal glycine aldehyde (formed from a glycine 
diol precursor) ligated to a peptide bearing a N-terminal hydroxylamine (available 
from Novabiochem as Bis-Boc-amino-oxyacetic acid, catalogue number 851028). 
Structure 3 is formed through the reaction of a peptide bearing a C-terminal side 
chain-amino-oxy-acetic acid (available from Novabiochem as Fmoc-Dpr(Boc-Aoa)- 
OH, catalogue number 852216) ligated to a peptide bearing an N-terminal glyoxal 
(fromed from an N-terminal serine precursor). Both of these bonds result in loss of 
two amino acid side chains, and show little structural similarity to the natural peptide 
sequence.
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Figure 3.1: Comparison of structures of natural tripeptide Xaa-Xaa-Xaa, with 
different chemoselective bond replacements
R3
R3
N-^ ^  'Y 'NH,
o o f .
1: Natural peptide sequence
2: C-terminal glycine aldehyde ligated to N-terminal amino-oxy acetic acid 
3: C-terminal side chain-amino-oxy-acetic acid ligated to N-terminal glyoxal 
4: C-terminal aldehyde ligated to N-terminal hydrazine 
5: C-terminal aldehyde ligated to N-terminal hydroxylamine 
6: C-terminal hydrazide ligated to N-terminal glyoxal
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Structures 4 and 5 show the ligated bonds formed through reaction of a peptide 
bearing a C-terminal aldehyde (formed from the eorresponding amino acid diol or 1, 
2-amino alcohol, described in Chapter 2), reacting a peptide bearing either an N- 
terminal hydrazide (was available from Novabiochem as Tri-boc-hydrazinoacetic 
acid catalogue number 04-12-0245, now discontinued) or N-terminal hydroxylamine 
(Bis-Boc-amino-oxyacetic acid, catalogue number 851028 as used for Structure 2). 
Both of these bonds result in loss of just one amino acid side chain, and have a closer 
similarity to the natural peptide sequence. All of these examples have one additional 
bond length compared to the natural peptide sequenee.
Chapter 2 concluded with the decision that the 1, 2-amino alcohol derivatives of 
Fmoc protected amino acids was not a suitable method for the synthesis of peptide 
fragments in high yield, which lead to the alternative investigation into reaction 
between an N-terminal aldehyde reacting with a C-terminal hydrazide. Structure 6 
shows the ligated bond formed between these two functionalities. Again there is loss 
of a single amino acid side chain and one extra bond length compared to the natural 
peptide bond, but the structure most closely resembles the natural peptide sequence.
3.2 N-terminal Serine as a Masked Aldehyde
An N-terminal serine is a 1 ,2  amino alcohol and is therefore a eonvenient aldehyde 
precursor, as it can be incorporated into any peptide sequence. An N-terminal 
threonine can also be used. Oxidation with sodium metaperiodate produces a 
glyoxal.The actual mechanism is complicated and proceeds via a number of steps to 
form a cyclic intermediate, which then spontaneously rearranges to form the glyoxal 
(Figure 3.2).
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Figure 3.2 N-terminal serine oxidation to glyoxal
HO.
o
N-terminal serine
'PEPTIDE
Nal0 4
Several steps
PEPTIDE
PEPTIDE N-terminal glyoxal
At the site of chemoselective ligation, the N-terminal residue of the C-terminal 
peptide fragment is replaced with a serine, so the ligation results in loss of the side 
chain coresponding to the amino acid that is replaced by serine. An N-terminal serine 
as an aldehyde precursor was first reported by Geoghegan et al (1992), and has since 
been used in numerous publications as a cheap and convenient route to an N-terminal 
aldehyde.
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3.3 Peptides Containing a C-terminal Hydrazide
A C-terminal peptide hydrazide is a simple modification to the C-terminus of a 
peptide, formed through the reaction of the C-terminal carboxylic acid to hydrazine 
through an amide bond. Synthesis of peptides containing a C-terminal hydrazide can 
be achieved in a number of different ways. One method is to synthesise a fully side 
chain and N-teminal protected peptide by SPPS using a hyperacid labile linker such 
as 2-chlorotrityl, and react this protected peptide in solution to hydrazine using a 
coupling agent such as DIC or HBTU. The main disadvantage to this technique is 
racémisation of the C-terminal residue. Activation of the carboxyl of a peptide is 
much more prone to racémisation than activation of the carboxyl of a single amino 
acid, mainly because an activated amino acid reacts more quickly than an activated 
peptide giving less time for racémisation to occur. A superior method of synthesis is 
one that forms the C-terminal hydrazide through reaction of a C-terminal amino acid 
directly onto a hydrazine modified solid support, followed by synthesis of the 
peptide.
Hydrazide peptides were originally synthesised using this method by Wang and 
Merrifield (1969) by Boc chemistry using ^-alkyloxycarbonylhydrazide resin and 
later by Wang (1973) using j?-alkoxybenzyloxycarbonylhydrazide resin and 2-(4- 
biphenyl)isopropyloxycarbonyl (Bpoc), a hyperacid sensitive amine protecting 
group, as an alternative to Boc, which allowed cleavage from the resin in TFA rather 
than HF. Since the development of Fmoc as an orthogonal amine protecting group, 
this resin has also been used with Fmoc chemistry for the synthesis of peptide 
hydrazides. However, reported low yields and side reactions during peptide cleavage 
lead to the use of hydrazine bound to 2-chlorotrityl resin by Stavropoulos et al. 
(1995), allowing cleavage in low TFA concentrations to avoid the side reactions 
associated with high concentrations of TFA.
This method of synthesis was used in this investigation for the synthesis of peptides 
bearing C-terminal peptide aldehdyes. 2-chlorotrityl chloride resin was loaded with 
hydrazine using a 2% solution of hydrazine monohydrate in DMF (Chapter 7, 
Method 7.2.8.1) . Peptides were then synthesised on this resin using the Symphony
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or Prelude automated peptide synthesisers (Protein Technologies Inc) . Cleavage 
from the chlorotrityl linker in 95% TFA and appropriate scavengers depending on 
the peptide synthesis produced C-terminal peptide hydrazides in high yield and 
purity (Section 3.4.2).
3.4 Synthesis of Peptides for use in Trial Ligations
Short peptide sequences were chosen and synthesised for use in trial scale oxidation 
and chemoselective ligation reactions. Two sequences were chosen that are peptides 
regularly ordered as custom peptides at PPR Ltd, which are straightforward to 
synthesise and purify in high yield.
3.4.1 Test peptide with N-terminal Serine
The peptide SLIGRL-NH2 which has an N-terminal serine and a C-terminal amide 
was chosen as a test sequence for the glyoxal peptide. This is a sequence derived 
from the N-terminus of the protease-activated receptor-2 (PAR2), and is a receptor 
agonist. The peptide was synthesised and purified by RP-HPLC as detailed in 
Chapter 7, Sections 7.2.1 and 7.3.1 (ESMS data shown in Figure 3.3). The peptide 
was synthesised on 500 mg polystyrene resin preloaded with Fmoc-Rink amide 
MBHA linker, at a substitution level of 0.36 mmol/g. The final purified yield was 69 
mg which corresponds to a 58% yield.
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Figure 3.3: ESMS data for SLIGRE-NH2
+2
329 18
+1
657.28
200 300 400 500 600 700 800 900 m /z
SLIGRL-NH2 [M + H] 657
3.4.2 Test peptide with C-terminai Hydrazide
The peptide 8Aoc-fQWAVGHL-NH-NH2 which has an N-terminal 8 -amino 
octanoyl group at the N-terminus, D-phenylalanine and a C-terminal hydrazide was 
chosen as a test sequence for the hydrazide peptide. This is a sequence derived from 
the C-terminus of bombesin and is a peptide antagonist.
The peptide was synthesised on hydrazine substituted 2-chlorotrityl chloride resin 
(CTR) (Chapter 7, Section 7.2.S.3). The substitution level of the hydrazine on CTR 
cannot be measured, but is assumed to be close to the level of substitution of the 
starting chloride resin (1.3 mmol/g). This is too high for peptide synthesis and so the 
substitution level was lowered during the first amino acid coupling by reacting 
Fmoc-Leu and Boc-Gly in a ratio of 4:1 to terminate a proportion of the resin with
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Boc-Gly. The Gly-NH-NH2 product is easily separable from the correct peptide by 
HPLC, and so this method is a convenient way to reduce resin substitution. The 
proportion of resin terminated with Boc-Gly does not exactly correspond to the 
proportion of Boc-Gly used in the coupling reaction. Glycine reacts more quickly 
than other amino acids and Boc amino acids have better solubility than Fmoc amino 
acids, so a higher proportion of Boc-Gly reacts than the Fmoc amino acid.
This method of resin lowering is used regularly at PPR Ltd to lower the substitution 
of Wang preloaded resins for use on peptide synthesisers. A resin substitution level 
of 0.5 mmol/g or above produces high levels of terminated sequences during peptide 
synthesis, and so a substitution level of between 0.2 and 0.4 mmol/g is ideal for 
minimising peptide chain aggregation, while maximising the yield of peptide without 
requiring use of large amounts of resin. Wang resins at 0.5-0.8 mmol/g substitution 
that are lowered using a 4:1 ratio of Fmoc-amino acid to Boc-Gly produces a 
substitution level of between 0.2-0.4 g (investigations performed at PPR Ltd, results 
not shown here), so approximately a halving of resin substitution.
If a large excess of amino acid is reacted to CTR the highest substitution achieved is 
approx 0.8 mmol/g. It was assumed that the hydrazine-CTR would react similarly, 
and so use of a 4:1 ratio of Fmoc-Leu to Boc-Gly would result in a substitution level 
of approx 0.4 mmol/g. The actual substitution level of the Fmoc-Leu-hydrazide resin 
was not measured due to difficulty accessing a photospectrometer, but the yield of 
8 Aoc-fQWAVGHL-NH-NH2 produced from 300 mg of resin was 48 mg, which 
would correspond to a 40% yield at 0.4 mmol/g substitution or an 80% yield at 0.2 
mmol/g substitution. As 50% yields are typical in peptide synthesis, and peptide 
synthesis proceeded without signs of terminated products it is likely that the 
substitution levels achieved were between 0.2-0.4 mmol/g. ESMS data for 8 Aoc- 
fQWAVGHL-NH-NH2 is shown in Figure 3.4.
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Figure 3.4: ESMS of 8Aoc-fQWAVGHL-NH-NH2
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3.5 Periodate Oxidation of Peptides bearing N-terminal Serine
The peptide SL1GRL-NH2 was oxidised using sodium metaperiodate to produce the 
N-terminal glyoxal. The method of Gaertner et al. (1992) was followed, which used 
a 2 fold excess of Nal0 4  in imidazole hydrochloride buffer (50 mM, pH 6.9) 
(Chapter 7, Section 7.2.10.2).
A trial scale oxidation was first performed using 1 mg of peptide at a concentration 
of 5 mg/ml. A small sample of the peptide was quenched after 10 minutes with 
ethylene glycol (2 equivalents over Nal0 4 ), and analysed by LCMS.
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LCMS was used to separate the immidizole buffer from the peptide by HPLC, 
allowing the peptide to be analysed by MS. The peptide was loaded onto the LCMS 
in 5% MeCN and after elution of the buffer the MeCN was increased to 50%, 
causing co-elution of the starting peptide and glyoxal product.
The major peak seen by ESMS was [M + H] 645 which would correspond to the 
hydrated form of the glyoxal, and also visble was [M + H] 658 which is the starting 
peptide. Samples were also taken at 15 minutes and 20 minutes, and complete 
oxidation was seen at 15 minutes (no [M + H] 658 visible by MS) with no side 
reactions visible in the 2 0  minute sample.
The reaction was repeated using 50 mg of peptide at a concentration of 5 mg/ml 
(Chapter 7, Section 7.2.10.2.1). The reaction was quenched after 20 minutes and the 
peptide was immediately purified by RP-HPLC and freeze dried. The ESMS of the 
purified glyoxal is shown in Figure 3.5. The purified glyoxal was stored at -20 ° C 
until required. The glyoxal peptide was used over several months and showed no 
signs of degradation or reduction in reactivity over this time, although no formal 
stability studies were performed.
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Figure 3.5: ESMS of glyoxal-LIGRL-NH2
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3.6 Chemoselective ligation between an N-terminal Glyoxal 
and a C-terminal Hydrazide
8Aoc-fQWAVGHL-NH-NH2 was ligated to glyoxal-LIGRL-NH2 in NaOAc buffer 
(0.1 M, pH 4.6). In an initial trial, the peptides were reacted in a 1:1 ratio at a 
concentration of 1 mg/ml, and the reaction was monitored by MS. After 24 h there 
was both starting peptides and ligated product visible by MS, and after 3 days the 
reaction had gone to completion (Chapter 7, Section 7.2.11.1). The ligation was 
repeated at 2  mg/ml, in an attempt to spead up the rate of recation, but there no 
noticeable difference in reaction rate. The ligation was attempted at 5 mg/ml, but the 
hydrazide peptide fragment was not soluble at this concentration.
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3.6.1 Use of Aniline as a Nucieophilic Catalyst
During these investigations a communication published by Dirksen et al (2006) 
demonstrated the use of aniline as a nucieophilic catalyst in oxime ligation to 
dramatically increase reaction rates.
A reason why ligation of hydroxylamines and hydrazides is so slow is that the 
reaction is in equilibrium between the imine (Schiff base) and the starting reagents, 
and the equilibrium constant ( K e q ) ,  (the ratio of the rate constant of formation to the 
rate constant of hydrolysis) for this reaction is low. This means that high 
concentrations of reactants are required to force the reaction to completion. Peptide 
ligation often requires quite low concentration of the peptides due to solubility 
problems and so long reaction times and incomplete reactions are often reported as a 
problem with this method of ligation.
The pKa of aniline is 4.6, which is approximately the same as the pKa of the 
hydrazide. Dirksen et al (2006) proposed the use of aniline in a large excess would 
cause Schiff base formation with aniline at the pH of the ligation. A transimination 
with hydroxylamine or hydrazide would then occur and this reaction is rapid at the 
pH of the ligation. Therefore the rate determining step would be controlled by the 
concentration of aniline used in the reaction, and not the concentration of the 
peptides being ligated. They demonstrated this in their 2006 communication with 
oxime ligation, and achieved up to 400 fold increases in reaction rate.
The use of aniline as a nucieophilic catalyst was therefore tested in this study for 
hydrazone ligation, as detailed below. A later publication by Dirksen et a l (2008) 
and so not available during this study used aniline to increase reaction rates in 
hydrazone ligation with similar effect.
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3.6.1.1 Trial Ligations using Aniline
The trial ligation of 8 Aoc-fQWAVGHL-NH-NH2 to glyoxal-LIGRL-NH2 in 
NaOAc buffer (0.1 M, pH 4.6) in a 1:1 ratio at a total peptide concentration of 1 
mg/ml was performed in four separate reactions, using no aniline, 1 mM, 10 mM and 
100 mM aniline. After 8  hours all the reactions were monitored by ESMS. Figure
3.6 shows the ESMS for each reaction after 8  hours. All had starting peptide and 
ligated product visible. For the reaction that did not contain aniline, the two starting 
peptides (peak C and peak D) are clearly visible, along with the ligated product 
(peaks A and B). As the amount of aniline is increased, the quantity of starting 
peptides reduces. After 8  hours in the prescence of 10 mM and 100 mM aniline, the 
glyoxal peptide is bearly visible and the hydrazide peptide is greatly reduced 
compared to the reactions containing 1 mM or no aniline.
After 18 hours the reactions were monitored by MS and the reactions with 10 mM 
and 100 mM aniline had proceeded to completion. The reaction using 1 mM aniline 
was completed in 2 days. The reaction without aniline took 3 days to reach 
completion. It was therefore decided that 10 mM aniline would be most suitable for 
ligations, as a 10 fold increase to 100 mM did not increase the reaction rate 
sufficiently for the reaction to be completed in a day. Both 10 mM and 100 mM 
additions resulted in complete ligation in 18 hours, meaning ligation reactions could 
be performed overnight.
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Figure 3.6: ESMS of trial ligation of 8Aoc-fQWAVGHL-NH-NH2 to glyoxal- 
L1GRL-NH2 after 8  hours
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C = glyoxal-LlGRL-NH2 [M + H3O] 645 ([M + H] 626)
D = 8Aoc-fQWAVGHL-NH-NH2 [M + 2H] 557 ([M + H] 1113)
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3.6.1.2 Large Scale Ligation
The optimised conditions for ligation determined by the trial scale ligation was 
scaled up, so that the hydrazone product could be purified. 8 Aoc-fQWAVGHL-NH- 
NH2 was ligated to glyoxal-LIGRL-NH2 in NaOAc buffer (0.1 M, pH 4.6) in a 1:1 
ratio at a total peptide concentration of 1 mg/ml in the prescence of 10 mM aniline 
(Chapter 7, Section 7.2.11.2). The ligated product was purified by HPLC. Figure
4.7 shows the ESMS trace for the purified hydrazone peptide.
Figure 3.7: ESMS of 8Aoc-fQWAVGHL-hydrazone-LIGRL-NH2
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3.7 Conclusion
Chemoselective ligation between two peptides, one bearing an N-terminal glyoxal 
and the other bearing a C-terminal hydrazide has been investigated as a potential 
method for use in the sequential ligation of several peptides. The studies detailed in
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this chapter confirmed that this method is suitable for the ligation of two peptides in 
high yield, and therefore should be a suitable method to use in sequential ligation, 
using the serine as a masked glyoxal. During sequential ligation the N-terminal 
serine acts as a masked glyoxal, allowing ligation of two peptides, before unmasking 
of the glyoxal for use in the next ligation reaction.
The rate of hydrazone formation was increased by use of aniline as a nucieophilic 
catalyst, reducing reaction times from 3 days to less than 24 hours.
This method, using an N-terminal glyoxal ligated to a C-terminal hydrazide was 
therefore adopted for use in the sequential ligation of peptides. Chapter 4 details the 
synthesis of peptide fragments of bovine pancreatic ribonuclease A and ligation of 
these peptides.
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4.0 Introduction
Bovine pancreatic ribonuclease A (RNase A) was chosen as the example protein for 
total synthesis of a protein by sequential chemoselective ligation. It is one of the 
most studied small proteins, and so its structure and mechanism of catalysis are well 
understood (Chapter 1, Section 1.4).
At 124 amino acids, it is possible to synthesise as a single chain by SPPS, but this 
has only been achieved using Boc chemistry (Gutte et al (1971), not Fmoc 
chemistry. Taking all this information into account it was decided that RNase A 
would be an ideal protein to synthesise by sequential chemoselective ligation, and to 
study the effects of the ligated non-natural bonds on the structure and function of the 
protein.
The sequence of ribonuclease was analysed for suitable ligation sites, and split into 
four sections. The N and C terminals of each fragment sequence needed the correct 
modifications added to allow sequential ligation. This chapter describes the design of 
peptide fragments using the original ligation method of an N-terminal hydrazide or 
hydroxylamine reacting with a C-terminal aldehyde as detailed in Chapter 2. The 
chapter then focuses on the design and synthesis of peptide fragments of RNase A 
containing an N-terminal glyoxal and C-terminal hydrazide following on from the 
studies described in Chapter 3.
4.1 Ligation Sites
The 124 amino acids that make up the primary sequence of bovine pancreatic 
ribonuclease were analysed for suitable ligation sites. It was decided to position the 
sites for ligation away from residues known to be involved in the active site, or
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catalytic mechanism (Figure 4.1), to reduce the likelihood of the ligated bonds 
affecting the structure or activity of the enzyme.
Figure 4.1: Primary sequence of bovine pancreatic ribonuclease A
KETAAAKFERQHMDSSTSAASSSNYCNQMMKSRNLTKDRCKPVNTFVHESLADVQAVCSQK
NVACKNGQTNCYQSYSTMSITDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
Residues in green are involved in the active site and pink are essential for catalytic 
activity (Chapter 1.4.1-1.4.2).
4.1.1 Chemoselective Ligation between an N-terminal Hydrazide
and C-terminal Aldehyde
At the ligation site the two amino acids either side of the ligated bond are important. 
In Figure 4.2, (a) shows a tetramer of four different amino acids with side chains Ri- 
R4 , (b) shows the two fragments that would be required for chemoselective ligation 
between a C-terminal aldehyde and N-terminal hydrazine (the original method of 
ligation detailed in Chapter 2) and (c) shows the product of the ligation. The amino 
acid with side chain R] is required as a C-terminal aldehyde and the amino acid side 
chain R3 is not present in the ligated product.
The ligation sites were chosen so that,
1) the C-terminal aldehyde of each peptide was an amino acid that did not require 
side chain protection, as the amino alcohol derivatives of these would be more 
simple synthetic targets, and
2 ) the amino acid side chain that would be lost would be a simple functional group so 
that removal of that side chain would be likely to have little effect on the structure of 
the enzyme. The best amino acid at this site would be a glycine as this amino does
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not have a side chain functional group, but there were no glycines in suitable 
positions.
Figure 4.2: Hydrazide chemoselective ligation of C-terminal aldehyde to N-terminal 
hydrazine
(a)
HoN OH
(b)
HgN
HgN
OH
(c)
HzN
OH
a) natural tetrapeptide
b) two peptide fragments required for chemoslective ligation
c) product of chemoselective ligation
Taking all these factors into consideration, three ligation sites were chosen splitting 
the sequence into four peptide fragments. Two of the ligation sites were able to be 
positioned at alanine residues, which has a simple methyl group side chain, and the 
third ligation site was positioned at a threonine residue which has a hydroxyl methyl 
side chain. Chapter 2, Section 2.6 details the original plan for sequential ligation
82
Chapter 4: Synthesis of Bovine Pancreatic Ribonuclease A
using the C-terminal amino alcohol as a masked C-terminal aldehyde. The ligation 
sites and peptide fragments that would have been required are shown in Chapter 2, 
Figure 2.12, and repeated in Figure 4.4 for clarity.
The crystal structure of bovine pancreatic ribonuclease A [3m3 (Howlin et al. 
(1989))] was manipulated using MOE.2007.09 to show the residues essential for 
enzyme catalytic activity, and the three residues that would be lost in the ligation 
strategy shown above (Figure 4.3). This confirmed that these sites are all spatially 
arranged on the opposite face of RNase A from the residues known to be required for 
activity.
Figure 4.3: Image of RNase A (3m3), showing sites of ligation and residues critical 
to ribonuclease activity
Green - active site residues, Pink - other important resides for catalytic activity. 
Orange -  amino acids that would be replaced by proposed ligation sites.
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4.2 Synthesis of Peptide Fragments Bearing C-terminal Amino
Alcohols
Chapter 2, Section 2.6 describes the attempted synthesis of the three peptides 
bearing C-terminal amino alcohols (Figure 4.4, peptides 1, 2 and 3), synthesised on 
chlorotrityl resin substituted with amino alcohol derivatives of Fmoc amino acids. 
This method is referred to in this chapter as strategy 1.
Figure 4.4 Primary sequence of RNase A, split into four peptide fragments, using 
strategy 1
KETAAAKFERQHMDSSTSAASSSNYCNQMMKSRNLTKDRCKPVNTFVHESLADVQAVCSQK
NVACKNGQTNCYQSYSTMSITDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
Peptide 1) KETAAAKFERQHMDSSTSA-al
Peptide 2) X-SSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-al
Peptide 3) X-DVQAVCSQKNVACKNGQTNCYQSYSTMSI-al
Peptide 4) X-DCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
X = N-terminal hydroxylamine or hydrazide
al = C-terminal aldehyde
pink = residues involved at active site
The fourth peptide required for the synthesis of RNase A (Figure 4.4, peptide 4) has 
a C-terminal carboxylic acid, and therefore could be synthesised by standard Fmoc 
peptide synthesis using pre-loaded Fmoc-Val Wang resin. The synthesis of this 
peptide using the Symphony automated peptide synthesiser required a number of 
attempted syntheses to optimise the route and maximise the yield. Initial attempts at 
the synthesis using resin with a substitution level of 0.39 mmol/g and standard Fmoc 
peptide synthesis (Chapter 7, Section 7.2.1) resulted in several truncated peptides 
and deletion peptides visible in the crude synthesis. The peptide was resynthesised 
using a low loaded Wang resin with a substitution level of 0.27 mmol/g, which 
improved the crude peptide purity. The quality of the crude peptide was improved
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further by the use of pseudoproline dipeptides (Mutter et al. (1995)), and the 
optimised location of these is shown in Figure 4.5.
Figure 4.5: Sequence of C-terminal peptide fragment of RNase A showing location 
of pseudoproline dipeptides (underlined)
Peptide 4) X-DCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV 
X = hydrazinoacetyl or hydroxylamine
The optimised synthesis of this peptide with an N-terminal hydrazinoacetyl group 
yielded 76 mg of purified peptide (20% yield from initial resin substitution) 
(Chapter 7, Section 7.2.9.1).
This approach to the synthesis of RNase A (strategy 1) was not continued due to the 
problems encountered when using the 1 ,2  amino alcohol at the C-terminus of the 
peptide fragments. The alternative method of synthesis (strategy 2) using C-terminal 
hydrazides ligated to N-terminal glyoxal was tested using short peptides (Chapter 
4), and then extended to the synthesis of peptide fragments of RNase A. This chapter 
details the synthesis of these peptides and the oxidation and chemoselective ligation 
reactions required for the synthesis of RNase A.
4.3 Synthesis of Peptide Fragments Bearing C-terminal
Hydrazides
Synthesis of RNase A by ligation between an N-terminal glyoxal and a C-terminal 
hydrazide required a redesign of the peptide fragments. The locations of the 
chemoselective bonds as detailed in Section 4.5.1 were kept the same, but the C- 
terminal aldehyde was replaced with a C-terminal hydrazide and the N-terminal 
hydroxylamine or hydrazide was replaced with a serine (Figure 4.6).
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Figure 4.6: Primary sequence of RNase A, split into four peptide fragments, using 
strategy 2
KETAAAKFERQHMDSSTSAASSSNYCNQMMKSRNLTKDRCKPVNTFVHESLADVQAVCSQK
NVACKNGQTNCYQSYSTMSITDCRETGSSKYPNCAYKTTQANKHnVACEGNPYVPVHFDASV
Peptide 1) KETAAAKFERQHMDSSTSA-NH-NH2 
Peptide 2) SSSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-NH-NH2 
Peptide 3) SDVQAVCSQKNVACKNGQTNCYQSYSTMSI-NH-NH2 
Peptide 4) SDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
X = amino acid replaced with serine 
NH-NH2 = C-terminal hydrazide 
pink = residues involved at active site
The three peptides with C-terminal hydrazides (Figure 4.6, peptides 1, 2 and 3) were 
synthesised on 2-chlorotrityl resin substituted with hydrazine (Chapter 7, Section 
7.2.8.1). The synthesis of peptide 1 produced high quality crude peptide that did not 
show signs of amino acid deletions or truncated peptides. After HPLC purification, 
125 mg of purified peptide was obtained. The initial substitution level of the 
hydrazide resin was not measured so the yield could not be calculated, but the yield 
was consistent with starting substitution levels of between 0.2-0.4 mmol/g.
Peptides 2 and 3 required optimisation of the synthesis to include pseudoprolines, 
and also extended coupling times of difficult reactions (Figure 4.7, Chapter 7, 
Section 7.2.9.1-2). The peptides were synthesised using the Prelude peptide 
synthesiser which enabled the synthesis of the peptides to include automated addition 
of the pseudoproline dipeptides.
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Figure 4.7: Sequence of peptides 2 and 3 showing location of pseudoproline 
dipeptides (underlined) and difficult couplings (bold)
Peptide 2) SSSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-NH-NH2 
Peptide 3) SDVQAVCSQKNVACKNGQTNCYQSYSTMSI-NH-NH2
After purification, peptide 2 yielded 65 mg and peptide 3 yielded 38 mg. If the 
substitution of the hydrazide resin was assumed to be the same as for peptide 1 , 
which was consistent with starting substitution levels of 0.2-0.4 mmol/g, then the 
yields for these two peptides was significantly lower. These peptides are longer and 
were more difficult to synthesise, so the lower yield is likely to be due to a lower 
quality crude peptide and also possibly due to a small amount of cleavage of peptide 
from the chlorotrityl linker during peptide synthesis.
The fourth peptide (Figure 4.6, peptide 4) has a C-terminal acid and so was 
synthesised on Fmoc-Val Wang resin using the same resin substitution and 
pseudoprolines outlined in the method in Section 4.1.2. The yield of this peptide was 
54 mg (15% yield based on starting resin substitution, experimental details given in 
Section 1.2.92). This yield was slightly lower than for the similar peptide with an N- 
terminal hydrazinoacetyl (Section 4.2), as the peptide was repurified by HPLC to 
achieve the highest purity possible. The peptide with N-terminal hydrazinoacetyl 
would be used in chemoselective ligation reactions directly, but the peptide with N- 
terminal serine required oxidation to the glyoxal so particular effort was made to 
achieve a very high purity. The repurified peptide was analysed by analytical HPLC 
and gave a single peak (Figure 4.8)
All four peptide fragments were analysed by HPLC and ESMS, and the ESMS data 
are shown in Figure 4.9 -  Figure 4.12 (Full HPLC and ESMS data is in appendix
II).
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Figure 4.8: HPLC of RNase A Peptide 4
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Figure 4.9: ESMS of RNase A Peptide 1
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KETAAAKFERQHMDSSTSA-NH-NH2 [M + H] 2110
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Figure 4.10: ESMS of RNase A Peptide 2
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SSSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-NH-NH2 [M + H] 3721
Figure 4.11: ESMS of RNase A Peptide 3
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SDVQAVCSQKNVACKNGQTNCYQSYSTMSI-NH-NH2 [M + H] 3274
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Figure 4.12: ESMS of Peptide 4 of RNase A
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SDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV [M + H] 4702
4.4 Chemoselective ligation of RNase A
Sequential chemoselective ligation of RNase A using the four peptides detailed in 
S ection  4 .3 , F ig u re  4 .6  requires a cycle of oxidation, to produce an N-terminal 
glyoxal, followed by ligation of this glyoxal to a peptide bearing a C-terminal 
hydrazide and N-terminal serine, and then a repeat of the cycle of oxidation and 
ligation until all four peptides have been joined together. A schematic of this process 
is shown in F ig u re  4 .13 .
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Figure 4.13: Proposed ligation of four peptide fragments by hydrazone ligation
S-PEP1DE4
Oxidation
glyoxal-PEPIDE4 
Ligation to S-PEPTIDE3-hydrazide
S-PEPTIDE-hydrazone-PEPTIDE4
Oxidation
glyoxal-PEPTIDE3-hydrazone-PEPTlDE4 
Ligation to S-PEPTIDE2-hydrazide
S-PEPTIDE2-hydrazone-PEPTIDE3-hydrazone-PEPTlDE4
Oxidation
glyoxal-PEPTIDE2-hydrazone-PEPTIDE3-hydrazone-PEPTIDE4
Ligation to PEPT1DE1-hydrazide 
PEPTlDE1-hydrazone-PEPTIDE2-hydrazon0-PEPTIDE3-hydrazone-PEPTIDE4
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4.4.1 Oxidation of Peptide Fragments of RNase A Containing N-
terminal Serine
The first stage in the process of chemoselective ligation required the generation of an 
N-terminal glyoxal from the oxidation of peptide 4, which contains an N-terminal 
serine (Figure 4.14).
Figure 4.14: Oxidation of RNase A peptide 4
SDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
NaI0 4  Oxidationi
glyoxal-DCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV
Peptide 4 was oxidised using the same conditions used for oxidation of the test 
peptide SLIGRL-NH2 (Chapter 3, Section 3.5). The reaction was quenched after 10 
minutes with ethylene glycol ( 2  equivalents over Nal0 4 ), and a small sample was 
analysed by LCMS (Figure 4.15). The molecular mass of the glyoxal would be 
4671, but ESMS of other glyoxal peptides shows the hydrated form which would be 
4689, giving a +5 ion at 939 m/z. There was no peak visible at this m/z. The peptide 
showed multiple peaks in the ESMS of higher mass than expected, which 
corresponds to parent ions separated by 16 mass units. This suggested that as well as 
oxidising the serine to a glyoxal, other oxidation was occurring. It is difficult by 
ESMS to extrapolate the exact molecular mass of the parent ion, as ESMS only has 
an accuracy of +/- 1 mass unit, but the masses extrapolate approximately to parent 
ions with 3 x +16 to 8  x +16 additional mass units than the expected hydrated form 
of the glyoxal.
There are no methionines in the sequence (an amino acid prone to oxidation by 
sodium metaperiodate), so it was thought that perhaps the cysteines were being 
oxidised to cysteic acid.
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Figure 4.15 ESMS showing periodate oxidation of RNase A peptide 4 after 10 
minutes
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Peaks correspond to +4 and +5 ions o f oxidised RNase A peptide 4 with multiple additional 
oxidations.
The oxidation reaction was repeated, but the reaction was quenched with ethylene glycol 
after 5 minutes. A sample was analysed by ESMS, and a similar pattern o f  peaks separated 
by 16 mass units was seen, except that peaks corresponding to the +5 and +4 ions o f  the 
hydrated glyoxal were visible along with the other oxidised products (Figure 4.16). 
Significant oxidation was therefore occurring even with short reaction times and so a 
solution to this oxidation needed to be found. As cysteine was the suspected source o f  the 
oxidation, protection o f  the cysteine during the oxidation and ligation reactions was 
proposed.
93
Chapter 4: Synthesis of Bovine Pancreatic Ribonuclease A
Figure 4.16; ESMS showing periodate oxidation of RNase A peptide 4 after 5 
minutes
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4.4.1.1 Protection of Cysteine During Periodate Oxidation
It was decided that a trial would be performed, where just the N-terminal 10 residues 
of RNase A peptide 4 would be synthesised with and without a protecting group on 
the single cysteine present in this sequence. Periodate oxidation of these peptides 
would determine whether cysteine was responsible for the aditional oxidation seen, 
as a protecting group on cysteine would prevent its oxidation to cysteic acid. The
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shorter peptide sequence would reduce the peptide complexity, by only containing 
one cysteine and also having a lower molecular mass making interpretation of MS 
data more straightforward.
The protecting group chosen for protection of the cysteine was a thio-tertiary butyl 
group (S-tBu). This group forms a disulfide with the thiol side chain, and can be 
removed by a reducing agent such as dithiothreitol (DDT) or tris(2-carboxyethyl) 
phosphine (TCEP). The peptides SDCRETGSSK and SDC(S-tBu)RETGSSK were 
synthesised by standard Fmoc peptide chemistry using the Prelude peptide 
synthesiser. Both peptides were oxidised using NaI0 4  under the same conditions as 
used previously (Chapter 3, Section 3.5). The ESMS results of the oxidation are 
shown in Figure 4.17.
Oxidation of the S-tBu protected peptide proceeded to the glyoxal, as shown by 
ESMS (Figure 4.17, D), visible as the glyoxal and the hydrated form of the glyoxal. 
Oxidation of the peptide containing an unprotected cysteine produced peptide 
containing multiple products (Figure 4.17 C). There were no peaks visible 
corresponding to the glyoxal or hydrated form of the glyoxal, but there were multiple 
peaks which were + 1  ions and + 2  ions separated by 8  mass units, and also a cluster 
of peaks at around 700 mass units, separated by 6  mass units.
It was clear from these results that the unprotected cysteine residues were responsible 
for the multiple products seen during oxidation of the 4^  ^ fragment of RNase A. As 
the focus of this investigation was on developing a route for sequential ligation, it 
was decided that the fragments of ribonuclease would be remade with S-tBu 
protection on the cysteines. No further investigation was made into the precise side 
reactions that were occurring with periodate oxidation in the presence of unprotected 
cysteine, but this is an area of study that can be investigated in the future.
The protection of cysteine with S-tBu allowed oxidation of the peptide to the 
glyoxal, and avoided the side reactions seen with unprotected cysteine.
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Figure 4.17: ESMS of SDCRETGSSK with and without cysteine protection, before 
and after oxidation
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A: SDCRETGSSK [M + H] 1069 
B: SDC(S-tBu)RETGSSK [M + H] 1157
C: multiple unidentified products (glyoxal-DCRETGSSK [M + H] 1038 [M + H3O] 1056 not 
visible)
D: glyoxal-DC(S-tBu)RETGSSK [M + H] 1026 [M + H3 O] 1144
4.6 Peptide Fragments of RNase A with Protected Cysteines
Three of the four peptide fragments of RNase A contained eysteine (Figure 4.6) and 
so these were resynthesised using Cys(S-tBu). The Prelude automated peptide 
synthesiser was used as this has capacity for up to 7 additional amino acids in 
addition to the 20 standard Fmoc amino acids. This meant that Cys(S-tBu) and the 
psuedoprolines required for the synthesis could be incorporated by the synthesiser.
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and so no manual synthesis was required. The peptides were cleaved and purified as 
described previously (Section 4.3). As before the yields of the two peptides with C- 
terminal hydrazide (Peptides 2 and 3) could not be calculated as the initial resin 
substitution was not measured. Peptide 4 was produced in 27% yield from starting 
resin substitution (Chapter 7, Section 7.2.9.4). Peptides eluted at a later retention 
time by HPLC, which is consistent with more hydrophobic peptides due to the 
protecting groups on the side chains of the cysteine residues. Peptide 3 was 
particularly hydrophobic and difficult to purify due to its late retention time.
4.6.1 Oxidation of Peptide 4 of RNase A with S-tBu Protected
Cysteines
Peptide 4 of RNase A protected with S-tBu on the three cysteines was oxidised to the 
N-terminal glyoxal. The peptide was not soluble in imidazole hydrochloride buffer, 
but was soluble in DMSO and so the peptide was first solubilised using a minimum 
quantity of DMSO and then diluted using imidazole buffer. The presenee of DMSO 
did not affect the oxidation reaction and oxidation with NaI0 4  proceeded smoothly to 
yield the glyoxal (Figure 4.18).
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Figure 4.18: Maximum Entropy plot for glyoxal of Peptide 4 protected with S-tBu
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glyoxal-DC(S-tBu)RETGSSKYPNC(S-tBu)AYKTTQANKHIIVAC(S-tBu)EGNPYVPVHFDASV 
[M + H] 4932 
[M + H3 O] 4950
4.6.2 Chemoselective Ligation with S-tBu Protected Cysteines
Ligation was attempted between the glyoxal of peptide 4 and the hydrazide of 
peptide 3, with both peptides protected at the eysteines with S-tBu. Both peptides 
were very difficult to solubilise in NaOAc buffer and required use of DMSO to 
initially dissolve the peptides. The reaction was stirred overnight and the peptides 
had preeipitated from solution. The reaction was resolubilised and a sample was 
analysed by ESMS, but only starting peptides were visible with no sign of ligated 
product.
Chemoselective ligation uses unprotected peptides as these are generally soluble in 
aqueous media. The use of S-tBu protection on the cysteines increased the 
hydrophobicity of the peptides such that they were no longer soluble in aqueous
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buffer, and so an alternative protection for the cysteines was investigated that would 
be more aqueous soluble.
4.6.3 Acetamidomethyl as Alternative Cysteine Protection
A common cysteine protection, usually used for forming disulfide bonds between 
cysteines is the acetamidomethyl group (ACM). ACM is less hydrophobic than S- 
tBu and so this was used as an alternative protection for the cysteines. The conditions 
for removal of this protection using h  forms a disulfide between two cysteines. 
Removal of the 8  ACM groups from the final ligated product would be likely to 
cause mixed disulfide formation, so these would need to be reduced using TCEP and 
the protein reoxidised to form the correct disulfides. For this reason ACM had 
initially been avoided. The other common cysteine protecting group is tBu but this is 
very difficult to remove from cysteine, and would be likely to have similar 
hydrophobicity problems as seen with S-tBu, therefore ACM was the only practical 
alternative.
The three peptide fragments were remade using Cys(ACM) and the same synthesis 
procedure as detailed in Section 4.6 and Chapter 7, Section 7.2.9.4. Solubilisation 
of the peptides was easier that with S-tBu protection and the peptides eluted with an 
earlier retention time during purification by RP-HPLC.
4.6.4 Oxidation of Peptide 4 of RNase A with ACM Protected
Cysteines
Peptide 4 of RNase A protected with ACM on the three cysteines was oxidised to the 
N-terminal glyoxal. The peptide was soluble in imidazole hydrochloride buffer and 
so no DMSO was required to solubilise the peptide. Oxidation with NaI0 4  proceeded 
smoothly to yield the glyoxal (Figure 4.19).
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Figure 4.19: Maximum Entropy plot for glyoxal of Peptide 4 protected with ACM
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glyoxal-DC(ACM)RETGSSKYPNC(ACM)AYKTTQANKHIIVAC(ACM)EGNPYVPVHFDASV 
[M + H] 4882 
[M + H3 O] 4900
4.6.5 Chemoselective Ligation with ACM Protected Cysteines
Ligation was attempted between the glyoxal of peptide 4 and the hydrazide of 
peptide 3, with both peptides proteeted at the eysteines with ACM. The glyoxal was 
easily solubilised in NaOAc buffer (pH 4.6), but peptide 3 required the use of DMSO 
to initially dissolve followed by dilution with NaOAc buffer. Ligation was tried at a 
number of different peptide concentrations and aniline concentrations but no ligation 
was achieved in any of these reactions. It was possible that the presence of DMSO 
was affecting the ligation, and so alternative solvents were also tried, including 
dimethylformamide (DMF) and hexafluoroisopropanol (HFIP). Use of DMF resulted 
in peptide precipitating from solution overnight. Use of HFIP maintained peptide 
solubility, but still did not result in any peptide ligation visible by ESMS.
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4.7 Conclusion
Peptide fragments of bovine pancreatic ribonuclease A have been synthesised with 
N-terminal serine as a masked glyoxal and C-terminal hydrazide, for use in 
sequential chemoselective ligation. This method enabled the peptides to be 
synthesised in high yield and purity.
Periodate oxidation of the C-terminal peptide fragment gave multiple products 
separated by 16 mass units which suggested oxidation was occurring as a side 
reaction. It was thought that cysteine could be responsible for this oxidation and so a 
shorter peptide fragment containing just a single cysteine and N-terminal serine was 
synthesised to test this theory. Protection of the cysteine with a S-tBu group allowed 
successful oxidation of the N-terminal serine to the glyoxal, whereas the 
corresponding peptide with an unprotected cysteine produced multiple products with 
no glyoxal visible by ESMS.
The peptide fragments were resynthesised using S-tBu protection for the cysteines. 
Oxidation of the C-terminal peptide fragment proceeded to the glyoxal without the 
additional oxidation products seen with the unprotected version of the peptide. 
Ligation could not be performed using these peptides due to poor peptide solubility 
in aqueous buffer, and so an alternative cysteine protection using ACM was tried. 
Peptide solubility was improved, particularly for peptide 2, but peptide 3 still 
required the use of organic solvent to solubilise. No ligation was possible between 
these peptides, and so further work is required to improve peptide solubility, either 
by use of alternative cysteine protection, or perhaps through the use of a solubilising 
peptide tag. This is discussed further in Chapter 6 .
During the time of this study, an alternative ligation approach using sequential native 
chemical ligation (NCL) has been used to synthesise the active protein by Fmoc 
synthesis in several fragments (Boerema (2007). The presence of the cysteines in that 
case provided the sites for ligation, and enabled synthesis of RNase A that was 
identical to the native protein. In the study presented in this thesis the presence of 
cysteines in the sequence caused problems with oxidation of peptide fragments. This
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was overcome by the use of protecting groups, but produced the problem of peptide 
solubility which prevented ligation occurring. It may be that the problems caused by 
cysteine are not surmountable and that this method of chemoselective ligation can 
only be applied to proteins that do not contain cysteine. However, peptides 
containing cysteine now have a method of synthesis, sequential NCL, and so it is 
only in peptides not containing cysteine, or perhaps where the positions of the 
cysteines are not suitable sites for ligation that an alternative method of ligation is 
required. This is discussed in further detail in Chapter 6 .
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5.0 Introduction
Non-amide chemoselective ligation produces quite different structures to a natural 
peptide bond. In the chemoselective bonds studied for this thesis, the peptide 
backbone is one bond length longer than the natural peptide bond, and one or more 
amino acid side chains are lost or replaced with a different chemical group (Chapter 
3, Section 3.1). Chemoselective ligation between an N-terminal glyoxal and C- 
terminal hydrazide produces a ligated product that closely resembles the natural 
peptide (Chapter 3, Figure 3.1). However there are still major structural differences, 
which when incorporated into a protein may have an effect on protein structure and 
function. The objective of this study was to model this chemoselective bond using a 
molecular dynamics (MD) simulation, and use these data to predict the implications 
of these non-amide bonds to protein structure and function, by studying the effect of 
these bonds on the structure of bovine pancreatic ribonuclease A (RNase A).
This chapter describes the basic theory behind MD calculations and the constraints 
that are required to allow calculations to be performed in hours, rather than days or 
weeks. The chapter then focuses on MD simulations of native ribounuclease and 
ribonuclease modified to contain chemoselective bonds. The structures were 
superposed and calculations performed to measure the similarity between the 
structures, allowing predictions to be made about the effect of chemoselective bonds 
on the structure of proteins.
5.1 Theory of Molecular Dynamic Simulations
Molecular dynamics, the computer simulation of interactions of atoms over time, 
using equations to approximate the physical interactions, has developed into an
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exceptionally powerful tool for the simulation of complex molecular systems. The 
ever increasing computational power and availability of increasingly powerful 
software packages mean that molecular dynamic simulations have moved from the 
realm of the computational chemist into an accessible tool for all chemists. The 
software package available at the University of Surrey and used in this study is called 
Molecular Operating Environment (MCE) (MOE.2007.09, Chemical Computing 
Group Inc^). This section briefly describes the theory behind MD calculations and 
energy minimisation calculations required to perform an MD simulation.
5.1.1 Forcefield
A molecular dynamics simulation takes a system of atoms in defined positions and 
applies a forcefield (potential energy) between each atom, at a series of timesteps. 
The forcefield is an equation that approximates the total potential energy of the 
system. This is usually split into bonded atoms, with the forces approximated by a 
simple harmonic oscillator for bond length, with additional terms for changes in 
angles and torsions, and non bonded atoms (Van der Waals and eleetrostatic 
charges).
AMBER (Assisted Model Building and Energy Refinement) is a set of forcefields 
developed for the simulation of biomolecules such as proteins by Cornell et al. 
(1995). There are many versions of Amber and the version available within MOE at 
the time of this study was AMBER99. The general equation for the AMBER force 
field has the following form:
V = - h f  -  OoŸ + + oosin^  -  ?)„)]
N-\ N
This equation calculates the total potential energy of a system V as the sum of four 
terms. The four terms in the equation describe the following four interactions:
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1:
= force constant 
/ = bond length 
Iq = ideal bond length
the sum of all covalently bonded atoms in the system, modelled in AMBER as 
simple harmonic motion, so each covalent bond is modelled as a simple harmonic 
oscillator:
2 :
= force constant 
6 = bond angle 
Oq = ideal bond angle
the sum of all angles, which calculates the energy due to the alignment of the orbitals 
in the covalent bonds also modelled as a simple harmonic oscillator;
3: +
= barrier to rotation
n = periodicity 
(J) -  torsion angle
^ 0  = phase factor
the sum of all torsions, which calculates the energy due to twisting of bonds, 
modelled as a periodic Fourier series, as bonds can rotate through 360°;
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for two atoms i and j
A and .B = Van der Waal constants
R = non-bond distance (Van der Waals)
q = atomic charge
Sq = dielectric constant
r = non-bond distance (Electrostatics)
the sum of all non-bonded atoms. This is split into two parts, the first representing 
Van der Waals interactions using the Lennard-Jones potential model (Lennard-Jones, 
1924)), and the second representing electrostatic charges. The AMBER forcefield 
models the electrostatic charges as excess or deficit of the sum of the total charge 
from the protons and electrons as a single partial point charge at the atom centre, 
using Coulomb’s law.
The AMBER forcefield requires a set of parameters (standard bond lengths, angles, 
torsions and charges). A specific parameter set called ff99 (Wang et al. (2000)) for 
modelling of organic and biological molecules such as peptides and proteins was 
used in this study.
5.1.2 Energy Minimisation
Energy minimisation is required before a molecular dynamics simulation is run. This 
adjusts the positions of all the atoms in the system until a local energy minimum is 
found, which ensures that no atoms are positioned too closely together. It is essential 
that this is run prior to the molecular dynamics simulation; otherwise the system may 
be started in a very unstable energy state, which causes the whole system to fall apart 
once the simulation is run.
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An energy minimisation calculation uses the principle that the forces on the system 
are equal to the negative gradient of the total potential energy. The calculation is 
performed on a static structure, i.e. the structure where temperature = 0 K. The 
potential energy of the system is calculated from the position of all the atoms, and 
then the confirmation of the atoms is changed in the direction of the forces on the 
atoms, which decreases the total potential energy of the system. The change in 
energy is plotted on an energy surface, and a minimum is found when the gradient of 
the potential energy is zero. The algorithms used for energy minimisation do not 
necessarily locate the global minimum of the system, as the calculations drive the 
energy of the system downwards (calculations would need to go upwards to move 
out of a local minimum), however a local minimum energy state is usually of 
sufficiently low energy that a MD simulation can be run.
5.1.3 Molecular Dynamics Calculations
Molecular dynamics most commonly uses classical mechanics as the basis of the 
calculations. Quantum mechanics can be used as a basis for calculations (defined as 
ab initio methods by Parr et al. (1950)). Quantum mechanical calculations model the 
electrons in a system as waves by approximating the Schrodinger equation, however 
the calculations are computationally complex and current computing power allows 
only small molecules containing tens of atoms to be studied in this way. For large 
biomolecules such as proteins, use of classical mechanics allows calculations to be 
performed on many hundreds of atoms.
The forcefields such as the AMBER forcefield described in Section 5.1.1 models the 
atoms using geometric terms such as bond lengths and angles and the dynamics 
simulation uses Newtonian mechanics. Newton’s second law of motion relates force 
to acceleration:
F  = ma
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The force on an atom can be related to the mass of each atom and its acceleration, 
expressed as the second derivative with respect to time.
F _ d ^r  
m dt^
Integrating this equation with respect to time gives the velocity of the atom:
dr (  F
dt
— \t + c = v 
y m
The force on each atom is calculated as the change in energy between its current 
position at time t and its position a small distance away at time t + ôt. The position at 
time t + 6 t can be calculated from the position at time t using a truncated Taylor 
series:
r(t + St) = r(t) +— At + ^ - ^ A —
The truncation of this series is required for computational simplicity, but creates a 
source of error. This error can be partially addressed by using an algorithm known as 
the Verlet algorithm (Verlet (1967)). This involves two Taylor series expansions, one 
for r(t + ôt) and the other for r(t - ôt). Combining the two expansions gives an 
expression for position at time r(t + ôt) that does not contain the velocity, so although 
the Verlet algorithm corrects some of the errors in the Taylor series expansion, 
velocities cannot be calculated directly.
An alternative, known as the leapfrog algorithm, developed by Hockney (1970), 
calculates the positions at integer time points and velocities at integer + 1 / 2  time 
points such that they leapfrog over each other.
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r{t + St) = r(t) + Stv(t + i  St) 
v(t + ^ à )  = v ( t - ^  St) + Sta(t)
The leapfrog algorithm therefore allows direct calculation of velocities and so was an 
improvement on the Verlet algorithm. The algorithm used within MOE is called 
velocity-Verlet (Swope et al. (1982)) and incorporates aspects of both the Verlet and 
leapfrog algorithms, calculating both position and velocity for the same timestep. 
The velocity-Verlet algorithm uses a half timestep to calculate the velocity but then 
uses this half timestep to calculate the velocity at the full timestep.
v{t 4—  St) — v(t) 4—  at + St 
^ 2 2
r(t + ^ à )  = r(t) + v{t + ^  St)St 
v(t + St) = v(  ^+ St) + ^ a ( t + St)St
The velocity-Verlet is the current best algorithm for compromise between 
computational efficiency and accuracy.
Another error in MD calculations is due to the assumption that acceleration and 
velocity remains constant between time t and time t + ôt. This means that the longer 
the timestep the larger the error, as velocity and acceleration are not actually 
constant. For this reason the timesteps in MD must be short, in the order of 10’^^  
seconds, so that they are in the same timescale as the smallest scale vibrations in the 
system, i.e. bond vibrations.
5.1.3.1 Initial Velocities
In MD simulations the position of the atoms are usually taken from a crystal 
structure, and an energy minimisation is performed to adjust the position of the
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atoms into a low energy state ready for the simulation to be performed. However an 
MD simulation also requires that each atom has an initial velocity, which is 
information that isn’t known. The initial velocities are therefore assigned using the 
Maxwell-Boltzmann distribution.
f(Y)  =
1
^  ^-mv^nkFT
y l 7 ± s T  j
/ (F) = distribution of speeds F 
m = mass
kg = Boltzmann constant
T = temperature
A constant temperature is required throughout the simulation, however temperature 
tends to change during the simulation due to the non-bonded cut-off constraint 
(Section 6.14.1). The velocities are therefore periodically rescaled during the 
simulation to keep the temperature constant.
5.1.4 Constraints
A molecular dynamics simulation requires a number of constraints to be applied to 
the system. The time a simulation takes to run will depend on the number of atoms in 
the system, the size of the timestep and number of timesteps. For the simulation to be 
of relevance the total length of the simulation must be in the timescale of molecular 
motion, so ideally in the nanosecond range. However, even with modem computers 
simulations can take from days to weeks on multiple computers, so a series of 
constraints are required to reduce the computational complexity of the calculation. 
The constraints used in this study were a non-bonded cut-off, solvent model, periodic 
boundary conditions and the NTP ensemble, which are described below.
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5.1.4.1 Non-bonded Cut-off
The most intensive part of the simulation is the calculation of the potential energy 
due to unbonded atoms, i.e. the calculation of Van der Waals and electrostatic 
interactions. These interactions are of importance throughout all space, but as 
distance increases the effect decreases as the reciprocal of distance, so short distance 
interactions have a greater importance than longer distance interactions. For this 
reason a non-bonded cut-off is applied which means that all non-bonded interactions 
at a distance greater than this cut-off are ignored. This compromise greatly reduces 
the size of the calculation without greatly affecting the outcome of the calculation.
5.1.4.2 Solvent
Simulations of biomolecules such as proteins are usually run in a solvent such as 
water, to most accurately model the system. There are two types of solvent that can 
be used, implicit or explicit. Implicit solvent models the solvent as a continuum 
rather than as discrete molecules. In explicit solvent models each solvent molecule 
individually interacts with the simulation giving a more realistic model than implicit 
solvent, but for computational efficiency the solvent is usually simplified to a rigid 
structure, therefore only interacting with the system via non-bonded interactions.
In this study water was used as an explicit solvent (to most closely simulate the 
laboratory environment), using a model called TIP3P (Jorgensen et al. (1983)), 
which models the water molecule as a rigid structure with the bond lengths and 
angles set to the average lengths and angles of a water molecule. Three point charges 
are applied to the three atoms, and the potential energy is calculated by a Lennard- 
Jones potential in a similar fashion to the non-bonded interactions in the AMBER 
forcefield (Section 5.1.1).
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5.1.4.3 Periodic Boundary Conditions
Periodic boundary conditions (PBC) are applied, which means that although the 
simulation is run in a three dimensional box, or unit cell, molecules on one edge of 
the box can interact with those on the opposite side; indeed a molecule can disappear 
from one side of the cell and reappear on the other side with the same velocity. This 
avoids edge conditions, which can produce unusual results in the energy calculation. 
PBC usually uses the minimum-image convention, which means that each atom will 
only interact with the closest image of each other atom.
6.1.4.4 NTP Ensemble
An ensemble is a concept in statistical mechanics and thermodynamics, which is 
used to describe a system containing a large number of particles, such as an MD 
simulation. Four properties, pressure P, volume V, temperature T, and number of 
particles N are used. Three of these properties are held constant, allowing only one 
property to change.
The most relevant constraining system used in biomolecular molecular dynamics is 
known as the Isothermal-Isobaric ensemble or NTP. In this system N - number of 
atoms, T - temperature and P -  pressure of the system are held constant, so only 
volume is allowed to change. This set of constraints most realistically represents the 
conditions of a laboratory experiment, and is the ensemble used in this study.
5.2 Root Mean Square Deviation as a Tool for Interpreting
Structural Similarities
Root mean square deviation (RMSD) is a common measure of the similarity between 
two protein structures. Two protein structures of the same residue length are 
superposed and the coordinate position of each C a atom that forms the backbone of 
the two structures is used to give the mean distance between each C a atom. The root
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of the square of the means gives a value in Â that can be used to compare structural 
similarities.
RMSD is calculated using the equation
RMSD =
where and r,. correspond to the three dimensional coordinates of the C a atoms for
the two protein chains and N=  number of residues. Within MOE, two protein 
sequences are superposed and aligned using a program called FITT (Finkelstein 
(1987)) which uses an algorithm to orientate the molecules so that the RMSD is 
minimised.
An RMSD value of zero would be produced for the superposition of two identical 
protein molecules. As the difference between the structures increases so does the 
RMSD value. A study comparing the RMSD of pairs of homologous proteins by 
Chothia et al (1986) found that the RMSD was always <3 Â for homologous 
proteins, and so this figure has since been adopted as the figure for defining 
structural similarity between protein molecules.
5.3 Molecular Dynamics Simulations
MD simulations were run on native RNase A and RNase A containing 
chemoselective bonds (Chapter 7, Section 7.4.1). MD was also performed on RNase 
A containing a single amino acid mutation of Cys to Ala, which allowed the method 
to be validated against published experimental results.
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5.3.1 Molecular Dynamics Simulation of Native Bovine 
Pancreatic Ribonuclease A
A molecular dynamics simulation was first performed for native RNase A (C h a p ter  
7 , S ection  7 .4 .1 .1 ), which would allow subsequent simulations of ribonuclease 
containing chemoselective bonds to be compared to the native protein. F ig u re  5.1  
shows the structure of native RNase A placed inside a virtual box of water. The box 
size was made as small as possible to minimise the number of water molecules in the 
simulation, therefore minimising the computational complexity. After energy 
minimisation of this structure the MD simulation was run using 200 timesteps of 0.5 
ps, to generate a database file with 2 0 0  entries representing 1 0 0  ps of simulation. 
This simulation took approximately 2 hours to run. 100 ps is a short simulation time, 
but as this simulation was of native ribonuclease with no modifications, it was only 
necessary to run a simulation until the energy of the system had stabilised, as any 
longer simulation would only produce a larger dataset giving the same information.
F ig u re  5.1: Native bovine pancreatic ribonuclease A solvated with H2 O
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The final frame of the MD simulation (t = 100 ps) was loaded into MOE together 
with the energy minimised structure prior to running the simulation (Figure 5.2). 
Root mean square deviation (RMSD) calculations were made using the superpose 
function in MOE, which gave a figure of 1.51 Â. Section 5.2 explains the theory and 
significance of RMSD as a tool for the comparison of superposed protein structures. 
The two structures contain identical atoms and bond connectivity. The only 
difference between the two structures is that a short MD simulation was run, 
allowing the atoms to shift from their energy minimised positions to final positions at 
the end of the simulation.
The two superposed structures are represented as ribbon cartoons, which show the 
backbone of each structure as a ribbon. The MOE software recognises regions of a- 
helix (red) and p-sheet (yellow) and loops (blue). Regions in green are recognised by 
the software as helical, but not of the exact a-helix conformation for the software to 
replace with the red ribbon. The process of MD has moved the atoms out of the rigid 
structures found in a crystal, and the final frame provides a snapshot of the molecule 
as it may exist at any one moment in solution.
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Figure 5.2: Superposition of native RNase A before and after MD
RMSD = 1.51 Â
Similar RMSD calculations were perfomed by superposing the initial structure of 
ribonuclease before MD with two other timepoints through the simulation, at t = 50 
ps and t = 75 ps. RMSD values of 1.45 Â and 1.10 A were obtained.
A study by Santoro et al. (1993) compared the structures of 16 MD simulations of 
native RNase, and produced an average RMSD of 0.92 Â from the crystal structure, 
which is slightly smaller than the RMSD values calculated in this investigation.
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5.3.2 Replacement of Ligation Sites with Chemoselective Bonds
RNase A containing oxime and hydrazide chemoselective bonds were created within 
MOE and these were used in MD simulations as detailed below.
5.3.2.1 Replacement of Ala20 with an Oxime Bond
The structure of ribonuclease was created with Ala20 replaced with an oxime bond, 
formed through reaction of an N-terminal hydroxylamine with a C-terminal aldehyde 
(Chapter 7, Section 7.4.1.2). The energy minimised structure of native ribonuclease 
A was loaded into MOE and, and superposed with the modified version of 
ribonuclease containing the Ala20 oxime replacement. The molecules were selected 
in cartoon mode, which draws the backbone as a coloured ribbon showing regions of 
loops, alpha helices and beta sheets. As the oxime bond is not recognised as protein 
backbone by the software, this was represented with a stick structure. The overlaid 
structures after energy minimisation visually showed close structural similarity 
(Figure 5.3), although no RMSD calculations were performed on these structures, as 
this was a preliminary study to the main investigation.
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F ig u re  5.3: Overlay of native ribunuclease and ribunuclease with Ala20 replaced 
with an oxime bond.
Whilst these molecular dynamic studies were being performed, the experimental 
synthesis of ribunuclease by chemoselective ligation was no longer continued using 
the oxime bond (C h a p ter  3 , S ection  3 .3 ), so no further modelling was perfomed 
using the oxime bond. The direction of the chemoselective bonds was reversed 
(C h a p ter  3 , S ection  3 .4 ), and all further modelling studies were performed using 
hydrazide bonds between an N-terminal glyoxal and a C-terminal hydrazide.
S.3.2.2 Replacement of Ala20, Ala52 and Thr82 with a Hydrazide 
Chemoselective Bond
Each site was in turn replaced with the structure of a hydrazide bond formed through 
reaction between an N-terminal glyoxal and a C-terminal hydrazide (C h a p ter  7,
118
Chapter 5: Molecular Dynamic Simulations
of Bovine Pancreatic Ribonuclease A
S ection  7 .4 .1 .3 ). F ig u re  5 .4  shows the structure of He81-Thr82-Asp83 in native 
RNAse A and in the ligated structure with a hydrazide bond.
F ig u re  5.4: Overlaid structures of He81-Thr82-Asp83 in native RNase A and RNase 
A containing a hydrazide chemoselective bond.
Hydrazide
After each bond was replaced, the structure was run through an energy minimisation 
using the AMBER 99 forcefield, firstly just on the replaced atoms, and then using the 
proximity tool to identify all atoms close to the changed bonds. Once all three bonds 
had been replaced the whole system was then minimised once more. The structure 
was then superposed with the structure of energy minimised native ribonuclease 
(F ig u re  5 .5 ). MOE was no longer able to recognise regions of a-helix or (3-sheet 
using the ribbon mode of representing the structures. Therefore all structural 
comparisons of ribonuclease containing chemoselective bonds were converted to line 
drawings representing the carbon framework of the protein, as this was a clearer way 
to visualise the structures. RMSD calculations were made using the superpose 
function in MOE and gave a figure of 1.17 Â, which represents close structural 
corrrelation.
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Figure 5.5; Native ribonuclease superposed with ligated ribonuclease before 
molecular dynamics simulation
Grey = native ribunuclease 
Blue = ligated ribunuclease 
RMSD = 1.17 Â
5.S.2.3 Molecular Dynamics Simulation of Bovine Pancreatic 
Ribonuclease A containing Three Hydrazide Bonds
The molecular dynamics simulation was run on the structure of ribonuclease 
containing three hydrazide bonds using the same constraints used for native 
ribonuclease (Chapter 7, Section 7.4.1.4). Figure 5.6 shows the total potential 
energy of the system plotted against time. For the first 30 ps of the simulation the 
energy of the system fluctuated quite dramatically which is due to the system being 
started in a high energy state, as energy minimisation calculations only find a local 
minimum energy state. This energy minimum allows the MD simulation to be run 
without the system falling apart due to calculation errors caused by unnaturally high
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forces in the system. After approximately 50 ps the energy of the system stabilised, 
but showed a gradual overall increase in energy over the next approximately 1 0 0  ps. 
The final 50 ps of the simulation gave a stable energy trace, and so it was not 
neeessary to run the simulation for longer timescales.
Figure 5.6: Energy plot (KJ/Mol) for MD simulation of ribonuclease containing 
hydrazide bonds
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The structure was then superposed with the structure of native ribonuclease after 
molecular dynamics using the final frame of the MD simulation (t = 200 ps) (Figure 
5.7). The calculated RMSD value was 2.20 Â. Any value under 3 A is eonsidered to 
be close structural similarity, and so a value of 2 . 2 0  A represents a structure of 
comparable similarity to two homologous proteins, that is two proteins from different 
organisms sharing a common catalytic mechanism, but with differences in primary 
sequence. The results of the dynamic experiment for ribonuelease A eontaining three 
hydrazide bonds can be interpreted as producing protein with sufficient structural 
similarity to native ribonuclease that any effect on catalytic mechanism is likely to be 
negligible.
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Figure 5.7: Native RNase A superposed with ligated RNase A after moleeular 
dynamics simulation (t = 2 0 0  ps)
Grey = native ribunuclease
Green = ligated ribunuclease 
RMSD 2.20 Â
Similar RMSD calculations were perfomed by superposing the initial structure of 
ribonuclease before MD with two other timepoints through the simulation, at t = 100 
ps and t = 150 ps. RMSD values of 2.38 A and 2.16 A were obtained. Figure 5.8 
shows the superposition of the three structures produced at the timepoints; t = 1 0 0  ps, 
t = 150 ps and t = 2 0 0  ps.
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Figure 5.8: Superposition of RNase A containing three hydrazide bonds from three
J.-'
different timepoints; t = 1 0 0  ps, t ^  150 ps and t = 2 0 0  ps
S.3.2.4 Replacement of Cys 65 with Ala
Bovine pancreatic ribonuclease A has 4 disulfide bonds. Extensive studies have been 
performed to elucidate the folding and order of disulfide formation of ribonuclease, 
including a study by Talluri et al. (1994). In this investigation they removed a single 
disulfide bond between Cys65 and Cys72, either by reaction of these two thiols 
groups with iodoacetate, or replacement of cysteine with cysteamine to form des-[65- 
72] RNase A. They were following previous studies by Rothwarf et al. (1991) who 
used dithiothreitol as a reductant to partly denature RNase A. Their work had 
suggested the disulfide between Cys65 and Cys72 was the final of the four disulfides 
to form during the folding process. Talluri et al. (1994) compared NMR solution 
structures of des-[65-72] RNase A to the crystal structure of native RNase A, and 
obtained an RMSD of 1.53 Â. Their conclusion was that the close structural 
similarity between the two structures meant there was no high energy barrier to
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overcome during formation of the final disulfide, as only minor conformational 
changes would be required.
Des-[65-72] RNase A was chosen to test the validity of the MD simulations used in 
this study. Superposition of the structure of native RNase A with the structure of des- 
[65-72] RNase A generated through MD simulation should produce a value for the 
RMSD close to the value of 1.53 Â found by Talluri et al. (1994), from experimental 
NMR solution data.
The easiest way to produce a structure for Des-[65-72] RNase A within MOE was to 
create a single mutation of one cysteine that would prevent formation of the 
disulfide. Cys 65 was replaced with Ala (Chapter 7, Section 7.4.1.5), which 
removed the disulfide bond, as alanine has no thiol side chain for disulfide formation. 
The structure was energy minimised, and the MD simulation was run (Chapter 7, 
Section 7.4.1.5) using the same set of constraints as used for the previous dynamics 
experiments (Sections 5.3.1 and 5.3.2.3, Chapter 7, Sections 7.4.1.1 and 7.4.1.4).
The structures of native RNase A and Des-[65-72] RNase A after MD were 
superposed (Figure 5.9), using the final structure from the dynamic simulation at t = 
200 ps. Ribbon structures were able to be used to represent the backbones of the 
structures as both molecules contain only natural amino acids and peptide bonds. The 
RMSD was calculated and gave a value of 1.29 Â.
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Figure 5.9: Cys65Ala RNase A superposed with native RNase A
RMSD = 1.29 Â
The value of 1.29 Â calculated from the dynamic simulation was in close agreement 
with the value of 1.53 Â ealculated by Talluri et al. (1994) from experimental data. It 
is therefore reasonable to assume that the MD simulations performed and RMSD 
values calculated in this study give a valid representation of the actual structure of 
RNase A containing chemoselective bonds.
5.4 Conclusions
Molecular dynamics simulations were run using bovine pancreatic ribonuclease A as 
an example protein, to compare the structures of native RNAse A to the structure of 
RNAse A containing chemoselective bonds. The study was limited to looking at the 
bonds used in the synthetic aspects of this thesis. The modelling studies were 
performed concurrently with the synthetic experimental studies, and so adaptations
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were made to mirror the directions taken during progression of the experimental 
work.
Simulations of native RNase A and RNase A containing hydrazone chemoselective 
bonds were performed, and the structures superposed. RMSD calculations gave 
values lower than 3 Â which means the proteins had close structural similarity. This 
implies that the presence of these chemoselective bonds does not greatly affect the 
structure of the protein, and should therefore have little effect on the catalytic activity 
of the enzyme.
The validity of the technique was tested using a version of RNase A mutated to 
contain an alanine in place of a cysteine, removing a single disulfide bond. The 
superposition of mutated and wildtype RNase A from the MD simulations gave 
similar RMSD values to published experimental RMSD values from NMR studies.
MD simulations on proteins containing chemoselective bonds have not been 
performed before, and so this study provides an important foundation for this type of 
study. The results of the MD simulations suggest that the method provides a realistic 
model of the structure and dynamics of a protein containing chemoselective bond. 
Further work is required, for example to look at the effect of positioning 
chemoselective bonds in positions that are predicted to affect the structure of the 
protein. This is discussed in more detail in Chapter 6.
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6.0 Conclusions and Future Work
Chemoselective ligation is a technique that can be used to join peptides together, and 
enable the total chemical synthesis of proteins that cannot be made in a single chain by 
solid phase peptide synthesis. The work presented in this thesis evaluates sequential 
chemoselective ligation as a method of joining more than two peptides, which can 
allow the production of larger peptides and proteins. A large number of different 
methods of chemoselective ligation have been reported, but this investigation has 
focused on the most common method, which is the reaction between an aldehyde and 
either hydroxylamine or hydrazine. In Chapter 1, the area of solid phase peptide 
synthesis for the total synthesis of peptides and proteins was introduced, and several of 
the chemoselective ligation methods that have been used in recent years for the 
synthesis of proteins have been described.
The basis of initial studies was an extension of the work of Sharma and Broadbridge 
(Broadbridge et al (2001)), which used a 1, 2-diol as a masked aldehyde, for the 
sequential ligation of several peptide fragments. This investigation started with the aim 
of increasing the yields both of individual peptide fragments and of the ligated peptide 
products, which would allow the technique to be used for the commercial production 
of peptides and proteins. A 1, 2-amino alcohol was investigated as a replacement for 
the 1, 2-diol, as an amine is more reactive than an alcohol towards the solid support 
used during synthesis, which was predicted to improve peptide yields. This required 
development of a synthetic route for conversion of the carboxylic acid group of an 
amino acid to an amino alcohol. In Chapter 2 the use of a 1, 2-diol as a masked 
aldehyde was reviewed, and then a synthetic route for the synthesis of 1, 2- amino 
alcohol derivatives of Fmoc protected amino acids was described, for use in the solid 
phase synthesis of peptides bearing C-terminal amino alcohols. The method of 
synthesis developed was successful, and was used to synthesise amino alcohol 
derivatives of several Fmoc protected amino acids in good yield. Unfortunately, a
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number of problems, detailed in Chapter 2, meant that these derivatives were not 
suitable for the synthesis of peptides bearing C-terminal amino alcohols or aldehydes, 
and so an alternative approach was investigated, swapping the amino alcohol to the N- 
terminus of the peptides, by using an N-terminal serine as a masked glyoxal.
In Chapter 3 the historical use of serine or threonine as an N-terminal masked 
aldehyde was reviewed. The structures of the chemoselective bond were compared 
between the initial approach of a C-terminal aldehyde and N-terminal hydrazine or 
hydroxylamine, and the alternative approach of an N-terminal aldehyde and C- 
terminal hydrazide. Short test peptides with either an N-terminal glyoxal or C-terminal 
hydrazide were synthesised in high yield and purity, and ligation of the peptides 
demonstrated the suitability of the technique for use in sequential chemoselective 
ligation. This investigation demonstrated the first use of aniline as a nucleophilic 
catalyst in hydrazone chemoselective ligation to dramatically increase ligation reaction 
rates. Similar results from experiments performed at the same time as this 
investigation have been published by Dirksen et al. (2008).
Bovine pancreatic ribonuclease A (RNase A) was chosen as an example protein to 
extend the method of ligation between an N-terminal glyoxal and C-terminal 
hydrazide to the total synthesis of a protein by sequential chemoselective ligation. A 
background to RNase A structure and catalysis was described in Chapter 1. In 
Chapter 4 the synthesis of peptide fragments of RNase A bearing N-terminal masked 
glyoxal and C-terminal hydrazides in high yield was presented. Periodate oxidation of 
the C-terminal peptide section of RNase A showed multiple oxidation, which was 
demonstrated to be due to the presence of unprotected cysteine residues in the peptide. 
The use of cysteine protection prevented the unwanted oxidation reaction occurring 
but the protecting groups increased peptide hydrophobicity, which caused problems 
with solubilising the peptides and prevented ligation from occurring.
Poor peptide solubility during solution phase reactions is a common problem and a 
possible solution to this could be use of a solubilising peptide tag. A penta-lysine tag 
attached to the C-terminus via a base cleavable linker was recently used by Hossain et 
al (2009) to increase peptide solubility of the A chain of human insulin glargine
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during disulfide bond formation. This peptide has known solubility problems and the 
presence of the five lysine residues was sufficient to solubilise the peptide and allow 
disulfide bond formation to occur. A similar approach could be applied for the 
solubilisation of peptide fragments for sequential ligation, but the N and C-termini of 
the peptides are required for ligation. Therefore the solubilising tag would be required 
at an alternative location, for example on the side chain of an aspartate or glutamate 
residue instead of the C-terminal carboxyl. This would require a minor modification to 
the tag so that instead of being used as a linker between the peptide and the solid 
support it could be incorporated onto the side chain of aspartate or glutamate during 
solid phase synthesis.
Alternatively the solubility issues could be resolved by using a different cysteine 
protection that instead of increasing the hydrophobicity of the peptide could be used to 
increase peptide solubility. All the commercially available cysteine protections used in 
solid phase peptide synthesis are more hydrophobic than an unprotected cysteine and 
so a new protecting group would have to be designed for this purpose. The S-tBu 
protection used initially in this study to protect the cysteines forms a disulfide bond 
between the thiol side chain of cysteine and the thio-tertbutyl group. One solution 
could be to protect the cysteines though formation of a disulfide bond to a hydrophilic 
thiol such as a polyethylene glycol (PEG) thiol. Woghiren et al. (1993) used an 
activated PEG thiol to reversibly modify a protein through disulfide formation and 
reduction to reform the native protein. In this example a long 5000MW PEG was used, 
but short PEG molecules from 2 ethylene glycol units up to 24 ethylene glycol units 
are commercially available, pre activated with pyridyl-2-disulfide. It should only be 
necessary to add a short PEG-thiol as a protecting group, as the peptide fragments with 
unprotected cysteine were soluble and it was only the presence of hydrophobic 
cysteine protecting groups that caused solubility problems. There are two possible 
ways that the PEG-thiol protection could be used. An N-alpha Fmoc protected 
cysteine could be synthesised with the cysteine side chain protected with PEG-thiol, 
for use in solid phase peptide synthesis. Alternatively the peptide could be synthesized 
with the normal trityl protection on cysteine and a PEG-thiol could be used to protect 
the cysteine on the fully deprotected and purified peptide, as a post synthesis 
modification.
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The presence of a chemoselective bond in replacement of a natural peptide bond 
would be expected to have an effect on the structure of the peptide or protein, which 
could have implications for the biological activity of that protein. An important aspect 
of this study was to investigate the structures formed through the presence of 
chemoselective bonds, and to compare these to the native protein structure. Molecular 
modelling using molecular dynamics simulations was chosen as a method to study the 
bond structures and to compare protein structures. Molecular dynamic simulations 
were performed on native RNase A containing only natural peptide bonds and RNase 
A with one or more peptide bonds replaced with chemoselective bonds. Final 
structures of the protein after the molecular dynamics simulations were superposed 
and calculation of root mean square deviation (RMSD) values was used to evaluate the 
effect of chemoselective bonds on the structure of the protein. Chapter 5 described 
the background to the theory of molecular dynamics simulations, and the experiments 
that were performed. The computational methods used are described in Chapter 7.
The results of the dynamics experiments gave RMSD values of less than 3 Â for the 
superposition of native RNase A and RNase A containing three hydrazone 
chemoselective bonds. A value of under 3 Â means that the two structures share 
significant structural similarity and suggest that the presence of these hydrazone bonds 
have little effect on the structure of ribunuclease, and therefore on the activity of the 
enzyme. The experiments presented here represent the first dynamics simulations 
performed on a protein containing chemoselective bonds. These initial studies gave 
promising results for the potential of dynamics simulations to accurately predict 
protein structure when natural peptide bonds are replaced with alternative non-amide 
bonds. More investigation is required to simulate the effect of placing chemoselective 
bonds in different locations within RNase A and other proteins and to compare the 
results to experimental data. This will allow further evaluation of this computational 
method for the prediction of the effect of positioning chemoselective bonds within 
proteins.
An original aim of this investigation had been to compare the enzyme activity of 
native RNase A with that of ligated RNase A using a simple kinetic assay such as the
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hydrolysis of cytidine 2':3'-phosphate (Crook et al (I960)) or hydrolysis of poly(C) 
(delCardayré et al (1994)). This would measure the effect of the chemoselective 
bonds on RNase A enzyme activity and allow comparison to the predictions of the 
dynamics simulations. Total synthesis of ligated RNase A was not achieved and so it 
was not able for this part of the investigation to be performed. If a successful synthesis 
of RNase A using this method of ligation can be achieved in future then these activity 
experiments will give valuable information about the effect of the bonds on enzyme 
activity.
It may be found that the synthesis of RNase A is not possible using this ligation 
technique, due to the side reactions and solubility issues related to cysteine that were 
discovered during this investigation. A large number of proteins exist which do not 
contain cysteine and some of these would be suitable proteins for testing the 
technique. One example could be Bamase, which is a 110 amino acid protein with 
ribonuclease activity that contains no cysteines. A version synthesised to contain 
ligated bonds could be compared to the native protein using an enzyme assay in a 
similar manner to RNase A, and also using molecular dynamics simulations to 
investigate the effect of the ligated bonds to the structure of the protein.
The work presented in this thesis evaluated the use of sequential chemoselective 
ligation for the synthesis of an example protein RNase A, and demonstrated the use of 
molecular dynamics simulations for the prediction of the effect of these bonds on the 
protein structure. In this chapter suggestions have been made to improve the solubility 
of peptide fragments while protecting cysteine residues, which may allow successful 
sequential ligation of RNase A. Additional dynamics experiments will be required to 
further evaluate the technique as a method of predicting protein structure enabling its 
use as a tool in peptide ligation.
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7.0 Introduction
This chapter lists materials and suppliers, and experimental detail for experiments 
performed. Method development is described in Chapters 2, 3, 4 and 5. The 
equipment and instrumentation used is listed and described. All work was carried out 
at Peptide Protein Research Ltd unless specified.
7.1 Materials
Chemicals were purchased from Novabiochem, Nottingham, UK; Sigma Aldrich, 
Dorset, UK; Alfa Aesar, Lancashire, UK; Fisher Scientific, Leicestershire, UK; 
BOG, UK, Iris Biochem, Waldershofer, Germany, and National Diagnostics, Hull, 
UK, as specified below.
Table 7.1: Chemicals and Suppliers
Chemical
Abbreviation / 
Formula Supplier
2-Chlorotrityl chloride resin 2-CTR Iris Biochem
Acetic anhydride AC2O Sigma Aldrich
Acetone Fisher
Acetonitrile MeCN National Diagnostics /  Sigma Aldrich
Amberlyst A26 Sigma Aldrich
Ammonium formate Alfa Aesar
Aniline Sigma Aldrich
Dichloromethane DOM Fisher
Diethyl ether EtzO Fisher
Diisopropyl ethylamine DIPEA Alfa Aesar
Dimethyl formamide (anhydrous) DMF Sigma Aldrich
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Dimethyl formamide DMF National Diagnostics
Di-tert-butyl dicarbonate B0 C2O Sigma Aldrich
Dry ice BOC
Ethyl acetate EtOAc Sigma Aldrich
Ethyl chloroform ate Sigma Aldrich
Fmoc amino acids Novabiochem
2-(1 H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium
hexafluorophosphate
HBTU
Novabiochem
Hydrochloric acid HCI Fisher
Hydrogen bromide HBr Sigma Aldrich
Imidazole hydrochloride Sigma Aldrich
N-Hydroxybenzotriazole HOBt Novabiochem
Magnesium sulfate MgS04 Alfa Aesar
Methanol MeOH Fisher
Methylamine hydrochloride Alfa Aesar
Ninhydrin Alfa Aesar
Palladium carbon (10%) PdC Sigma Aldrich
Piperidine Alfa Aesar
Phenol Sigma Aldrich
Potassium cyanide KCN Alfa Aesar
Potassium hydroxide KOH Sigma Aldrich
Benzotriazole-1-yl-oxy-tris-pyrrolidino- 
phosphonium hexafluorophosphate
PyBOP
Novabiochem
Pyridine Alfa Aesar
Silica Gel 60 Alfa Aesar
Sodium acetate NaOAc Alfa Aesar
Sodium azide NaNa Alfa Aesar
Sodium borohydride NaBH4 Alfa Aesar
Sodium hydrogen carbonate NaHCOs Sigma Aldrich
Sodium metaperiodate Nal04 Sigma Aldrich
Sodium nitrite Alfa Aesar
Sodium sulfate NaS2 0 4 Sigma Aldrich
Tetrahydrofuran THF Sigma Aldrich
Triethylamine TEA Sigma Aldrich
Trifluoroacetic acid TFA Apollo Scientific
Triisopropyl silane TIS Alfa Aesar
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Urea Alfa Aesar
Water H2O Fisher
All solvents and reagents used were AnalR grade or peptide synthesis grade. 
Solvents for HPLC purification and analysis were Chromasolv grade from Sigma 
Aldrich.
7.2 Experimental Methods
All general methods used are detailed in this section, and are refered to in subsequent 
chapters.
7.2.1 Solid Phase Peptide Synthesis
All peptides were synthesised either on the Symphony or Prelude automated peptide 
synthesisers (Protein Technologies) or by manual peptide synthesis. Fmoc chemistry 
was used throughout. For more detailed descriptions of peptide synthesis using Fmoc 
chemistry see Chapter 1 Section 1.2.1 and also “Solid phase peptide synthesis. A 
practical approach” (Atherton and Sheppard (1989)). Peptides were synthesised 
either on Wang resin pre-loaded with an Fmoc amino acid (Novabiochem), or on 2- 
chlorotrityl chloride resin (Iris Biochem) as detailed below.
7.2.1.1 Fmoc Amino Acid Side Chain Protecting Groups
The amino acids used for peptide synthesis and as starting material for the various 
amino acid derivatives were Fmoc protected on the alpha amino group, and side 
chain protected where necessary, as shown in Table 7.2.
134
Chapter 7: Experimental Methods
Table 7.2: The standard side chain protecting groups used in Fmoc peptide synthesis
Amino acid Side chain protection Amino acid Side chain protection
Alanine None Leucine None
Arginine Pbf Lysine Boc
Asparagine Trt Methionine None
Aspartic acid ^-Bu Phenylalanine None
Cysteine Trt Proline none
Glutamic acid r-Bu Serine ^-Bu
Glutamine Trt Threonine t-Qu
Gycine None Tyrosine r-Bu
Histidine Trt Tryptophan Boc
Isoleucine None Valine None
For synthesis of long peptide fragments of ribonuclease, cysteine was protected with 
either thio-tertbutyl (S-tBu) or acetamidomethyl (ACM). The use of pseuodoproline 
dipeptides (Mutter et al (1995)) at regular invervals throughout long peptide 
fragments enabled the synthesis of these long peptides in high crude purity.
7.2.1.2 Fmoc Deprotection
The N-terminal Fmoc protecting group was removed by agitating (shaking or 
nitrogen bubbling) the Fmoc protected peptidyl-resin (100-200mg) with 20% (v/v) 
piperidine in DMF (5 min and 20 min respectively, 2 ml each). The resin was then 
washed with DMF ( 3 x 2  ml, 2 mins each). The resin was tested for a free primary 
amine by using qualitative ninhydrin assay (Section 7.2.1.6).
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7.2.1.3 Coupling Reaction
An Fmoc protected amino acid (3 equivalents (equiv.) to the resin bound amine), 
HBTU (3 equiv.) and HOBt (3 equiv.) were added to the resin in DMF (2 ml), and 
DIPEA (9 equiv.) was added. The resin was agitated at room temperature (45-60 
mins) and washed with DMF ( 2 x 2  ml, 2 mins each). A portion of the resin was 
tested by qualitative ninhydrin assay (Section 7.2.1.6), and if a blue colour was 
produced, indicating incomplete coupling, the coupling step was repeated using the 
same conditions as before. Amino acids succeeding a proline were coupled twice, as 
the ninhydrin assay only produces a blue colour in the presence of amino and not 
imino groups.
7.2.1.4 Acétylation
Difficult couplings (coupling reactions which were not negative by ninhydrin assay 
after 2 couplings) were capped with AciO (100 pi) and pyridine (100 pi) in DMF (2 
ml, 10 mins), then the resin washed with DMF ( 2 x 2  ml, 2 mins each).
7.2.1.5 Cleavage
The peptidyl resin was washed with DCM ( 2 x 2  ml) and EtiO ( 2 x 2  ml) and 
allowed to air dry prior to cleavage. Peptides were cleaved in TFA/TIS/H2 O (96:2:2) 
or for peptides containing Cys or Met were cleaved in TFA/TIS/H2 O/EDT 
(94:2:2:2). The peptidyl resin (300 mg) was stirred at room temperature in the 
appropriate cleavage mix (2 ml) for 2-4 hours. The filtrate was collected and the 
resin washed with TFA ( 2 x 2  ml). The filtrate and washings were combined and the 
peptide precipitated by the addition of diethyl ether ( 1 0 ml), and centrifuged to form a 
pellet. The pellet was resuspended in MeCN/H2 0  (1:5, 5ml) and freeze dried.
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7.2.1.6 Qualitative Ninhydrin Assay
7.2.1.6.1 Preparation of Ninhydrin Assay Solutions
Solution A: Phenol (40 g) was dissolved in MeOH (10 ml) and stirred at room
temperature. A solution of KCN (6.5 mg) in H]0 (100 ml) was prepared and 1ml of 
this solution was added to pyridine (49 ml). This was added to the phenol/MeOH 
solution.
Solution B: Ninhydrin (500 mg) was dissolved in MeOH (10 ml)
7.2.1.6.2 Ninhydrin Assay
A small portion of peptidy 1-resin was placed into a 2 ml test tube. Solution A (40 pi) 
and ninhydrin B (20 pi) were added to the resin, and the tubes heated for 3 mins at 
100 °C. A blue colour (positive result) indicates the presence of a primary amine.
7.2.1.7 Automated Peptide Synthesis
Peptide fragments for ligation were synthesised by automated peptide synthesiser on 
either a Symphony or Prelude (Protein Technologies). The standard program cycle 
used is shown in Table 2.3:
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Reagant(s) Time (mins) Replicants
DMF 0.5 3
20% piperidine in DMF 2.5 2
DMF 0.5 6
Amino acid/HBTU/ DPEA 20 1
DMF 0.5 1
Amino acid/HBTU/ DPEA 20 1
DMF 0.5 3
The Symphony peptide synthesiser was used for synthesis of peptide containing only 
the 20 natural amino acids with standard protecting groups for Fmoc chemistry as 
listed in Table 7.2. The Prelude peptide synthesiser has spaces for 27 amino acids 
and so this was used for synthesis of peptides containing pseudoprolines and cysteine 
with S-tBu and ACM protection.
7.2.1.8 Calculation of Resin Substitution Level
The substitution level of polystyrene resins was measured using the absorbance at 
304 nm for removal of the Fmoc protecting group, using the method recommended 
by Novabiochem A portion of dry resin (approx 10 mg, accurately weighed) was 
treated with DBU (2% in DMF, 2 ml) for 30 mins, then diluted to 10 ml with MeCN. 
A 2ml sample of this solution was diluted to 25 ml with MeCN and the optical 
density of this solution measured in a spectrophotometer at 304 nm using a 1 ml 
silica cell. A reference sample prepared in the same manor, but without the resin was 
measured and the substitution level calculated using the following equation (derived 
from the Beer Lambert equation A = scl):
Resin loading(mmolZg) = AbSsampie-AbSrefX 16.4 / mg of resin
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7.2.2 Synthesis of N-nitrosomethyl Urea
Methylamine hydrochloride (60 g, 0.9 mol) and H2 O (to a final weight of 300 g) was 
stirred at room temperature, and urea (180 g, 3 mol) was added. The solution was 
refluxed for 5 hr, allowed to cool and left at room temperature overnight. The 
solution was cooled to 0°C and 98% sodium nitrite ( 6 6  g, 0.9 mol) was added with 
stirring. Separately, a mixture of ice (360 g) and concentrated H2 SO4 was stirred, and 
the cold methylurea-nitrite solution was added over a period of 3 hr, adding dry ice 
as necessary to maintain the temperature below 0 °C. The resultant solid N- 
nitrosomethyl urea (60 g) was collected via filtration under reduced pressure through 
a sintered glass funnel, washed with ice-cold water ( 1 0 0  ml), and desiccated in vacuo 
over silica gel. The product was stored at 4 °C.
7.2.3 Generation of Diazomethane
Nitrosomethyl urea ( 6  g) was added to diethyl ether (20 ml) on ice, and KOH (50% 
aq) was added dropwise over 10-15 mins until the solid nitrosomethyl urea had 
completely dissolved. The yellow ether layer was separated and dried over KOH 
pellets, then used immediately.
7.2.4 Synthesis of Fmoc-Phe-epoxide
The epoxide derivative of phenylalanine [3] was synthesised starting with the 
commercially available F mo c-pheny lalanine.
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7.2.4.1 Preparation of Fmoc-Phe-diazomethylketone [1]
Fmoc-phenylalanine (3.8 g, 10 mmol) was dissolved in dry THF, and TEA (1.01 g, 2 
eq) was added. This was added dropwise to a solution of ethyl chloroformate (1 g, 2 
eq) in dry THF, whilst stirring on ice. Stirring was continued for 3 hours. A saturated 
solution of diazomethane in ether (Section 7.2.3) was added, and the reaction stirred 
for a further 3 hours. H2 O (20 ml) was added slowly, and the reaction stirred until 
effervescence had stopped. The organic layer was separated and washed with 
saturated NaHCOs (20 ml) and H2 O (2 x 20 ml), then dried over NaS0 4 , and the 
solvent removed by evaporation in vacuo. The crude product was purified by column 
chromatography (65% hexanes / ethyl acetate), to yield a pale yellow solid.
Yield of Fmoc-Phe-diazomethylketone [1] 3.2 g, 76 %, IR: 2105 cm"^  (s, diazo), 
300MHz NMR (CDCI3 20°C) Ô 192.8 (CO ketone), 155.6 (CO amide), (143.8, 141.4,
129.4, 128.7, 127.8, 127.1, 125.1, 120.0 (C, CH aromatic)), 6 6 . 8  (CH2 Fmoc), 58.7 
(CH Phe), 54.7 (CH2 diazo methyl ketone), 47.3 (CH Fmoc), 38.4 (CH2 Phe). *H 
300mHz NMR (CDCI3 20°C) 5 7.8-7.2 (m, 13H), 5.4 (d, IH), 5.1 (s, IH), 4.5 (m, 
IH), 4.4 (m, 2H), 4.2 (m, 2H), 3.0, (m, IH). CHN: expected: C, 72.80; H, 5.38; N, 
10.19, found: C, 72.78; H, 5.01; N, 9.16. IH NMR, IH COSY, 13C NMR and FTIR 
data in Appendix 11a.
7.2.4.2 Preparation of Fmoc-Phe-bromomethylketone [2]
The diazomethylketone [1] (3.2 g) was dissolved in acetone (20 ml), and HBr (48% 
aq, 440 pi, 1 eq) was added dropwise. The reaction was stirred for 5 minutes, then 
saturated NaHCOg solution (20 ml) added. The product was extracted into ethyl 
acetate (2 x 1 0  ml), the layers combined and washed with H2 O ( 2  x 2 0  ml), and then 
dried over NaS0 4 . The solvent was removed by evaporation in vacuo to yield a white 
solid.
Yield of Fmoc-Phe-bromomethylketone [2] 2.4 g, 98 %, LCMS: Purity 97.9% ESMS 
[M+H] 466, IR 1735 cm '\s, bromomethylketone). ^^ C 300MHz NMR (CDCI3 ô ppm
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20°C) 200.4 (CO ketone), 155.7 (CO amide), (143.6, 141.4, 135.5 129.1, 129.0,
127.8, 127.4, 127.1, 125.0, 120.1 (C, CH aromatic)), 67.0 (CH2 Fmoc), 58.8 (CH 
Phe), 47.2 (CH Fmoc), 37.8 (CH2 Phe), 32.9 (CH2 bromomethylketone). ^H 
300mHz NMR (CDCI3 20°C) Ô 7.8-7.1 (m, 13H), 5.3 (d, IH), 4.8 (m, IH), 4.4 (m, 
2H), 4.2 (m, 2H), 3.9 (d J  = 13.5, IH) 3.7 (d J  = 13.5, IH), 3.0, (m,lH). CHN: 
expected: C, 62.66; H, 4.78; N, 3.02, found: C, 64.68; H, 4.65; N, 2.80. IH NMR, IH 
COSY, 13C NMR, FTIR and LC M S data in Appendix 11a.
7.2.4.3 Preparation of Fmoc-Phe-epoxide [3]
The bromomethylketone [2] (100 mg) was dissolved in MeOH (20 ml), and NaBH4 
(12 mg, 1.4 eq) was added. The reduction of the ketone was monitored by TLC 
(ethyl actetate / hexanes 7:3) and was complete in 10 minutes. The reaction was then 
refluxed for 15 minutes and then cooled on ice. The methanol was removed in vacuo, 
and the residue redissolved in ethyl acetate (10 ml). This was washed with dilute HCI 
(10 ml), H2 O (2 X 10 ml) and dried over NaS0 4 . The solvent was removed by 
evaporation in vacuo to yield a white solid. Yield of Fmoc-Phe-epoxide [3] 60 mg, 
72 %, ESMS [M+H] 386, [M+Na] 408.
7.2.5 Synthesis of 1-amino, 2-aicohoi Derivatives
Amino alcohol derivatives were synthesised starting from the appropriate Fmoc 
protected amino acid (see Table 2.2). Phenylalanine is used here as an example. 
Fmoc-Phe-diazomethylketone [1] and Fmoc-Phe-bromomethylketone [2] were 
synthesised as above (7.2.4.1 and 7.2.4.2).
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7.2.5.1 Preparation of Fmoc-Phe-azidomethylketone [4]
The bromomethylketone derivative of Fmoc-phenylalanine [2] (1.7 g) was dissolved 
in ethyl acetate (25 ml). Sodium azide (2.3 g 10 eq) was dissolved in H2 O and this 
was added to the solution of [2] with vigorous stirring. The reaction was stirred at 
room temperature overnight, then the ethyl acetate layer separated and washed with 
H2 O (2 X 20 ml). This was dried over sodium sulfate, and the solvent removed by 
evaporation in vacuo. The crude product was purified by column chromatography 
(65% hexanes / ethyl acetate), to yield a white solid.
Yield of Fmoc-Phe-azidomethylketone [4] 1.5 g, 96 %, LCMS: Purity 98.0% ESMS 
[M+H] 427. "C  300MHz NMR (CDCI3 5 ppm 20°C) 203.4 (CO ketone), 155.8 (CO 
amide), (143.6, 143.5, 141.3, 135.2, 129.2, 129.1, 127.8, 127.5, 127.1, 125.0, 120.1 
(C, CH aromatic)), 67.0(CH2 Fmoc), 58.7 (CH Phe), 56.5 (CH2 azidomethyl 
ketone), 47.2 (CH Fmoc), 37.5 (CH2 Phe). IH NMR (CDCI3) Ô 7.8-7.1 (m, 13H), 5.2 
(d, IH), 4.5 (m, IH), 4.4 (m, 2H), 4.2 (m, IH), 3.9 (d, J =  16 Hz, IH) 3.7 (d, J =  16 
Hz, IH) 3.0 (dc/=  7.5, IH). CHN: expected: C, 70.41; H, 5.20; N, 13.14, found: C, 
68.64; H, 5.09; N, 12.19. IH NMR, IH COSY, 13C NMR, FTIR and LCMS data in 
Appendix 11a.
7.2.5.2 Preparation of Fmoc-Phe-azidomethylalcohoi [5]
The azidomethylketone [4] (1.5 g) was dissolved in MeOH (20 ml), and NaBH4 (200 
mg, 1.4 eq) was added. The reduction was monitored by TLC (ethyl actetate / 
hexanes 7:3) and was complete in 10 minutes. The methanol was removed in vacuo, 
and the residue redissolved in ethyl acetate (30 ml). This was washed with dilute HCI 
(20 ml), H2 O (2 X 20 ml) and dried over NaS0 4 . The solvent was removed by 
evaporation in vacuo. The crude product was purified by column chromatography 
(65% hexanes / ethyl acetate), to yield a white solid.
Yield of Fmoc-Phe-azidomethylalcohol [5] 1.3 g, 87 % LCMS: Purity 90.7% ESMS 
[M+H] 429 ‘^ C 300MHz NMR (CDCI3Ô ppm 20°C) 156.5 (CO amide), (143.8,
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141.4, 137.4, 137.0, 129.3, 129.2,128.7,127.8, 127.1,126.8, 125.0,120.0 (C, CH 
aromatic)), (72.2, 70.3 (CH alcohol)), 66.5(CH2 Fmoc), (55.0, 54.3, (CH2 
azidomethylalcohol)), 47.3 (CH Fmoc), 38.3(CH), 35.9 (CH2 Phe).‘HNMR; (500 
MHz CDC13) Ô 7.8-7.1 (m, 13H), 5.1 (d, IH) 4.8 (m, IH), 4.4 (m, 2H), 4.2 (m, IH), 
3.9 (m, IH) 3.7 (m, IH), 3.3 (m, 2H), 2.9 (m, IH). Stereochemistry of hydroxyl 
shown by HPLC to be approximately 60:40. CHN: expected: C, 70.08; H, 5.65; N,
13.08, found: C, 69.92; H, 5.54; N, 12.79. IHNMR, IH COSY, 13C NMR, FTIR 
and LCMS data in Appendix 11a.
7.2.S.3 Preparation of Fmoc-Phe-amino-alcohol [6]
Fmoc-Phe-azidomethylalcohol [5] (500 mg) was dissolved in MeOH (15 ml) and 
ammonium formate (290 mg, 4 eq) was added. This was stirred at 30°C, and Pd-C 
(10%, 25 mg) was added with continual stirring. After 30 minutes the reaction was 
allowed to cool to room temperature, and the reaction was filtered through celite. The 
MeOH was removed by evaporation in vacuo. Yield of Fmoc-Phe-amino-alcohol [6 ] 
420 mg, 85%, LCMS: Purity 84.1% ESMS [M+H] 403, LCMS data in appendix Ila. 
Fmoc-Phe-amino-alcohol was immediately used, due to its instability.
7.2.S.4 Synthesis of Amino Aicohol Derivatives of Other Amino 
Acids
Amino alcohol derivatives of Fmoc-leucine, Fmoc-isoleucine and Fmoc-alanine were 
synthesised following the same method used for the amino alcohol derivative of 
phenylalanine. These derivatives were not analysed by NMR due to a lack of access 
to NMR facilities when this work was performed, however the methods used were 
identical to those used for phenylalanine. All compounds were analysed by ESMS 
and gave the expected results.
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7.2.5.4.1 Preparation of Fmoc-Leu-diazomethylketone [7]
Fmoc-Leu-diazomethylketone was synthesised using the method in Section 7.2.4.1, 
starting from Fmoc-leucine (1.8 g, 5 mM). Yield of Fmoc-Leu-diazomethylketone 
[7] 1.6 g, 83 %, IR (thin film) 2100 cm '\s, diazo).
7.2.S.4.2 Preparation of Fmoc-Leu-bromomethylketone [8]
Fmoc-Leu-bromomethylketone was synthesised using the method in Section 7.2.4.2, 
starting from Fmoc-Leu-diazomethylketone [7] (1.6 g). Yield of Fmoc-Leu- 
bromomethylketone [8 ] 1.7 g, 93 %, ESMS [M+H] 430/432.
7.2.5.4.S Preparation of Fmoc-Leu-azidomethylketone [9]
Fmoc-Leu-azidomethylketone was synthesised using the method in Section 7.2.5.1, 
starting from Fmoc-Leu-bromomethylketone [8 ] (1.7 g). Yield of Fmoc-Leu- 
azidomethylketone [9] 1.4 g, 90 %, ESMS [M+H] 393.
7.2.S.4.4 Preparation of Fmoc-Leu-azidomethylalcohol [10]
Fmoc-Leu-azidomethylalcohol was synthesised using the method in Section 7.2.5.2, 
starting from Fmoc-Leu-azidomethylketone [9] (1.4 g). Yield of Fmoc-Leu- 
azidomethylketone [10] 1.3 g, 90 %, ESMS [M+H] 395.
7.2.5.4.S Preparation of Fmoc-Leu-amino alcohol [11]
Fmoc-Leu-amino alcohol was synthesised using the method in Section 7.2.5.3, 
starting from Fmoc-Leu-azidomethylketone [10] (500 mg). Yield of Fmoc-Leu- 
azidomethylketone [11] 430 mg, 92 %, ESMS [M+H] 369.
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7.2.S.4.6 Preparation of Fmoc-lie-diazomethylketone [12]
Fmoc-Ile-diazomethylketone was synthesised using the method in Section 7.2.4.1, 
starting from Fmoc-isoleucine (1 g, 2.7 mM). Yield of Fmoc-Ile-diazomethylketone 
[12] 1 g, 93 %, IR (thin film) 2100 cm"\s, diazo).
7.2.5.4.7 Preparation of Fmoc-lle-bromomethylketone [13]
Fmoc-Ile-bromomethylketone was synthesised using the method in Section 7.2.4.2, 
starting from Fmoc-Ile-diazomethylketone [12] (1 g). Yield of Fmoc-Ile- 
bromomethylketone [13] 950 mg, 83 %, ESMS [M+H] 430/432.
7.2.5.4.S Preparation of Fmoc-iie-azidomethylketone [14]
Fmoc-Ile-azidomethylketone was synthesised using the method in Section 7.2.5.1, 
starting from Fmoc-Ile-bromomethylketone [13] (950 mg). Yield of Fmoc-Ile- 
azidomethylketone [14] 800 mg, 92 %, ESMS [M+H] 393.
7.2.5.4.9 Preparation of Fmoc-lle-azidomethylalcohol [15]
Fmoc-Ile-azidomethylalcohol was synthesised using the method in Section 7.2.5.2, 
starting from Fmoc-Ile-azidomethylketone [14] (800 mg). Yield of Fmoc-Ile- 
azidomethylketone [15] 800 mg, 100 %, ESMS [M+H] 395.
7.2.5.4.10 Preparation of Fmoc-lle-amino alcohol [16]
Fmoc-Ile-amino alcohol was synthesised using the method in Section 1.2.53, 
starting from Fmoc-Ile-azidomethylketone [15] (500 mg). Yield of Fmoc-Ile- 
azidomethylketone [16] 450 mg, 96 %, ESMS [M+H] 369.
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7.2.5.4.11 Preparation of Fmoc-Ala-diazomethylketone [17]
Fmoc-Ala-diazomethylketone was synthesised using the method in Section 7.2.4.1, 
starting from Fmoc-alanine (1.65 g, 5 mM). Crude yield of Fmoc-Ala- 
diazomethylketone [17] 1.7 g, 88 %. 1 g purified by column chromatography (65% 
hexanes / ethyl acetate), to yield a pale yellow solid, 800 mg IR (thin film) 2100 cm'^ 
(s, diazo).
7.2.5.4.12 Preparation of Fmoc-Ala-bromomethylketone [18]
Fmoc-Ala-bromomethylketone was synthesised using the method in Section 7.2.4.2, 
starting from Fmoc-Ala-diazomethylketone [17] (800 mg). Yield of Fmoc-Ala- 
bromomethylketone [18] 800 mg, 94 %, ESMS [M+H] 388/390.
7.2.5.4.13 Preparation of Fmoc-Ala-azidomethylketone [19]
Fmoc-Ala-azidomethylketone was synthesised using the method in Section 7.2.5.1, 
starting from Fmoc-Ala-bromomethylketone [18] (800 mg). Yield of Fmoc-Ala- 
azidomethylketone [19] 650 mg, 90 %, ESMS [M+H] 351.
7.2.5.4.14 Preparation of Fmoc-Ala-azidomethylalcohol [20]
Fmoc-Ala-azidomethylalcohol was synthesised using the method in Section 7.2.S.2, 
starting from Fmoc-Ala-azidomethylketone [19] (650 mg). Yield of Fmoc-Ala- 
azidomethylketone [20] 600 mg, 92 %, ESMS [M+H] 353.
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7.2.5.4.15 Preparation of Fmoc-Ala-amino alcohol [21]
Fmoc-Ala-amino alcohol was synthesised using the method in Section 7.2.S.3, 
starting from Fmoc-Ala-azidomethylketone [20] (200 mg). Yield of Fmoc-Ala- 
azidomethylketone [21] 450 mg, 96 %, ESMS [M+H] 327. Due to stability issues 
this was immediately attached to 2-CTR resin (using the method in Section 1.1.13 
for Fmoc-Phe amino alcohol).
7.2.6 Stability of 1, 2 Amino Alcohol derivatives of Fmoc
Protected Amino Acids
1, 2 amino alcohol derivatives of a-Fmoc protected amino acids showed signs of 
Fmoc removal upon storage. A stability study was performed to assess the extent of 
Fmoc removal.
A 5 mg sample of Fmoc-Phe, Fmoc-Leu and Fmoc-Ala azido alcohol and amino 
alcohol derivatives were stored at 4° C. A 1 mg sample of each was dissolved in 
MeCN / H2 O (1:1, 300 pi) and analysed after 24 h, 1 week and 1 month by ESMS.
7.2.7 Synthesis of Peptides with a C-terminai 1, 2 Amino Alcohol
Peptides were synthesised on 2-chlorotrityl chloride resin, loaded either with the 
commercially available 1 , 3-amino-2 -hydroxypropane (glycine amino alcohol), or 
the 1,2 amino alcohol derivatives of Fmoc protected amino acids.
7.2.7.1 Substitution of 2-Chlorotrityl Resin with 1, 3-amino-2- 
hydroxypropane
2-chlorotrityl resin was substituted with 1, 3-amino-2-hydroxypropane for the 
synthesis of peptides containing a C-terminal glycine amino alcohol. Chlorotrityl
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resin (200 mg) was swelled in dry DMF/DCM (1:1, 2 ml). 1, 3-amino-2- 
hydroxypropane (30 pi) and DIPEA (125 pi) was added and the resin agitated for 2 
hours. The solution was drained and the resin capped with MeOH /DMF (1:1, 2ml) 
containing DIPEA (125 pi) for 30 minutes, then the resin washed with DMF (3 x 
2ml). The resin was tested by ninhydrin rection and gave a positive (blue) result.
7.2.7.2  Synthesis of Peptides on 1, 3-amino-2-hydroxypropane
Substituted 2-chlorotrityl Resin
The C-terminal amino acid was loaded onto the 1, 3-amino-2-hydroxypropane 
substituted resin (200 mg). The Fmoc amino acid (125 mg), PyBOP (1 M equiv to 
Fmoc amino acid) and DIPEA (3 M eq) were added in NMP, and the resin agitated 
for 1 hour. The solution was drained, and the resin washed with DMF (3 x 2ml). A 
sample of the resin was tested by nihydrin assay, and if positive the reaction was 
repeated.
The Fmoc-amino acid-1, 3-amino-2-hydroxypropane functionalised resin was loaded 
onto an automated peptide synthesiser (Symphony or Prelude).
7.2J.3 Substitution of 2-Chlorotrityl Resin with Fmoc-Phe amino 
alcohol [6]
2-chlorotrityl chloride resin (200 mg) was swelled in dry DMF/DCM (1:1, 2ml). 
Fmoc-Phe amino alcohol [6 ] (50 mg) and DIPEA (125 pi) was added and the resin 
agitated for 48 hours. The solution was drained and the resin capped with MeOH 
/DMF (1:1, 2 ml) containing DIPEA (125 pi) for 30 minutes, then the resin washed 
with DMF ( 3 x 2  ml). The side chain hydroxyl was protected by adding t-butyl- 
2,2,2-trichloroacetamidate (lOOpl) and DIPEA (125 pi) in DMF. The N-terminal 
amine was deprotected by removing the Fmoc group using the method given in 
Section 7.2.I.2.
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7.2.7.3.1 Synthesis of Z-RLF-amino alcohol
Phe-amino alcohol-CTR (200mg, Section 1,2.13) was reacted with Fmoc-Leu-OH 
(140 mg, 3eq), HBTU (150 mg, 3 eq) and DIPEA (125 pi) for 1 h and the reaction 
monitored by ninhydrin assay (Section 7.2.1.6). The N-terminal amine was 
deprotected by removing the Fmoc group using the method given in Section 7.2.1.2, 
and the reaction again monitored by ninhydrin assay. Fmoc-Arg-OH (260 mg, 3eq), 
HBTU (150 mg, 3 eq) and DIPEA (125 pi) were reacted for 1 h and the reaction 
monitored by ninhydrin assay (Section 7.2.1.6). The N-terminal amine was 
deprotected by removing the Fmoc group using the method given in Section 7.2.1.2, 
and the reaction again monitored by ninhydrin assay. Z-chloroformate (55 pi, 3eq), 
and DIPEA (125 pi) in DMF were reacted for 1 hour and the reaction monitored by 
ninhydrin assay. The resin was washed with DCM (3 x 2ml) and allowed to dry 
before cleavage. The peptide was cleaved using the method in Section 2.7.5.1, and 
purified by RP-HPLC (Section 7.3.1.2), to yield Z-RLF-amino alcohol (7.1 mg), 
LCMS: purity 100% ESMS [M + H] 584 (data in appendix Ilb).
7.2.7.3.2 Synthesis of Z-RLF-aldehyde
Z-RLF-amino alcohol (7.1 mg) was dissolved in NaOAc buffer (7ml, O.IM, pH5.5) 
and NaI04 (10 pi, from a stock of 10 mg in 100 pi NaOAc buffer (7ml, O.IM, 
pH5.5)) was added. The reaction was stirred for 30 mins and the recation monitored 
by ESMS. The peptide was immediately purified by RP-HPLC (Section 7.3.1.2), 
freeze dried and stored at -20 °C. ESMS [M + H] 553, [M + H3O] 571 (data in 
appendix lib).
7.2.8 Synthesis of Peptides with a C-termlnal Hydrazlde
Peptides bearing a C-terminal hydrazide were synthesised on 2-chlorotrityl chloride 
resin, substituted with hydrazine.
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7.2.8.1 Hydrazine Substituted 2-chlorotrityl Chloride Resin
Chlorotrityl resin (200 mg) was swelled in dry DMF/DCM (1:1, 2ml). Hydrazine 
monohydrate (40 pi) and DIPEA (125 pi) was added and the resin agitated for 45 
minutes. The solution was drained and the resin capped with MeOH /DMF (1:1, 2 
ml) containing DIPEA (125 pi) for 30 minutes, then the resin was washed with DMF 
( 3 x 2  ml).
7.2.8.2 Synthesis of Peptides on Hydrazine Substituted 2- 
chlorotrltyl Resin
The C-terminal amino acid was loaded onto hydrazine substituted resin (200 mg). 
The Fmoc amino acid (125 mg), PyBOP (IM eq to Fmoc amino acid) and DIPEA 
(3M eq) were added in NMP, and the resin agitated for 1 hour. The solution was 
drained, and the resin washed with DMF ( 3 x 2  ml).
The Fmoc-amino acid-hydrazide functionalised resin was loaded onto an automated 
peptide synthesiser (Symphony or Prelude), and the peptides synthesised as detailed 
below. As the starting resin substitution level was not measured final yields are in mg 
only, not as a percentage.
7.2.8.S Synthesis of 8Aoa-fQWAVGHL-NH-NH2
Hydrazine substituted 2-chlorotrityl chloride resin (300 mg) was prepared using the 
method in Section 7.2.8.I. The C-terminal leucine was loaded using Fmoc-Leu-OH 
(125 mg), Boc-Gly-OH (6.5 mg), PyBOP (185 mg, 1 eq) and DIPEA (125 pi), and 
the reisn agitated for 1 hour. The rsin was transferred to the Synpony eptide 
synthesiser and the peptide elongated to make QWAVGHL-NH-NH2-CTR resin. 
The final two residues D-Phe and 8Aoa were added by manual peptide synthesis
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using the method in Section 7.2.1. The peptide was cleaved (Section 7.2.1.5) and 
purified (Section 7.3.1.2) to yield 48 mg of peptide.
7.2.S.4 Synthesis of KETAAAKFERQHMDSSTSA-NH-NH2 (Rib 1 )
Peptide KETAAAKFERQHMDSSTSA-NH-NH2 (RNase peptide 1) was made using 
hydrazine substituted CTR (Section 7.2.S.2). All amino acids, pseudoprolines and 
HBTU were used in a 3 fold excess, using the standard program detailed in Section 
7.2.1.7. The peptide was cleaved from the resin using the method in Section 2.7.5.1, 
and purified by RP-HPLC (Section 7.3.1.2), to yield the final peptide (125 mg, 71% 
pure by HPLC).
7.2.8.S Synthesis of SSSSNYCNQMMKSRNLTKDRCKPVNTFVHE 
SL-NH-NH2 (Rib 2)
Peptide SSSSNYCNQMMKSRNLTKDRCKPVNTFVHESL-NH-NH2 (RNase 
peptide 2) was made using hydrazine substituted CTR (Section 7.2.S.2) and 
pseudoprolines LT and ES. All amino acids, pseudoprolines and HBTU were used in 
a 3 fold excess, using the standard program detailed in Section 7.2.I.7. The peptide 
was cleaved from the resin using the method in Section 2.7.5.1, and purified by RP- 
HPLC (Section 7.3.1.2), to yield the final peptide (65 mg, 94% pure by HPLC)
7.2.8.6 Synthesis of SDVQAVCSQKNVACKNGQTNCYQSYSTMSI- 
NH-NH2 (Rib 3)
Peptide SDVQAVCSQKNVACKNGQTNCYQSYSTMSI-NH-NH2 (RNase peptide 
3) was made using hydrazine substituted CTR (Section 7.2.S.2) and pseudoprolines 
QT and ST. All amino acids, pseudoprolines and HBTU were used in a 3 fold excess, 
using the standard program detailed in Section 7.2.1.7, apart from the three 
asparagines reactions which were triple coupled instead of the standard double
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coupling reaction. The peptide was cleaved from the resin using the method in 
Section 2.7.5.1, and purified by RP-HPLC (Section 7.3.1.2), to yield the final 
peptide (38 mg, 84% pure by HPLC).
7.2.S.7 Synthesis of SSSSNYC(S-tBu)NQMMKSRNLTKDRC(S- 
tBu)KPVNTFVHESL-NH-NH2 (Rib 2 StBu)
Peptide SSSSNYC(S-tBu)NQMMKSRNLTKDRC(S-tBu)KPVNTFVHESL-NH- 
NH2 was made using hydrazine substituted CTR (Section 7.2.S.2) and 
pseudoprolines LT and ES. All amino acids, pseudoprolines and HBTU were used in 
a 3 fold excess, using the standard program detailed in Section 7.2.I.7. The peptide 
was cleaved from the resin using the method in Section 2.7.5.1, and purified by RP- 
HPLC (Section 7.3.1.2), to yield the final peptide (24 mg).
7.2.8.S Synthesis of SDVQAVC(S-tBu)SQKNVAC(StBu)KNGQT 
NC(S-tBu)YQSYSTMSI-NH-NH2 (Rib 3 StBu)
Peptide SDVQAVC(S-tBu)SQKNVAC(S-tBu)KNGQTNC(S-tBu)YQSYSTMSI- 
NH-NH2 was made using hydrazine substituted CTR (Section 7.2.S.2) and 
pseudoprolines QT and ST. All amino acids, pseudoprolines and HBTU were used in 
a 3 fold excess, using the standard program detailed in Section 7.2.1.7, apart from 
the three asparagines reactions which were triple coupled instead of the standard 
double coupling reaction. The peptide was cleaved from the resin using the method 
in Section 2.7.5.1, and purified by RP-HPLC (Section 7.3.1.2), to yield the final 
peptide (17 mg).
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7.2.8.9 Synthesis of SSSSNYC(ACM)NQ1V1MKSRNLTKDRC(ACM) 
KPVNTFVHESL-NH-NH2 (Rib 2 ACM)
Peptide SSSSNYC(ACM)NQMMKSRNLTKDRC(ACM)KPVNTFVHESL-NH- 
NH2 was made using hydrazine substituted CTR (Section 7.2.8.2) and 
pseudoprolines LT and ES. All amino acids, pseudoprolines and HBTU were used in 
a 3 fold excess, using the standard program detailed in Section 7.2.I.7. The peptide 
was cleaved from the resin using the method in Section 2.7.5.1, and purified by RP- 
HPLC (Section 7.3.1.2), to yield the final peptide (34 mg).
7.2.8.10 Synthesis of SDVQAVC(ACM)SQKNVAC(ACM)KNGQT 
NC(ACM)YQSYSTMSI-NH-NH2 (Rib 3 ACM)
Peptide SDVQAVC(ACM)SQKNVAC(ACM)KNGQTNC(ACM)YQSYSTMSI- 
NH-NH2 was made using hydrazine substituted CTR (Section 7.2.8.2) and 
pseudoprolines QT and ST. All amino acids, pseudoprolines and HBTU were used in 
a 3 fold excess, using the standard program detailed in Section 7.2.1.7, apart from 
the three asparagines reactions which were triple coupled instead of the standard 
double coupling reaction. The peptide was cleaved from the resin using the method 
in Section 2.7.5.1, and purified by RP-HPLC (Section 7.3.1.2), to yield the final 
peptide (19 mg).
7.2.9 Synthesis of N-terminally modified peptide fragments for
use in ligation
Not all peptides required for ligation needed C-terminal modification, and so these 
peptides were synthesised using commercially available preloaded Wang polystyrene 
resins. The N-terminal modifications were either hydrazine actetic acid, or serine for 
subsequent oxidation to the glyoxal.
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7.2.9.1 Synthesis of H2N-HN-DCRETGSSKYPNCAYKTTQANKHIIV 
ACEGNPYVPVHFDASV (Rib 4)
Peptide DCRETGSSKYPNC A YKTTQANKHIIV ACEGNPYVPVHFDASV was 
synthesised on the Prelude peptide synthesiser using Fmoc-Val Wang resin (300 mg, 
0.27 mmol/g) and using the pseudoprolines GS, KT and AS. All amino acids and 
pseudoprolines and HBTU were used in a 3 fold excess, using the standard program 
detailed in Section 7.2.I.7. The N-terminus was modified using hydrazinoacetic acid 
(lOOmg), PyBop (135 mg) and DIPEA (125 pi) in DMF. The reaction was moitored 
by pervorming a small scale cleavage of the resin and monitoring by MS. The 
peptide was cleaved from the resin using the method in Section 2.7.5.1, and purified 
by RP-HPLC (Section 7.3.1.2), to yield the final peptide (76 mg, 20% from initial 
resin substitution)
7.2.9.2 Synthesis of SDCRETGSSKYPNCAYKTTQANKHIiVACEGN 
PYVPVHFDASV (Rib 4)
Peptide SDCRETGSSKYPNCAYKTTQANKHHVACEGNPYVPVHFDASV was 
synthesised on the Prelude peptide synthesiser using Fmoc-Val Wang resin (300 mg, 
0.27 mmol/g) and using the pseudoprolines GS, KT and AS. All amino acids and 
pseudoprolines and HBTU were used in a 3 fold excess, using the standard program 
detailed in Section 7.2.I.7. The peptide was cleaved from the resin using the method 
in Section 2.7.5.1, and purified by RP-HPLC (Section 7.3.1.2). The peptide was 
repurified by RP-HPLC to achieve the highest purity possible, to yield the final 
peptide (54 mg, 15% from initial resin substitution, 100% purity by HPLC (data in 
appendix II)).
7.2.9.S Synthesis of SDC(S-tBu)RETGSSKYPNC(StBu)AYKTTQA 
NKHIIVAC(S-tBu)EGNPYVPVHFDASV (Rib 4 StBu)
Peptide SDC(S-tBu)RETGSSKYPNC(S-tBu)AYKTTQANKHIIVAC(S-tBu)EGNP
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YVPVHFDASV was synthesised on the Prelude peptide synthesiser using Fmoc-Val 
Wang resin (300 mg, 0.27 mmol/g) and using the pseudoprolines GS, KT and AS. 
All amino acids and pseudoprolines and HBTU were used in a 3 fold excess, using 
the standard program detailed in Section 1.2.1.1. The peptide was cleaved from the 
resin using the method in Section 2.7.5.1, and purified by RP-HPLC (Section
7.3.1.2), to yield the final peptide (45 mg, 11% from initial resin substitution)
7.2.S.4 Synthesis of SDC(ACM)RETGSSKYPNC(ACM)AYKTTQAN 
KH1IVAC(ACM)EGNPYVPVHFDASV (Rib 4 ACM)
Peptide SDC(ACM)RETGSSKYPNC(ACM)AYKTTQANKHHVAC(ACM)EGNP 
YVPVHFDASV was synthesised on the Prelude peptide synthesiser using Fmoc-Val 
Wang resin (300 mg, 0.27 mmol/g) and using the pseudoprolines GS, KT and AS. 
All amino acids and pseudoprolines and HBTU were used in a 3 fold excess, using 
the standard program detailed in Section 7.2.I.7. The peptide was cleaved from the 
resin using the method in Section 2.7.5.1, and purified by RP-HPLC (Section
7.3.1.2), to yield the final peptide (52 mg, 13% from initial resin substitution)
7.2.9.5 Synthesis of SDCRETGSSK
Peptide SDCRETGSSK was synthesised on the Prelude peptide synthesiser using 
Fmoc-Lys Wang resin (300 mg, 0.33 mmol/g). All amino acids and HBTU were 
used in a 3 fold excess, using the standard program detailed in Section 7.2.1.7. The 
peptide was cleaved from the resin using the method in Section 2.7.5.1, and purified 
by RP-HPLC (Section 7.3.1.2), to yield the final peptide (54 mg, 51% from initial 
resin substitution).
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7.2.9.G Synthesis of SDC(S-tBu)RETGSSK
Peptide SDC(S-tBu)RETGSSK was synthesised on the Prelude peptide synthesiser 
using Fmoc-Lys Wang resin (300 mg, 0.33 mmol/g). All amino acids and HBTU 
were used in a 3 fold excess, using the standard program detailed in Section 7.2.I.7. 
The peptide was cleaved from the resin using the method in Section 2.7.5.1, and 
purified by RP-HPLC (Section 7.3.1.2), to yield the final peptide (38 mg, 34% from 
initial resin substitution).
7.2.10 Oxidation of Peptide Fragments Bearing an N-terminal 
Serine or C-terminai Amino Alcohol
Peptides were oxidised using sodium metaperiodate, at an N-terminal serine to yield 
a glyoxal or a C-terminal amino alcohol to yield an aldehyde. Oxidation was either 
performed using solid supported NaI0 4  or in solution as described below.
7.2.10.1 Polymer Supported Oxidation
Polymer supported periodate resin was prepared from Amberlyst A26 by ion 
exchange with sodium metaperiodate. Amberlyst A26 (20 g) was treated with an 
aqueous solution of NaI0 4  (1 M, 100 ml), by slowly passing the solution through the 
resin in a PD 10 column.
The peptide to be oxidised was dissolved in MeOH (5-10 mg/ml) and this was added 
to polymer supported periodate resin. The slurry was stirred at room temperature for 
30-60 mins then the solution filtered away from the resin and analysed by MS. If the 
oxidation reaction was not complete the solution was returned to the resin and 
stirring continued for a further 30-60 mins. Once the reaction was complete as 
determined by MS the MeOH was removed by evaporation, and the peptide aldehyde 
stored at -20 °C.
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7.2.10.1.1 Polymer Supported Oxidation of KPVNTFVHESL-amino 
alcohol
KPVNTFVHESL-amino alcohol (1.3 mg) was oxidised to KPVNTFVHESL- 
aldehyde using polymer supported NaI0 4  using the method in Section 7.2.10.1. The 
peptide was analysed by ESMS [M + H] 1254.
7.2.10.1.2 Polymer Supported Oxidation of YQSYSTMSI-amino 
alcohol
YQSYSTMSI-amino alcohol (2.4 mg) was oxidised to YQSYSTMSI -aldehyde 
using polymer supported NaI0 4  using the method in Section 7.2.10.1. The peptide 
was analysed by ESMS [M + H] 1063.
7.2.10.2 Solution Phase Oxidation
The peptide to be oxidised was dissolved in imidazole buffer (50 mM, pH 6.9) at a 
concentration of 5mg/ml. NaI0 4  (2 eq) was added and the reaction stirred at room 
temperature. The reaction was monitored using LC-MS until oxidation was 
complete, usually 10-30 mins. The reaction was quenched using ethylene glycol (2 
eq) and the product immediately purified by RP-HPLC. The purified peptide 
aldehyde or glyoxal was lyophilised and stored at -20 °C.
7.2.10.2.1 Oxidation of SLIGRL-NH2
Peptide SLIGRL-NH2 (50 mg) was dissolved in imidazole buffer (50 mM, pH 6.9) at 
a concentration of 5mg/ml. NaI0 4  (32 mg, 2 eq) was added and the reaction stirred at 
room temperature for 20 minutes. The reaction was quenched using ethylene glycol 
(8.5 pi, 2 eq) and the product immediately purified by RP-HPLC, and analysed by 
MS. [M + H] 626, [M + H2 O] 64
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7.2.10.2.2 Oxidation of SDCRETGSSK
Peptide SDCRETGSSK (20 mg) was oxidised in solution using the method in 
Section 7.2.10.2. The reaction was monitored by MS and gave multiple 
unidentifiable products.
7.2.10.2.3 Oxidation of SDC(S-tBu)RETGSSK
Peptide SDC(S-tBu)RETGSSK (15 mg) was oxidised in solution using the method in 
Section 7.2.10.2. The reaction was monitored by MS and gave the expected glyoxal- 
DC(S-tBu)RETGSSK and the hydrated version. [M + H] 1026 [M + H3O] 1144
7.2.10.2.4 Oxidation of SDCRETGSSKYPNCAYKTTQANKHIIVACEGN 
PYVPVHFDASV, and S-tBu and ACM protected versions
Peptide SDCRETGSSKYPNCAYKTTQANKHIIVACEGNPYVPVHFDASV was 
oxidised in solution was oxidised in solution using the method in Section 7.2.10.2. 
The reaction was monitored by MS and gave multiple peaks separated by 6  mass 
units corresponding to multiple oxidation products.
Peptide SDC(S-tBu)RETGSSKYPNC(S-tBu)AYKTTQANKHIIVAC(S-tBu)EGNP 
YVPVHFDASV was oxidised in solution by the same method and analysed by MS, 
which gave the expected mass for the hydrated glyoxal. The peptide was purified by 
HPLC and stored at -20 °C until required. ESMS [M + H3 O] 4689.
Peptide SDC(ACM)RETGSSKYPNC(ACM)AYKTTQANKHIIVAC(ACM)EGN 
PYVPVHFDASV was oxidised in solution by the same method and analysed by MS, 
which gave the expected mass for the glyoxal and hydrated glyoxal. The peptide was 
purified by HPLC and stored at -20 °C until required ESMS [M+ H] 4882 [M + H3 O] 
4900.
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7.2.11 Chemoselective Ligation of Peptides
The peptides to be ligated were dissolved in NaOAc buffer (0.1 M, pH 4.6), at a 
concentration of 1 mg/ml unless specified otherwise, and the reaction stirred at room 
temperature. The reaction was monitored by LC-MS, using the HPLC to remove the 
buffer, allowing analysis of the reaction by ESMS. When ligation was compete, the 
product was purified by RP-HPLC, and the ligated product was lyophilised and 
stored at 4 °C.
7.2.11.1 Initial Ligations of 8Aoc-fQWAVGHL-NH2-NH2 to glyoxal- 
LIGRL-NH2
8 Aoc-fQWAVGHL-NH2-NH2 (7 mg) and glyoxal-LIGRL-NH2 (4 mg) were 
dissolved in NaOAc buffer (11 ml, 0.1 M, pH 4.6). The reaction was stirred at room 
temperature for 3 days and monitored by ESMS after 24 hours and 3 days. The 
reaction had proceeded to completion so the reaction mixture was purified by HPLC 
and the purified peptide was lyophilised and stored at 4 °C.
8 Aoc-fQWAVGHL-NH2-NH2 (7 mg) and glyoxal-LIGRL-NH2 (4 mg) were 
dissolved in NaOAc buffer (5.5 ml, 0.1 M, pH 4.6). The reaction was stirred at room 
temperature for 3 days and monitored by ESMS after 24 hours, 48 hours and 3 days. 
The recation as not complete after 48 hours. The reaction had proceeded to 
completion after 3 days, so the reaction mixture was purified by HPLC and the 
purified peptide was lyophilised and stored at 4 °C.
7.2.11.2 Optimised Ligation of 8 Aoc-fQWAVG H L-N H2-N H 2 to 
glyoxal-LIGRL-NH2
8 Aoc-fQWAVGHL-NH2-NH2 (7 mg) and glyoxal-LIGRL-NH2 (4 mg) were 
dissolved in NaOAc buffer (11 ml, 0.1 M, pH 4.6 containing 10 mM aniline). The 
reaction was stirred at room temperature for 18 hours and monitored by ESMS to
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ensure it had reached completion. The reaction mixture was purified by HPLC and 
the purified peptide was lyophilised and stored at 4 °C.
7.3 Equipment and Instrumentation
Manual peptide synthesis was performed using an orbital shaker (IKA). Empty PD 
10 columns (Amersham Bioscience) were used as peptide synthesis reaction vessels. 
Alternatively Teflon peptide synthesis reaction vessels (Activotec) were used. 
Automated peptide synthesis was carried out on either the Symphony or Prelude 
peptide synthesisers (Protein Technologies Inc.). Solvent was evaporated under 
reduced pressure using a rotary evaporator (Buchii) and Laboport® pump (KNF).
Column chromatography was performed using silica gel 60 (Alfa Aesar). Column 
chromatography was monitored by thin layer chromatography (TLC) on Keiselgel 60 
F2 5 4  pre coated plates (Sigma Aldrich). Compounds were observed under a UV lamp 
at 254 nm.
7.3.1 Reverse Phase High Performance Liquid Chromatography
Reverse phase high performace liquid chromatography (RP-HPLC) was used to 
purify peptides and to analyse crude and purified peptides. RP-HPLC was also used 
to analyse derivatives of amino acids.
7.3.1.1 HPLC Analysis
Peptides and amino acid derivatives were analysed by reverse phase high pressure 
liquid chromatography (RP-HPLC) using a Gilson HPLC machine running either 
712 or Unipoint software. The system consisted of two slave Gilson 306 pumps, 805 
manometric module, 118C dynamic mixer, and 155 UVWis detector. Columns used 
were C l8 primesphere or Waters symmetry analytical columns, 5 pm, 4.6 mm x 150
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mm 100 Â pore size. Analysis was performed using a linear gradient of two solvents, 
A (H2 O containing 0.1% v/v TFA) and B (acetonitrile containing 0.1% v/v TFA), 
running from 0%-80% B over 20 mins or 10%-90% B over 20 mins at 1 ml/min.
7.3.1.2 HPLC Purification
Peptides were purified by preparative RP-HPLC using a Varian Prostar 210 system, 
consisting of two slave pumps and UVWis detector running Varian Star software. 
The column used was a C l8  Gemini column, 5 pm, 10.0 mm x 250 mm 300 Â pore 
size. Purification was performed using a linear gradient of two solvents, A (H2 O 
containing 0.1% v/v TFA) and B (acetonitrile containing 0.1% v/v TFA), typically 
running from 10%-60% B over 20 mins at 5 ml/min.
7.3.2 Mass Spectrometry
Mass spectrometry (MS) of amino acid derivatives and peptides were recorded at 
Peptide Protein Research Ltd, on a Micromass ZMD 4000 mass spectrometer. Liquid 
Chromatography-Mass Spectrometry (LC-MS) was performed using an Agilent 1100 
series Liquid Chromatography-Mass Spectrometer, running Chemstation software. 
Mass spectra were recorded for all amino acid derivatives and peptides. LC-MS was 
used to monitor oxidation and ligation reactions, and for analysis of amino acid 
derivatives and peptides.
7.3.2.1 Electrospray Mass Spectrometry of Peptides
All peptide mass spectra were recorded using an electrospray mass spectrometer. 
Electrospray ionisation is particularly suitable for peptides as it allows the peptide to 
be ionised without fragmentation. Ionised peptides are often multiply charged, which 
means that the spectra recorded show multiple peaks on a mass/charge (m/z) scale.
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correlating to the different ionisation states of the peptide. A computer program can 
then be used to calculate the actual mass of the peptide from the original spectrum.
7.3.3 Nuclear Magnetic Resonance Spectroscopy
Nuclear Magnetic Resonance (NMR) Spectroscopy was recorded at Surrey 
University using a Brucker DRX-300 pulse Fourier transform spectrometer operating 
at 300 MHz, or at Reading University Chemical Analysis Facility (CAF) using a 
Brucker DPX400 Fourier transform spectrometer operating at 400 MHz. Spectra 
were recorded for final compounds and key intermediates.
7.3.4 Optical Spectroscopy
Fourier Transform Infra-red Spectroscopy (FTIR) was recorded at Reading 
University CAF using a PerkinElmer Spectrum 100 FTIR spectrometer.
7.4 Molecular Dynamics Simulations
The software package used for molecular dynamics (MD) simulations at the 
University of Surrey was Molecular Operating Environment (MCE 2007.09, 
Chemical Computing Group Inc.).
7.4.1 Running a Molecular Dynamics Simulation
A number of individual processes were performed in order to carry out a protein 
molecular dynamics simulation using MCE. The relative positions of all the atoms 
were first loaded into the software from a Protein Data Bank (pdb) file, which has the 
co-ordinates of every atom position taken from a solved crystal structure. This 
structure was placed inside a virtual box of water, and then an energy minimisation
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was performed, Once the energy minimisation was performed, the molecular 
dynamics process was started. The simulation generated a database of entries after 
each individual energy calculation, which are essentially snapshots of the system as 
an experimentally derived timecourse through the simulation.
7.4.2 Molecular Dynamics Simulation of Bovine Ribonuclease A
A pdb file for bovine ribonuclease A was loaded into MCE. The crystal structure that 
was chosen for the dynamic simulation was a pdb file called 3m3, from the 
publication by Howlin et al. (1989). An energy minimisation was run on this 
structure using the AMBER 99 forcefield. The energy minimised structure was saved 
and this was placed inside a box of water by running a function called water soak. 
The size of the box was set to just larger than the ribonuclease molecule, and 
periodic boundary conditions were applied (Chapter 5, Section 5.1.4.3). The system 
was constrained to NTP (Chapter 5, Section 5.1.4.4) and the molecular dynamics 
simulation was run using a timestep of 0.5 ps and the number of timesteps set to 200.
7.4.2.1 Replacement of Ala20 with an Oxime Bond
Using the original crystal structure of bovine ribonuclease A, 3m3 (Howlin et al. 
(1989)) loaded into MOE, the site for a single chemoselective ligation replacement 
for Ala20 was identified. The software has the facility to delete parts of the structure 
and draw replacement structures atom by atom. Using the software to hide the entire 
molecule except Ala20 and the immediately adjacent amino acids, the atoms in the 
native peptide bond were deleted and replaced with the structure of an oxime bond, 
formed through reaction of an N-terminal hydroxylamine with a C-terminal 
aldehyde. An energy minimisation using the AMBER 99 forcefield was performed, 
firstly just on the replaced atoms, and then using a proximity tool to identify all 
atoms within a 10 Â distance of the changed atoms. The whole system was then 
energy minimised.
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7.4.2.2 Replacement of Ala20, Ala52 and Thr82 with a hydrazide 
chemoselective bond
Using the original crystal structure of bovine ribonuclease A, 3m3 (Howlin et al. 
(1989)), loaded into MOE, the site for a single chemoselective ligation replacement 
for Ala20 was identified. The atoms in the native peptide bond were deleted and 
replaced with the structure of a hydrazide bond formed through reaction between an 
N-terminal glyoxal and a C-terminal hydrazide. After the bond was replaced, the 
structure was run through an energy minimisation using the AMBER 99 forcefield, 
firstly just on the replaced atoms, and then using the proximity tool to identify all 
atoms within a 1 0  A distance of the changed atoms. The process was repeated for 
Ala52 and Thr82, replacing these with the hydrazide bond. Once all three bonds had 
been replaced and the energy minimised, the whole system was energy minimised 
once more.
7.4.2.3 Molecular Dynamics Simulation of RNase A containing 
ligated bonds
The energy minimised structure of ribonuclease containing three hydrazide bonds 
(Section 7.4.1.2) was placed inside a box of water using the water soak function in 
MOE. The same constraints were applied as used for the MD simulation of native 
ribonuclease (Section 7.4.1.1). The MD simulation was run using a timestep of 0.5ps 
and the number of timesteps set to 400.
7.4.2.4 Replacement of Cys65 with Ala
Using the original crystal structure of bovine ribonuclease A, 3m3 (Howlin et al. 
(1989)), loaded into MOE, the amino acid Cys65 was located. The disulfide between 
Cys65 and Cys72 was deleted and the side chain of Cys65 was replaced with a 
methyl group to produce the mutant Ala65. The structure was run through an energy 
minimisation using the AMBER 99 forcefield, firstly using the proximity tool to
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identify all atoms within a 10 A distance of the changed atoms, and then on the 
whole system.
7.4.2.5 Molecular Dynamics Simuiation of Cys65Ala RNase A
The energy minimised structure of ribonuclease containing Cys65Ala was placed 
inside a box of water using the water soak function in MOE. The same constraints 
were applied as used for the MD simulation of native RNase A (Section 7.4.1.1). 
The MD simulation was run using a timestep of 0.5ps and the number of timesteps 
set to 400.
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Analytical data for derivatives of Phenylalanine
Fmoc-phenylalanine diazomethylketone 
‘H NM R,‘H COSY,'^C NMR, FTIR
Fmoc-phenylalanine bromomethylketone 
LCMS, 'H NMR, 'H COSY, "C NMR, FTIR
Fmoc-phenylalanine azidomethylketone
LCMS, 'H NMR, 'H COSY, "C NMR, FTIR
Fmoc-phenylalanine azidomethylalcohol
LCMS, ‘H NMR, 'H COSY, "C NMR, FTIR
Fmoc-phenylalanine amino alcohol
LCMS,'HNMR
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1.5mls/min 
60ul
Analysis carried out using a lOOA 4.6 x 50mm column, gradient from 2 
- 80% Acetonitrile, in 8 minutes. At 60°C.
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Analysis carried out using a lOOA 4,6 x 50mm column, gradient from 2- 
- 80% Acetonitrile, in 8 minutes. At 60°C.
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Appendix lib
Analytical data for small peptide aldehyde
Z-Arg-Leu-Phe-amino alcohol
LCMS, ‘HNMR
Z-Arg-Leu-Phe-aldehyde 
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